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risks such as obesity, physical inactivity and smoking, which 
have a high prevention potential. As behaviour-related risk 
factors are closely settings bound, i.e. tied to people's 
social, cultural and work environments or their physical 
environments, this translates into a responsibility for the 
whole of society to promote the prevention and contain-
ment of type 2 diabetes, other frequent noncommunicable 
diseases and contribute to reducing health inequalities [3, 4]. 
Next to type 2 diabetes, which is the most frequent form 
of diabetes at adult age, diabetes surveillance also covers 
the far rarer type 1 diabetes that usually develops at child 
and adolescent age as well as gestational diabetes. Both 
primary data from the RKI from national health surveys as 
well as disease registry data and disease management pro-
gram (DMP) data for diabetes types 1 and 2 as well as 
routine billing data from the statutary health insurance sys-
tem for secondary use (called secondary data) are contin-
uously being used to fill indicators in the four fields of 
action: 1. Reducing diabetes risks, 2. Improving early detec-
tion and treatment of diabetes, 3. Limiting diabetes com-
plications, 4. Reducing the disease burden and costs. To 
ensure the use of external data sources in the long term, 
develop potential uses, identify and reduce data use limits, 
annual tenders for cooperation projects have been pub-
lished in the context of diabetes surveillance and selected 
based on standardised criteria. The articles in this issue of 
the Journal of Health Monitoring on New Results from 
Diabetes Surveillance in Germany provide an overview of 
the key results diabetes surveillance has provided towards 
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Against the backdrop of the great public health importance 
of diabetes mellitus, receiving funds from the Federal Min-
istry of Health (BMG), the Robert Koch Institute (RKI) has 
begun a research project to establish diabetes surveillance 
in Germany. In the public health context, surveillance refers 
to a systematic long-term collection and analysis of health 
data to facilitate decisions regarding the planning, imple-
mentation and evaluation of public health measures [1]. 
Diabetes surveillance is thereby fundamentally concerned 
with transparently providing key information on diabetes 
in Germany for actors in health policy, health research and 
practice as well as the general public. This includes infor-
mation on risk factors, disease rates, disease outcomes 
and the quality of medical care. Within the first four-year 
project phase (2015-2019), a scientific framework concept 
with four fields of action and 40 key indicators was devel-
oped, data sources to map these indicators were estab-
lished, and formats for user-oriented reporting created. 
An interdisciplinary scientific advisory board has continu-
ously guided the project [1].
Type 2 diabetes is the dominant form of diabetes at adult 
age and as one of the globally most common chronic dis-
eases now stands in the focus of international action plans 
for the prevention of noncommunicable diseases [2]. Ele-
vated blood sugar levels as a result of decreased insulin 
action (insulin resistance) are the hallmark of this type of 
diabetes. Besides genetic factors, the important risk fac-
tors for type 2 diabetes and other common noncommuni-
cable diseases include in particular older age and health 
Journal of Health Monitoring
Journal of Health Monitoring 2019 4(2)
Editorial: Diabetes surveillance in Germany – status and perspectives
4
EDITORIAL
care, the results do not indicate pronounced levels of 
educational inequality at either survey point. Over time, 
clear improvements in particular in the low education 
group are visible. This applies to meeting guideline-based 
objectives for glycated haemoglobin (HbA1c or long-term 
blood sugar), blood pressure and blood lipids, self-mea-
surement of blood sugar, and regularly attending medical 
examinations of the ocular fundus and the feet. At least 
between 1997 and 1999, taking statins was less common 
in both genders in the low education group in comparison 
to the medium or high education groups. However, these 
differences may not be statistically significant due to the 
very low number of statin users at the time. Yet, as even 
countries with universal access to their health care system 
report social differences in the quality of care [5-7], there is 
a need for further research here. In future, it will be impor-
tant to include hard endpoints such as overall mortality 
and cardiovascular complications next to figures on care 
processes and target achievement criteria for the regula-
tion of blood sugar, blood pressure and cholesterol values. 
In addition, the operationalisation of social inequality 
should be extended beyond merely education. Observa-
tions from Germany show that in children and adolescents 
with type 1 diabetes both lower individual social status and 
a higher regional deprivation index are associated with 
poorer quality of care [8-10].
The second article by Rosenbauer et al. shows how the 
data gaps on type 1 diabetes and type 2 diabetes in chil-
dren and adolescents in Germany could be closed in the 
future. In contrast to the civilisation disease type 2 dia betes, 
type 1 diabetes, the second major form of diabetes melli-
tus, is much less common and has often already developed 
the end of the first project phase set to conclude at the end 
of 2019. 
In the first article, Heidemann et al. ask whether dia-
betes-related social inequalities have increased for adults 
in Germany over time. The findings are based on data from 
continuous health monitoring at the RKI with information 
that was collected in national population representative 
interview and examination surveys on adult health in Ger-
many between 1997 and 1999 (German National Health 
Interview and Examination Survey, GNHIES98) and 2008 
to 2011 (German Health Interview and Examination Survey 
for Adults, DEGS1). As the results convincingly show, lev-
els of education have a clear impact on diabetes prevalence 
and estimated 5-year diabetes risks in Germany, however, 
not on quality of life and certain aspects of quality of care. 
During both survey points and for both genders, diabetes 
prevalence is considerably higher among adults with low 
education compared to those with high education. This 
finding applies for both medically diagnosed diabetes as 
well as to unknown diabetes. That the prevalence of 
unknown diabetes has dropped across all education groups, 
with a concomitant increase in medically diagnosed dia-
betes and relatively constant overall prevalence could 
indicate improved early detection. It is, however, problem-
atic that over the same period the education gap in the 
estimated 5-year diabetes risk among adults in Germany 
has continued to widen. For both genders, a significant 
decline can only be seen in the high education group. This 
represents a major challenge for health promotion and pri-
mary care, the successes of which should be closely mon-
itored at the population level. Regarding the developments 
of the impact of diverging levels of education on quality of 
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18, current prevalence estimates (493 per 100,000 people 
or a total of 341,000 people for the year 2016) and inci-
dence (6.1 per 100,000 person years or 4,150 new patients 
per year) are significantly higher than the earlier estimates 
based on analyses of statutory health insurance data. In 
the synopsis with the data on children and adolescents up 
to 18 years already available, the results for Germany indi-
cate that there are currently 373,000 people with type 1 dia-
betes, implying an estimated absolute number of 7,265 
new patients per year. For type 2 diabetes among children 
and adolescents, in addition to estimates based on the 
available NRW and DPV registry data, further surveys were 
conducted in diabetes registry clinics in Baden-Württem-
berg and Saxony. The results for the period 2014-2016 show 
that type 2 diabetes among children and adolescents in 
Germany remains a rare disease with a prevalence of an 
estimated 12 to 18 per 100,000 persons, a total of about 
950 children and adolescents and an estimated 175 new 
cases per year. Based on the rare occurrence of type 1 dia-
betes and especially of type 2 diabetes in children and ado-
lescents, population-based samples are poorly suited to 
record disease rates over time. Analyses of routine data, 
too, from statutory health insurances have their limits 
because of often unclear or incomplete coding and chang-
ing case definitions. An expansion of the available registry 
data with improved completeness detection is therefore 
essential for reliable, comparable trend estimates over time 
on the disease burden and need for care in the context of 
diabetes surveillance. 
The third article by Schmidt et al. discusses the ques-
tion of secondary data. Secondary data refers to data that 
has been primarily collected for a different purpose [15]. 
in childhood or adolescence. Type 1 diabetes is caused by 
a not hitherto fully understood autoimmune reaction that 
destroys the pancreas’ insulin-producing cells. The conse-
quence is a lifelong insulin dependency that places high 
demands on the self-management of patients and the qual-
ity of medical care. Not least, this applies with regard to 
the important technological advances made in insulin 
pumps and measuring instruments for continuous glucose 
measurement in the subcutaneous tissue as well as on-de-
mand insulin delivery by means of so-called ‘closed loop 
systems’ [11, 12]. Estimates on the prevalence of type 1 dia-
betes among children and adolescents in Germany have 
been based on (one national and three regional) incidence 
registries since the mid-1990s with a high degree of com-
pleteness [13, 14]. Still lacking in Germany are standardised 
comparable estimates over time on the prevalence and 
incidence of type 1 diabetes among adults and overall esti-
mates across all age groups. An increase in type 2 diabetes 
in children and adolescents is generally suspected, yet so 
far no time series based on systematic and continuous data 
collection has been established. Both the regional registry 
in North Rhine-Westphalia (NRW) and the national DPV 
registry (Diabetes-Patienten-Verlaufsdokumentation) 
meanwhile include all newly diagnosed cases of type 1 dia-
betes in adults and type 2 diabetes in children and adoles-
cents - however coverage is not complete. Based on statis-
tical methods (capture-recapture), data from the registry 
in NRW was used to estimate coverage rates. Assuming 
varying degrees of completeness, capture-adjusted esti-
mates of the prevalence and incidence of type 1 diabetes 
in adults aged over 18 were established based on German 
DPV registry data. For type 1 diabetes in adults aged over 
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the one hand on establishing the validity of data sources 
and possibly reviewing the methodology. On the other hand, 
it is important to determine the availability and potential 
of continuity in terms of a regular provision of data for 
surveillance. Such an approach is highly important because 
14 of the 40 indicators of diabetes surveillance exclusively 
use secondary data and a further eleven indicators, which 
are mainly based on RKI health monitoring data, in addi-
tion require secondary data. The article describes the two 
‘work packages’ diabetes surveillance has devoted to sec-
ondary data. First, cooperation projects were conducted in 
which external partners examined data sources regarding 
their validity, availability and usability for surveillance. Sec-
ondly, based on the DaTraV dataset (according to the Data 
Transparency Regulations), criteria for the operationalisa-
tion of diabetes prevalence were defined and the data eval-
uated. 
The following projects were realised: 
1. On the basis of data from the diagnosis related groups 
statistics (DRG statistics), trends in outpatient-sensi-
tive hospital cases in diabetes mellitus were analysed: 
There was a marked decrease in age-adjusted amputa-
tion rates, which - at least partially - could be related to 
improvements in care [21].
2. The usability of DMP data for diabetes surveillance was 
tested: It turned out that DMP data, despite some lim-
itations (selection, questionable validity of the docu-
mentation), can provide important results, such as the 
achievement of quality objectives and the implementa-
tion of care in accordance with guidelines.
3. The presentation of relevant quality of care indicators based 
on AOK data was analysed: The project highlighted 
This can be data which has been collected for a study and 
is then analysed to answer a new research question. Often, 
secondary data is data that is primarily collected for routine 
or billing purposes, for example the data of social security 
institutions such as health or pension insurances, medical 
record data or disease management program data. It has 
clear disadvantages compared to primary data such as the 
survey data referred to above. For example, it does not usu-
ally contain any patient-reported variables (such as quality 
of life). The validity of this data for the research question 
needs to be carefully evaluated. However, such data also 
has a number of relevant advantages. Large populations 
can be observed. There is no selection due to non-partici-
pation. Regional stratifications are possible. Some events, 
which are of key importance as outcome indicators, are well 
and fully described, for example amputations or strokes. 
Furthermore, process variables can be collected that can-
not be validated easily in interviews, such as the number of 
doctors’ appointments or certain examinations, that 
patients either do not reliably remember or are not aware 
of. In addition, longer periods of time can be surveyed in a 
tight temporal sequence [15]. Many key findings on dia-
betes in Germany are based on secondary data, such as 
diabetes prevalence, stroke and amputation incidence 
[16, 17], referrals to doctors [18], and cost of medical care 
[19]. However, little data has routinely been available so far 
and separate studies are required. In addition, method-
ological aspects need to be critically reflected, such as differ-
ences between different health insurance organisations 
regarding the composition of the insured population or the 
suitability of routine data to assess health events [20]. Using 
routine data in diabetes surveillance therefore depends on 
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data on renal replacement therapy with data on the diag-
nosis of terminal renal replacement therapy can provide 
insights as to whether information on a terminal renal 
replacement therapy is continuously available for dia-
betes surveillance based on DaTraV data and can there-
fore provide a valid measure.
The second work package, in cooperation with experts 
from epidemiology and health services research, developed 
a reference definition for the future presentation of the doc-
umented prevalence of diabetes in the context of diabetes 
surveillance, which is based on DaTraV data. Overall, the 
article clearly shows that secondary data is a key element 
to map indicators of diabetes surveillance that substan-
tially complements RKI health monitoring. This data can 
provide time series for the development of numerous indi-
cators. 
In the final article, Reitzle et al. consider the central 
question of data processing and dissemination of the 
results of surveillance to actors in politics, research and 
practice. Taking diabetes as a concrete example, between 
April and September 2018, the models and experiences in 
46 countries, among them 28 EU member states, five fur-
ther European nations and 13 non-European OECD mem-
ber states, were taken stock of. Structured online interviews 
with public health and health policy experts in 27 countries 
as well as structured internet searches (key word searches 
on the websites of public health institutes, health minis-
tries, statistical offices and keyword-based searches on 
Google) provided the basis. There were 19 countries in 
which no interviews could take place. Information from 
web searches that were not available either in English, 
that adequately prepared secondary data has the potential 
to close data gaps in diabetes surveillance. Based on the 
project results, four further indicators were included in 
the diabetes surveillance indicator set.
4. DaTraV data was used to project future scenarios of dia-
betes development in Germany: Assuming that demo-
graphic developments continue and diabetes prevalence 
remains constant, the absolute number of persons with 
diagnosed type 2 diabetes would increase by 21% 
between 2015 and 2040 [22].
5. The potential value of geocoding services data to make 
statements on the obesogenicity of an environment, 
which means an environment that potentially increases 
obesity, was analysed: The project developed a method 
that allows areas with obesogenic and/or protective 
environmental factors to be identified. Potentially, this 
could be used in diabetes surveillance.
6. Healthy life years and life years lost were calculated as 
indicators for diabetes burden: The majority of mod-
els indicated an increase in healthy life years between 
2015 and 2040 as well as a relative decline in lost life 
years by up to 64%.
7. The incidence trends for renal replacement therapy were 
analysed based on medical records and a concept was 
established for analysis based on the data of statutory 
health insurances. Furthermore, the usability of DaTraV 
data for monitoring the trends in terminal renal insuf-
ficiency was analysed: Unlike for other complications, 
no decline in the incidence of renal replacement thera-
py was observed during the 2000s. Currently, the trend 
between 2002 and 2016 is being analysed. An analysis 
of DaTraV data showed that validation by comparing 
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The German version of the article is available at: 
www.rki.de/journalhealthmonitoring
Conflicts of interest
The authors declared no conflicts of interest.
References 
1. Gabrys L, Heidemann C, Schmidt C et al. (2018) Selecting and 
defining indicators for diabetes surveillance in Germany. Journal 
of Health Monitoring 3(S3):3-21.  
https://edoc.rki.de/handle/176904/5679 (As at 11.06.2019)
2. World Health Organization (2018) The General Meeting of the 
WHO Global Coordination Mechanism on the Prevention and 
Control of Noncommunicable Diseases.  
https://www.who.int/global-coordination-mechanism/news/gen-
eral-meeting-2018/en/ (As at 11.06.2019)
3. Lampert T, Kroll LE, Kuntz B et al. (2018) Health inequalities in 
Germany and in international comparison: trends and develop-
ments over time. Journal of Health Monitoring 3(S1):1-24.  
https://edoc.rki.de/handle/176904/3046 (As at 11.06.2019)
4. Heidemann C, Du Y, Baumert J et al. (2019) Social inequality and 
diabetes mellitus – developments over time among the adult 
population in Germany. Journal of Health Monitoring 4(2): 11-28. 
www.rki.de/journalhealthmonitoring-en (As at 27.06.2019)
5. Grintsova O, Maier W, Mielck A (2014) Inequalities in health care 
among patients with type 2 diabetes by individual socio-econom-
ic status (SES) and regional deprivation: a systematic literature 
review. Int J Equity Health 13:43
6. Rawshani A, Svensson AM, Rosengren A et al. (2015) Impact of 
Socioeconomic Status on Cardiovascular Disease and Mortality 
in 24,947 Individuals With Type 1 Diabetes. Diabetes Care 
38(8):1518-1527
7. Rawshani A, Svensson AM, Zethelius B et al. (2016) Association 
Between Socioeconomic Status and Mortality, Cardiovascular 
Disease, and Cancer in Patients With Type 2 Diabetes. JAMA 
Intern Med 176(8):1146-1154
8. Lindner LME, Rathmann W, Rosenbauer J (2018) Inequalities in 
glycaemic control, hypoglycaemia and diabetic ketoacidosis 
according to socio-economic status and area-level deprivation in 
Type 1 diabetes mellitus: a systematic review. Diabet Med 
35(1):12-32
French or German were translated into English and included 
where appropriate. The results highlight the great impor-
tance awarded to health reporting on diabetes in 80% of 
the 46 countries (n=37), which is underwritten in more 
than three quarters of these countries by a national dia-
betes strategy or a national diabetes action plan. Reporting 
is mainly based on indicators (n=29) and in many coun-
tries (n=21) not diabetes specific but set within the context 
of an indicator-based reporting on a number of noncom-
municable diseases. As in Germany, many countries use a 
diverse set of data sources in reporting, in many cases pri-
mary data from health surveys, but they also use sec ondary 
data from available routine data. The results of this analy-
sis are already being considered in the development of for-
mats for continuous diabetes reporting in Germany. The 
first report (print and online) will be published at the end 
of the first project phase of diabetes surveillance at the end 
of 2019. During the second project phase (2020-2021), 
expanding cooperation with actors in politics, public health 
research and practice in Germany, as well as with interna-
tional public health institutes, will play a fundamental role. 
Corresponding author
Dr Christa Scheidt-Nave
Robert Koch Institute 




Please cite this publication as
Scheidt-Nave C, Icks A (2019) 
Editorial: Diabetes surveillance in Germany – status and perspectives. 
Journal of Health Monitoring 4(2): 3-10. 
DOI 10.25646/5985
Journal of Health Monitoring
Journal of Health Monitoring 2019 4(2)
Editorial: Diabetes surveillance in Germany – status and perspectives
9
EDITORIAL
19. Kähm K, Laxy M, Schneider U et al. (2018) Health Care Costs 
Associated With Incident Complications in Patients With Type 2 
Diabetes in Germany. Diabetes Care 41(5):971-978
20. Icks A, Hoffmann F (2011) Unterschiede in der Versichertenstruk-
tur von Krankenkassen und deren Auswirkungen für die Versor-
gungsforschung: Ergebnisse des Bertelsmann-Gesundheitsmoni-
tors. Gesundheitswesen 74:291-297
21. Pollmanns J, Weyermann M, Geraedts M et al. (2018) Kranken-
hausfälle und Amputationen bei Diabetes mellitus – Zeitreihen 
und Unterschiede auf kleinräumiger Ebene in Deutschland. Bun-
desgesundheitsbl 61(11):1462-1471
22. Tönnies T, Röckl S, Hoyer A et al. (2019) Projected number of 
people with diagnosed Type 2 diabetes in Germany in 2040.  
Diabet Med (efirst) 
9. Auzanneau M, Lanzinger S, Bohn B et al. (2018) Area Depriva-
tion and Regional Disparities in Treatment and Outcome Quality 
of 29,284 Pediatric Patients With Type 1 Diabetes in Germany:  
A Cross-sectional Multicenter DPV Analysis. Diabetes Care 
41(12):2517-2525
10. Mönkemöller K, Müller-Godeffroy E, Lilienthal E et al. The associ-
ation between socio-economic status and diabetes care and out-
come in children with diabetes type 1 in Germany: The DIAS 
study (diabetes and social disparities). Pediatric Diabetes (efirst)
11. Karges B, Schwandt A, Heidtmann B et al. (2017) Association of 
Insulin Pump Therapy vs Insulin Injection Therapy With Severe 
Hypoglycemia, Ketoacidosis, and Glycemic Control Among  
Children, Adolescents, and Young Adults With Type 1 Diabetes. 
JAMA 318(14):1358-1366
12. DeSalvo DJ, Miller KM, Hermann JM et al. (2018) Continuous 
glucose monitoring and glycemic control among youth with type 
1 diabetes: International comparison from the T1D Exchange and 
DPV Initiative. Pediatr Diabetes 19(7):1271-1275
13. Bendas A, Rothe U, Kiess W et al. (2015) Trends in Incidence 
Rates during 1999-2008 and Prevalence in 2008 of Childhood 
Type 1 Diabetes Mellitus in Germany--Model-Based National  
Estimates. PLoS One 10(7):e0132716
14. Rosenbauer J, Neu A, Rothe U et al. (2019) Types of diabetes are 
not limited to age groups: type 1 diabetes in adults and type 2 
diabetes in children and adolescents. Journal of Health Monitor-
ing 4(2): 29-49.  
www.rki.de/journalhealthmonitoring-en (As at 27.06.2019)
15. Swart E, Gothe H, Geyer S et al. (2015) Gute Praxis Sekundär-
datenanalyse (GPS): Leitlinien und Empfehlungen. Gesundheits-
wesen 77(2):120-126
16. Claessen H, Narres M, Haastert B et al. (2018) Lower-extremity 
amputations in people with and without diabetes in Germany, 
2008-2012 - an analysis of more than 30 million inhabitants. Clin 
Epidemiol 10:475-488
17. Icks A, Scheer M, Genz J et al. (2011) Stroke in the diabetic and 
non-diabetic population in Germany: relative and attributable 
risks, 2005-2007. J Diabetes Complications 25(2):90-96
18. Icks A, Dittrich A, Brune M et al. (2017) Agreement found 
between self-reported and health insurance data on physician 
visits comparing different recall lengths. J Clin Epidemiol 82:167-
172
Journal of Health Monitoring
Journal of Health Monitoring 2019 4(2)




This work is licensed under a 
Creative Commons Attribution 4.0 
International License.
The Robert Koch Institute is a Federal Institute within  
the portfolio of the German Federal Ministry of Health






Susanne Bartig, Johanna Gutsche, Dr Birte Hintzpeter,  
Dr Franziska Prütz, Martina Rabenberg, Dr Alexander Rommel,  
Dr Livia Ryl,Stefanie Seeling, Martin Thißen, Dr Thomas Ziese
Robert Koch Institute













External contributions do not necessarily reflect the opinions of the 
Robert Koch Institute.
Journal of Health Monitoring
11
FOCUS
Journal of Health Monitoring 2019 4(2)
Social inequality and diabetes mellitus – developments over time among the adult population in Germany
Journal of Health Monitoring · 2019  4(2) 
DOI 10.25646/5986 
Robert Koch Institute, Berlin  
 
Christin Heidemann, Yong Du, Jens Baumert, 
Rebecca Paprott, Thomas Lampert,  
Christa Scheidt-Nave
Robert Koch Institute, Berlin  





Social inequality and diabetes mellitus – developments over time 
among the adult population in Germany
Abstract
The connection between social disadvantage and the presence of known diabetes and specific risk factors is well 
documented. This article summarises the results from the Robert Koch Institute examination surveys that were conducted 
between 1997 and 1999 as well as 2008 and 2011 to address social inequality – operationalised by level of education – 
with regard to prevalences of known and unknown diabetes, risk of diabetes and care of diabetes as well as their 
development over time. Both survey periods showed that the low education group has higher prevalences of known and 
unkown diabetes as well as a higher risk of developing diabetes within the next five years compared to the medium and 
high education group. Over time, prevalence tended to increase for known diabetes and to decrease for unknown diabetes 
for all education groups. For the 5-year diabetes risk, only the high education group showed a clear decrease over time. 
The chosen indicators of diabetes care indicated no clear differences between education groups and an improvement of 
diabetes care over time. For some indicators of care (foot examination, statins), improvements were only seen in the 
low education group. In conclusion, social inequalities in the prevalence of known and unknown diabetes as well as in 
diabetes risk remain in Germany; for the indicators of care, however, no clear education gradient is evident. Over time, 
inequality regarding the prevalence of diabetes has not increased further. However, with regard to diabetes risk, inequality 
has become slightly more evident. For individual care indicators, improvements are limited to specific education groups.
  DIABETES MELLITUS · EDUCATION · PREVALENCE · DIABETES RISK · DIABETES CARE 
1.  Introduction
Diabetes mellitus is a metabolic disease with a disturbed 
regulation of blood glucose (blood sugar) [1]. The main risk 
factors of the disease’s most common form, type 2 dia-
betes, include unfavourable health-relevant behaviours 
such as lack of exercise, an unhealthy diet, and smoking, 
along with being overweight as a frequent consequence [2]. 
Unknown or inadequately treated diabetes leads to 
chronically elevated blood glucose concentrations. Blood 
vessels and the nervous system can be subsequently dam-
aged, resulting in diabetes-specific complications (such as 
renal dysfunction, eye disease, diabetic foot syndrome, and 
amputations of the lower limb) as well as cardiovascular 
diseases (such as heart attack and stroke). These severe 
diabetes-related diseases lead to a loss of health-related 
quality of life and life expectancy for affected individuals 
and place a high financial burden on the health system [3]. 




2.1  Study population
This article is based on data collected by two nationwide 
interview and examination surveys, the German National 
Health Interview and Examination Survey 1998 (GNHIES98, 
1997-1999) and the German Health Interview and Exami-
nation Survey for Adults (DEGS1, 2008-2011) conducted 
as part of the continuous health monitoring at the RKI 
(Info box 1). Figure 1 shows the study populations as they 
were defined for both survey periods and used for the esti-
mation of indicators of diabetes prevalence, diabetes risk 
and diabetes care.
2.2  Indicators
The definitions can be found for the indicators known dia-
betes and unknown diabetes in info box 2, for the indicator 
5-year risk of developing type 2 diabetes in info box 3, for 
indicators related to the quality of care for type 2 diabetes 
in the areas of achieving treatment goals and self-manage-
ment or medical care in info box 4 and info box 5, and for 
subjectively assessed health-related quality of life of type 2 
diabetes in info box 6.
The data used to calculate indicators stem from 
GNHIES98 and DEGS1 and were collected in the form of 
self-administered written questionnaires (including ques-
tions on smoking habits, physical activity, diet, health-re-
lated quality of life), physical examinations (including mea-
surements of body height, waist circumference, systolic 
and diastolic blood pressure), a computer-assisted medical 
interview (including questions on physician-diagnosed 
Due to these health impacts and the rising prevalence of 
diabetes – particularly of type 2 diabetes, which tends to 
become more frequent with increasing age – diabetes pre-
sents a major public health challenge in Germany and most 
other countries [2, 4].
Analyses of the temporal development of the presence 
of diabetes and its risk factors as well as the diabetes care 
situation are a decisive prerequisite to adapt or monitor 
prevention and care measures and to estimate the devel-
opment of diabetes-related health system expenditure. As 
socioeconomic factors are often related to health-relevant 
behaviour and its associated diseases, comparing popula-
tion groups and, where appropriate, developing target 
group- or setting-specific measures are important [5].
Such an analysis and provision of results on risks, pres-
ence and care of diabetes in Germany is the purpose of the 
national diabetes surveillance currently being developed 
at the Robert Koch Institute (RKI) [6]. The aim is to regu-
larly provide information on 40 defined indicators or indi-
cator groups [7]. This article considers the development 
over time of some key indicators of diabetes surveillance 
from the fields of diabetes risk, diabetes prevalence (fre-
quency of diabetes) and diabetes treatment for the overall 
German adult population as well as stratified by level of 
education and gender. It is based on the data of the pop-
ulation-representative health interview and examination 
surveys of the RKI.
Info box 1: 
Nationally representative interview and exam-
ination surveys for adults conducted by the 
Robert Koch Institute (cross-sectional surveys)
 German National Health Interview and 
Examination Survey 1998 (GNHIES98, 
1997-1999)
 German Health Interview and Examination 
Survey for Adults (DEGS1, 2008-2011) 
Objectives: Providing information on health status, 
health behaviour and health care of the population 
in Germany and analysis of trends over time 
Survey methods: Self-administered written ques-
tionnaire, physical examinations and tests, com-
puter-assisted medical interview, assessment of 
currently used medications, laboratory analyses 
of blood and urine samples
Target population: Adults aged 18 to 79 years with 
permanent residence in Germany
Sampling method: GNHIES98: Registry office sam-
ple; randomly selected individuals from 120 munic-
ipalities in Germany were invited to participate
DEGS1: Registry office sample; randomly selected 
individuals from 180 municipalities in Germany 
were invited to participate (120 original sample 
points of the GNHIES98 and 60 new sample 
points). 
Participants: GNHIES98: 7,124 adults
DEGS1: 7,987 adults (3,795 GNHIES98 revisiting 
participants, 4,192 first time participants)
Response rate: GNHIES98: 61%
DEGS1: 64% for GNHIES98 revisiting participants, 
42% for first time participants
More information can be found at Thefeld et al. 1999 
[8], Kamtsiuris et al. 2013 [9] and Scheidt-Nave et al. 
2012 [10] as well as at www.degs-studie.de/en
Journal of Health Monitoring 2019 4(2)
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(SF-36). However, a recommended standardisation proce-
dure was used to ensure comparability between the two 
versions [11]. The family history of diabetes was assessed 
exclusively in DEGS1. Detailed descriptions of the data col-
lection process have been published elsewhere [11-14].
All indicators are stratified by level of education and, 
additionally, gender. Level of education as an indicator of 
social inequality was defined via the CASMIN Index (Com-
parative Analysis of Social Mobility in Industrial Nations). 
This is based on the data provided by self-administered 
written questionnaires in GNHIES98 and DEGS1, which 
take both general and vocational training into account and 
diseases, family history of diabetes, self-monitoring of blood 
glucose, medical examinations of the eyes and feet), an 
assessment of currently used medications (including docu-
mentation of medications to treat diabetes (anti-diabetic 
drugs) and certain medications to treat lipid metabolism 
disorders (statins)) as well as laboratory analyses of blood 
samples (including determination of glycated haemoglo-
bin (HbA1c, a long-term blood sugar value), total and 
high-density lipoprotein cholesterol (HDL cholesterol)). In 
both surveys, indicators were obtained by similar methods. 
Only the health-related quality of life was assessed 
by different versions of the Short Form-36 Health Survey 
Info box 2: 
Indicator known diabetes: 
 Physician-diagnosed diabetes mellitus or 
 Taking anti-diabetic drugs (ATC-Code A10)
Indicator unknown diabetes:
 No known diabetes and
 Glycated haemoglobin (HbA1c) value ≥6.5%
Both indicators are given as a prevalence, i.e. a 
proportion (in %) of people with known or 
unknown diabetes mellitus (without differentiat-
ing between types of diabetes) in the population.
Source: Nationale Diabetes-Surveillance am Robert
Koch-Institut 2018 [7], Heidemann et al. 2016 [12]
ATC = Anatomical Therapeutic Chemical Classification System
Figure 1 
Study populations of the German National 
Health Interview and Examination Survey 1998 
and the German Health Interview and 
Examination Survey for Adults
Source: GNHIES98 (1997-1999), 
DEGS1 (2008-2011)
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prevalence of known diabetes as well as the prevalence of 
unknown diabetes (Info box 2). For the survey periods 1997 
to 1999 and 2008 to 2011, the prevalence of known dia-
betes was 5.6% and 7.2%, the prevalence of unknown dia-
betes was 3.8% and 2.0%, and the prevalence of total dia-
betes was 9.3% and 9.2%,respectively. Once differentiated 
by level of education, higher prevalence estimates of known 
and unknown diabetes, and therefore also of total diabetes, 
were found in the low compared to the medium and high 
education group in both survey periods. For the period 
between the two surveys, tendencies towards an increase 
in the prevalence of known diabetes and a decrease in the 
prevalence of unknown diabetes were evident in all educa-
tion groups. For overall diabetes, no significant changes in 
prevalence over time were observed [12] (Figure 2).
The sex-stratified analysis showed no significant differ-
ences in the prevalence of known diabetes between women 
(1997-1999: 5.7%, 2008-2011: 7.4%) and men (5.5%, 7.0%) 
[12]. Men, however, had a higher prevalence of unknown 
diabetes (1997-1999: 4.3%, 2008-2011: 2.9%) compared to 
women (3.2%, 1.2%) [12]. During the first survey period, 
this difference was particularly clear for the high education 
group, and during the second period, it was apparent for 
all education groups. Overall, however, for both survey peri-
ods, the pattern of higher prevalence estimates of known 
and unknown diabetes in the low education group com-
pared to the medium and high education groups has been 
observed for both genders. Over time, the prevalence of 
known diabetes increased and the prevalence of unknown 
diabetes decreased for both genders [12], whereby a further 
differentiation by education group was not always permit-
ting robust findings due to the low number of diabetes 
allow a categorisation into low, medium and high educa-
tion groups [15]. To depict indicators of care among per-
sons with type 2 diabetes, the medium and high education 
group were combined to avoid that the number of cases 
in the subgroups become too small.
2.3  Statistical analysis
All prevalence estimates and mean values as well as cor-
responding 95% confidence intervals have been calculated 
using weighting factors. Weighting factors correct for devi-
ations within the sample from the population structure as 
of 31 December 1997 for GNHIES98 and 31 December 2010 
for DEGS1 (regarding sex, age, region, German citizenship, 
size of municipality and education) and also consider the 
deviations in probability of participation in DEGS1 between 
participants who previously took part in GNHIES98 and 
DEGS1 first time participants [8-10]. For a comparison over 
time of the total samples of GNHIES98 and DEGS1 that 
was independent of the changes in the age pyramid, 
GNHIES98 data were age-standardised based on the pop-
ulation as of 31 December 2010. To take into account both 
weighting and the correlation of participants within one 
municipality, results were calculated using SAS 9.4 survey 
procedures. Differences with p-values <0.05 were consid-
ered as statistically significant.
3.  Results
3.1  Prevalence of known and unknown diabetes
To reflect the total diabetes burden in the population, the 
diabetes surveillance provides data for both indicators the 
Info box 3: 
Indicator 5-year risk of developing type 2 diabetes
The German Diabetes Risk Score (DRS) developed 
by the German Institute of Human Nutrition Pots-
dam-Rehbrücke calculates the absolute 5-year risk 
of developing type 2 diabetes (in %) for people who 
have so far not been diagnosed with diabetes. For 
example, a 5-year risk of 8% means that eight out 
of 100 people with the same DRS points will be 
diagnosed with type 2 diabetes over the course of 
the next five years.
   Diabetes Risk Score (DRS) points =
    5,1 x age (years)
 +7.6 x waist circumference (cm)
 –2.7 x body height (cm)
 +47 x physician-diagnosed hypertension
 –2 x physical activity (hours/week)
 +15 x former smoker <20 cigarettes/day
 +45 x former smoker ≥20 cigarettes/day
 +23 x smoker <20 cigarettes/day
 +77 x smoker ≥20 cigarettes/day
 –7 x whole grain consumption 
        (per 50g portion/day)
 – 5 x coffee consumption (per 150ml cup/day)
 + 55 x red meat consumption 
        (per 150g portion/day)
 + 56 x 1 parent with diabetes
 + 106 x both parents with diabetes 
 + 48 x brother or sister with diabetes
 
   5-year risk of developing type 2 diabetes = 
   1 – 0.99061 exp [(DRS points – 474.17096591)/100]
    This article indicates the average 5-year risk of devel-
oping diabetes for the population without known 
diabetes.
     Source: Nationale Diabetes-Surveillance am Robert
Koch-Institut 2018 [7], Paprott et al. 2017 [13]
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3.3  Type 2 diabetes care
Achieving treatment goals
The indicators for treatment goals of HbA1c-, non-HDL 
cholesterol and blood pressure were defined in the context 
of the diabetes surveillance based on treatment targets set 
out in the national guideline for the therapy of type 2 dia-
betes [16] or in the international recommendations on the 
treatment of high blood glucose levels [17, 18] and lipid 
metabolism disorders in people with type 2 diabetes [19, 
20] (Info box 4). By outlining the proportion of persons 
with type 2 diabetes who achieve the respective treatment 
goal, they provide intermediate outcome measures on the 
quality of care for type 2 diabetes.
For the indicator HbA1c treatment goal, no substantial 
differences between the low education group and the 
medium and high education group were evident for both 
survey periods. Over time, the proportion of people with 
type 2 diabetes that achieve the HbA1c goal increased 
almost equally in all education groups. The patterns and 
temporal developments were similar for both genders 
(Figure 4). The same applies for the indicators non-HDL 
cholesterol goal and blood pressure goal. However, only a 
small proportion of persons with type 2 diabetes reached 
the non-HDL cholesterol goal; only men from the medium 
or high education group achieved a more moderate result 
(nearly 50%) in the more recent survey period. For the pro-
portion of people with type 2 diabetes who reach the blood 
pressure goal, the overall increase over time was less pro-
nounced compared to the proportion of those who reached 
the HbA1c or non-HDL cholesterol goal. As a tendency, a 
slightly higher proportion of men in the medium and high 
cases for certain subgroups – this applies in particular to 
women with high education in the survey period 1997 to 
1999 (Figure 2).
3.2  5-year risk of developing type 2 diabetes
The indicator for the 5-year diabetes risk combines a set of 
established diabetes risk factors and helps to estimate how 
likely it is that a person will be diagnosed with type 2 dia-
betes within the next five years (Info box 3). For the survey 
periods 1997 to 1999 and 2008 to 2011, the average 5-year 
diabetes risk for the population was 1.5% and 1.1%, respec-
tively. For both survey periods, the risk of getting diagnosed 
with diabetes was significantly higher for the low education 
group compared to the medium and high education groups. 
Over time, a significant decrease in the 5-year diabetes risk 
was only observed in the high education group [13] (Figure 3).
Stratified by gender, the analysis of both survey periods 
indicated a higher 5-year diabetes risk for men (1997-1999: 
2.2%, 2008-2011: 1.5%) relative to women (1.1%, 0.8%). 
This difference between genders was observed across all 
education groups. In both genders, the pattern of a higher 
5-year diabetes risk for the low education group compared 
to the medium and high education groups was evident. 
While for women, only the high education group showed 
a decrease in the 5-year diabetes risk over time, this ten-
dency was visible across all education groups for men. 
However, it was also most pronounced in the high educa-
tion group among men (Figure 3).
Info box 4: 
Indicators of quality of care for type 2 diabetes – 
achieving treatment goals 
Treatment goal for HbA1c: 
  In the presence of diabetes-specific complica-
tions (diabetic renal dysfunction, diabetic eye 
disease, diabetic neuropathy, diabetic foot, dia-
betes-related amputation) or cardiovascular 
comorbidity (physician-diagnosed stroke, heart 
insufficiency, heart attack or other coronary 
heart diseases) and an age ≥45 years: HbA1c 
value <8.0%
  In the absence of diabetes- specific complica-
tions and cardiovascular comorbidity: 
 For an age ≥65 years: HbA1c value <7.5%
 For an age 45 to 64 years: HbA1c value 
<7.0%
Treatment goal for non-HDL cholesterol:
 Total cholesterol serum value minus HDL 
cholesterol serum value <130 mg/dl
Treatment goal for blood pressure: 
 Systolic blood pressure <140 mmHg and 
 Diastolic blood pressure <80 mmHg
Each indicator is given as proportion (in %) of 
persons with type 2 diabetes who achieve the 
respective treatment goal in relation to all persons 
with type 2 diabetes.
Source: Nationale Diabetes-Surveillance am Robert
Koch-Institut 2018 [7], Du et al. 2015 [14]
HbA1c = glycated haemoglobin (long-term blood sugar value)
non-HDL = non-high-density lipoprotein 
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5-year risk of developing type 2 diabetes over 
time for the 18- to 79-year-old population 
without known diabetes according 
 to gender and education level 
(GNHIES98 n=3,281 women, n=3,158 men; 
DEGS1 n=3,211 women, n=2,873 men)
Source: GNHIES98 (1997-1999), 
DEGS1 (2008 –2011), Paprott et al. 2017 [13]
Figure 2
Prevalence of known and unknown diabetes 
over time for the 18- to 79-year-old population 
according to gender and education level 
(GNHIES98 n=3,328 women, n=3,147 men; 
DEGS1 n=3,628 women, n=3,342 men)
Source: GNHIES98 (1997-1999), 
DEGS1 (2008-2011), Heidemann et al. 2016 [12]
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recommendations for the prevention of cardiovascular dis-
eases in the presence of diabetes [20] (Info box 5). These 
indicators reflect results on the quality of diabetes care pro-
cesses through the respective proportion of type 2 diabetes 
patients with self-management or medical care.
For both survey periods, the indicator self-monitoring 
of blood glucose showed no significant differences between 
the low education group and the medium and high educa-
tion group. Over time, the proportion of type 2 diabetes 
patients who self-monitor their blood glucose level 
education group reached the blood pressure goal com-
pared to those in the low education group. 
Self-management and medical care
The diabetes surveillance system also considers further indi-
cators such as self-monitoring of blood glucose, medical eye 
and foot examinations as well as taking lipid-lowering 
statins based on national guidelines for the therapy of 
type 2 diabetes [16] and the prevention and treatment of 
retinal and foot complications [22, 23] as well as European 
Figure 4 
Comparison over time of the proportion of 
45- to 79-year-old persons with type 2 diabetes 
who reach the treatment goal for HbA1c, 
non-HDL cholesterol or blood pressure 
according to gender and education level 
(GNHIES98 n=161 women, n=156 men; 
DEGS1 n=226 women, n=297 men)
Source: GNHIES98 (1997-1999), 
DEGS1 (2008-2011), Du et al. [14, 21]
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twelve months tended to be lower compared to those 
with low education. And the proportion of men with higher 
levels of education who have had this examination increased 
to a smaller extend over time than for men with low edu-
cation. The proportion of persons with type 2 diabetes who 
have had their feet examined by a doctor during the last 
twelve months was lower in the higher education groups 
compared to the low education group for the period 2008 
to 2011, and this is related to the increase observed over 
time in the low education group only.
increased considerably, and this increase was similar across 
the education groups. These findings apply in principle to 
both genders, whereby the proportion of men in the two 
upper education groups who self-monitor their blood glu-
cose level is slightly higher in both survey periods com-
pared to the low education group (Figure 5). These obser-
vations cannot be fully transferred to the indicators for eye 
and foot examination. For eye examination in both survey 
waves, the proportion of women with higher levels of edu-
cation who have had this examination during the last 
Info box 5:  
Indicators of quality of care for type 2 diabetes – 
self-management and medical care
Self-monitoring of blood glucose:
 Self-monitoring of blood sugar levels
Eye examination: 
 Ophthalmologic examination of the ocular 
fundus during the last twelve months
Foot examination: 
 Medical examination of the feet during the 
last twelve months
Statin use:
 Taking the prescribed statin group medica-
tions (cholesterol synthesis-enzyme inhibi-
tors; ATC codes C10AA, C10BA)
Each indicator is given as proportion (in %) of 
persons with type 2 diabetes who achieve the 
respective care target in relation to all persons 
with type 2 diabetes.
Source: Nationale Diabetes-Surveillance am Robert
Koch-Institut 20188 [7], Du et al. 2015 [14]
ATC = Anatomical Therapeutic Chemical Classification System
Figure 5
Comparison over time of the proportion of 
 45- to 79-year-old type 2 diabetes patients 
with self-monitoring of blood glucose, 
eye examination and foot examinations 
according to gender and education level 
(GNHIES98 n=161 women, n=156 men; 
DEGS1 n=226 women, n=297 men)
Source: GNHIES98 (1997-1999), 
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time is apparent. This pattern applies to both genders 
(Figure 7).
4.  Conclusion
For public health research and health policy, analyses of 
trends in health inequality over time are a key factor to 
develop necessary target group focused prevention mea-
sures and evaluate existing prevention programmes.
As the results of this and other studies indicate, higher 
prevalence of diabetes in the low education group appears 
to be a persistent issue [12, 25-28]. The prevalence of both 
known and unknown diabetes remains twice as high in the 
low education group compared to the medium or high edu-
cation group [12]. The observed decline of unknown dia-
betes between the two survey periods, 1997 to 1999 and 
2008 to 2011, across all education groups and the simul-
taneous and roughly equivalent increase of known dia betes 
could indicate general improvements in the early detection 
of diabetes (secondary prevention). However, additional 
measures that aim at reducing the risk of developing dia-
betes (primary prevention) and focus primarily on the low 
education group seem necessary.
This fact is highlighted by the results for the 5-year risk 
of developing type 2 diabetes, which is twice as high for 
the low education group compared to the medium and 
high group and has clearly decreased only in the high edu-
cation group [13]. Studies of the individual behaviour-re-
lated risk factors of smoking and physical inactivity indicate 
a similar widening of inequality due to improvements exclu-
sively in the groups with high education or high profes-
sional status [29, 30]. In addition to prevention strategies 
For the period 1997 to 1999, a higher proportion of 
type 2 diabetes patients with higher levels of education 
took statins compared to those with low levels of educa-
tion, whereas for the period 2008 to 2011, the proportion 
of those taking statins tended to be higher in the low edu-
cation group. This result is due to a greater increase in the 
use of statins in the low education group compared to the 
higher education groups. These observations apply to both 
genders (Figure 6).
Health-related quality of life
In the diabetes surveillance, subjective assessments are 
also considered as relevant care indicators. These include 
self-perceived health-related quality of life, which is obtained 
by summing up the scales for the physical and mental 
dimensions of quality of life (Info box 6). In addition to 
objectively measureable care indicators (such as the treat-
ment goals mentioned above), self-perceived quality of life 
plays an important role for health and well-being and is 
therefore anchored as a general therapy objective in the 
national guideline for the therapy of typ 2 diabetes (‘main-
taining or regaining quality of life’) [16].
Regarding the physical dimension of health-related qual-
ity of life for type 2 diabetes patients, the period 1997 to 
1999 showed a similar – and the period 2008 to 2011 a 
slightly more positive – self-assessment in the higher edu-
cation groups compared to the low education group. This 
can be traced back to a marginally improved self-assess-
ment over time in the higher education groups. Regarding 
the self-assessed mental dimension of health-related qual-
ity of life, no differences between education groups were 
present in either survey period and a slight decline over 
Info box 6: 
Health-related quality of life of people with type 2 
diabetes 
Based on 36 questions (Short Form-36 Health Sur-
vey questionnaire, SF-36) and the scales devel-
oped from these on eight dimensions of health, 
two sum scales are calculated:
Physical dimension:
 Physical sum scale as the sum of the eight 
scales, whereby the highest weighting is given 
to the scales for physical functioning, physical 
role functioning, bodily pain and general 
health perception.
Mental dimension:
 Mental sum scale as the sum of the eight 
scales, whereby the highest weighting is giv-
en to the scales for vitality, social functioning, 
emotional role functioning and mental 
health.
Both dimensions of health-related quality of life 
can potentially achieve values between 0 and 100 
and have been transformed for a comparison 
between GNHIES98 (SF-36V1) and DEGS1 
(SF-36V2) into a sample mean of 50 and a stan-
dard deviation of 10. This article compares the 
mean values for different groups of people with 
type 2 diabetes, whereby a higher mean value rep-
resents a higher health-related quality of life.
Source: Nationale Diabetes-Surveillance am Robert
Koch-Institut 2018 [7], Ellert et al. 2013 [11]
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that aim to promote healthy lifestyles (behavioural preven-
tion), such as those already anchored in the national health 
target for type 2 diabetes [31], more emphasis needs to be 
put on the development of living environments and frame-
works that promote healthy living (structural prevention) 
and reach all education groups.
With regard to the diabetes care situation, a positive 
development has been that improvements over time have 
been achieved in several areas with no clearly visible dif-
ferences between education groups. Improvements are not 
only reflected for several indicators (HbA1c, non-HDL 
choles terol and blood pressure treatment goals, blood glu-
cose self-monitoring and eye examination) across different 
education groups in this study on the basis of RKI survey 
Figure 6
Comparison over time of the proportion of 
45- to 79-year-old persons with type 2 diabetes 
who take statins according to gender 
and education level 
(GNHIES98 n=161 women, n=156 men; 
DEGS1 n=226 women, n=297 men)
Source: GNHIES98 (1997-1999), 
DEGS1 (2008-2011), Du et al. [14, 21]
Figure 7
Comparison over time of mean values of sum 
scales for the physical and mental dimensions 
of health-related quality of life in 45- to 79-year-
old persons with type 2 diabetes 
according to gender and education level 
(GNHIES98 n=161 women, n=156 men; 
DEGS1 n=226 women, n=297 men) 
Source: GNHIES98 (1997-1999), 
DEGS1 (2008-2011), Schmidt et al. [24]
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guideline for the therapy of type 2 diabetes on specific dia-
betes complications, which encourage diabetes patients 
to play an active role in their treatment [38] as well as the 
DMP implementation for type 2 and type 1 diabetes [39]. 
Analysis of DMP data shows that a continuous DMP par-
ticipation increases the chance for patients to achieve 
defined targets for diabetes quality of care [40].
Nonetheless, the currently available study results on 
care of people with type 2 diabetes all highlight the consid-
erable potential for improvement in the prevention of sec-
ondary and concomitant diseases (tertiary prevention). In 
the present study, for example, the proportions of persons 
with type 2 diabetes who achieved the non-HDL cholesterol 
treatment goal or took statins were below 50% across all 
education groups in the period 2008 to 2011, and less than 
70% had their feet examined by a doctor. In spite of the 
mentioned improvements, KORA and DIAB-CORE data 
also indicate a suboptimal management of blood sugar 
levels and of the cardiovascular risk factors of high blood 
pressure and high LDL cholesterol levels in persons with 
type 2 diabetes [32, 33]. Moreover, DMP data from the North 
Rhine region show that only 51% of type 2 diabetes patients 
with severe foot ulcers also receive treatment from an insti-
tution specialized in treating the feet of diabetics, although 
the agreed target value is at least 75% [40]. In addition, for 
certain aspects the development over time has stagnated 
or begun to reverse. In this study, an increase in the pro-
portion of persons with type 2 diabetes who had their feet 
examined by a doctor and took statins was limited to the 
low education group. With regard to the physical dimen-
sion of quality of life, however, improvements were only 
seen in the high education group. Irrespective of the edu-
data [14]. Moreover, further sources providing additional 
data also indicate improvements in a row of aspects of 
care. Regional KORA (Cooperative Health Research in the 
Region of Augsburg) study data, for example, show an 
increase in the proportion of persons with type 2 diabetes 
who achieve their treatment goal for HbA1c, blood pressure 
and LDL cholesterol as well as a decline in the 10-year risk 
for coronary heart diseases [32]. Current data from studies 
by the DIAB-CORE (Diabetes-Collaborative Research of 
Epidemiologic Studies) consortium indicate an increase in 
awareness, treatment and control of hypertension of people 
both with and without type 2 diabetes [33]. An earlier anal-
ysis of DIAB-CORE data showed that educational level had 
no influence on the presence of a high blood pressure or 
lipid metabolism disorders in persons with type 2 diabetes 
[34]. Furthermore, data from the Disease Management Pro-
gram (DMP) from the North Rhine region reflect an 
increase in type 2 diabetes patients who achieve their blood 
pressure quality targets and have taken part in the recom-
mended diabetes course as well as a stably high proportion 
of patients with an HbA1c value <8.5%. In 2017, ten out of 
14 quantitatively assessable and contractually defined DMP 
quality targets were achieved [35]. Moreover, data from a 
regional stroke registry show that while the stroke rate has 
remained nearly constant for people without diabetes, it 
has decreased for people with diabetes [36]. National data 
from hospital statistics (DRG statistic) show a decrease in 
lower limb amputations (major amputations) in hospi-
talised diabetes patients [37]. Jointly, these positive trends 
could indicate improved outpatient care or better self-mon-
itoring of diabetes. These positive developments may also 
stem from the introduction of modules to the national 
The prevalences of known 
and unknown diabetes and 
the 5-year risk of diabetes are 
considerably higher in the 
low education group than  
in the medium or high 
education group.
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points to a less strict tertiary preventive medication ther-
apy of female compared to male diabetes patients. A pos-
sible explanation currently under discussion is the higher 
frequency of the unintended side-effects statins have on 
women than on men [49]. A further possibility is that dia-
betes is underrated as a cardiovascular risk factor in women. 
It has been shown that the cardio-protective effect in 
women compared to men is significantly reduced by the 
presence of a diabetes, in particular with regard to lipid 
metabolism disorders, central obesity and the risk for a 
heart attack [50-53]. Because cardiovascular diseases in 
men develop on average around ten years earlier compared 
to women [50, 51], it is plausible that the proportion of peo-
ple with cardiovascular comorbidities, including among 
diabetes patients, is overall considerably higher for men 
than for women, as is shown, for example, in regional reg-
istry and DMP data for the North Rhine region [36, 54, 55].
This article presents selected indicators related to dia-
betes risk, prevalence and quality of care, which will be 
continuously presented in the context of the national dia-
betes surveillance based on RKI survey data. The strengths 
of this data resource lie in the possibilities to combine 
interview data with measurement and laboratory data as 
well as with subjective perceptions, and thereby compare 
population groups stratified by gender, age or education. 
For the interpretation of stratified results in this article, it 
is important to remember that this is a descriptive analy-
sis. Extended complex analyses would be useful to analyse 
the effects of explanatory factors, such as potential age dif-
ferences between education groups and possible cohort 
effects [56], on the observed results. Furthermore, the 
assessment of social inequality in this article is based exclu-
cation level, persons with type 2 diabetes generally saw a 
slight deterioration in the mental dimensions of quality of 
life. Interestingly, an education gradient for the physical 
dimension of quality of life, with better values achieved by 
the high education group, was also observed for the 30- to 
49-year-old general population based on socioeconomic 
panel (SOEP) data. This was not, however, observed for 
the mental dimension [41]. For first-time renal replacement 
therapy, no decline was observed either in the diabetic or 
non-diabetic population based on data of a regional dialy-
sis centre [42]. Further, North Rhine DMP data indicate a 
decline in the proportion of type 2 diabetes patients who 
have had their kidney function tested during the last twelve 
months [35]. According to epidemiological studies, the inci-
dence rates of complications such as heart attack, stroke, 
lower limb amputations, loss of sight and renal insuffi-
ciency remains two to eight times higher for people with 
diabetes than for those without diabetes, despite improve-
ments observed in some of these complications [43].
Moreover, our results and further studies highlight that 
in addition to educational differences, gender differences 
also persist with regard to prevalence, risk and care of dia-
betes. Men, for example, show a higher prevalence of 
unknown diabetes compared to women [12, 44] as well as 
a higher risk of type 2 diabetes [45-47]. Regarding treatment, 
the results of this study show that for women with known 
diabetes the proportions of those who achieve the non-
HDL cholesterol treatment goal or take statins are lower 
than that of men. Extended analyses based on RKI survey 
data reflect that gender differences in statin use are no 
longer significant once a cardiovascular disease is diag-
nosed in addition to diabetes [21, 48]. This observation 
There is no evident shift of 
the education gradient in the 
prevalence of known and 
unknown diabetes over time.
For the 5-year risk of 
diabetes, there are indica-
tions of a further divergence 
in the educational gap, which 
can be attributed to a clear 
reduction of this risk in the 
high education group.
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ing new available data sources or updating of guideline 
recommendations) as well as a regular and structured pro-
vision of results [61] to promote the planning and evalua-
tion of measures aiming at reducing diabetes risk and sup-
porting early detection and optimal treatment of diabetes. 
It will thereby remain relevant to consider socioeconomic 
factors to assess the need, orientation and prevention 
potential of target group- or settings-focused measures.
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Types of diabetes are not limited to age groups: type 1 diabetes in 
adults and type 2 diabetes in children and adolescents
Abstract
Based on data from the national diabetes registry DPV (Diabetes patient documentation), the diabetes registry of North 
Rhine-Westphalia and surveys conducted at hospitals and practices in Baden-Württemberg and Saxony, this study 
estimates the incidence and prevalence of type 1 diabetes in over-18-year-old adults and type 2 diabetes in 11- to 18-year-
old children and adolescents.
The national incidence of type 1 diabetes in adults was 6.1 per 100,000 person-years from 2014 to 2016, with slightly 
lower figures for women compared to men. Annually, around 4,150 adults develop type 1 diabetes. In 2016, the prevalence 
of type 1 diabetes was estimated at 493 per 100,000 persons and was lower in women at 445 per 100,000 people than 
in men at 544 per 100,000. Based on this data, there were around 341,000 adults with type 1 diabetes in 2016.
For 11- to 18-year-old children and adolescents, the national incidence of type 2 diabetes was 2.8 per 100,000 person-years 
between 2014 and 2016 and higher for girls than for boys. Annually, around 175 adolescents in this age group develop 
type 2 diabetes. The incidence estimates for Saxony were higher (4.3 per 100,000 person-years). The prevalence of type 2 
diabetes between 2014 and 2016 for 11- to 18-year-old children and adolescents was estimated between 12 and 18 cases per 
100,000 persons. During this period, there were about 950 children and adolescents of this age group with type 2 diabetes 
in Germany.
  TYPE 1 DIABETES · TYPE 2 DIABETES · INCIDENCE · PREVALENCE · DIABETES SURVEILLANCE 
1.  Introduction
Diabetes mellitus means a chronic increase of glucose lev-
els in the body. From a health policy perspective, two forms 
of diabetes in particular play an important role: immune-me-
diated type 1 diabetes, which generally leads to absolute 
insulin deficiency, and type 2 diabetes, in which both insu-
lin resistance as well as reduced insulin secretion play a 
role. The disease reduces both life expectancy and quality 
of life, mainly due to chronic damage to small and large 
blood vessels. Data on the incidence and prevalence of 
diabetes, therefore, provide important information to build 
and further develop a diabetes care infrastructure.
Three regularly updated regional paediatric diabetes 
incidence registries from Baden-Württemberg, North 
Rhine-Westphalia (NRW) and Saxony, as well as the national 
DPV registry, provide sound data on the incidence of type 
1 diabetes in under-15-year-old children and adolescents. 
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were estimated for the first time for the age group up to 
55 years of age [11]. The incidence for 15- to 55-year olds was 
7.1 and 6.1, respectively, per 100,000 person-years.
A better data situation is given for type 2 diabetes in 
adulthood. A number of national and representative 
regional studies have analysed the prevalence and inci-
dence of known and unknown diabetes. Various publica-
tions present the results of these studies [3, 12, 13]. In par-
ticular, there are estimates based on the data from statutory 
health insurances and claims data from statutory health 
insurance-authorised physicians [7, 8].
For type 2 diabetes in adolescents, however, there is 
only insufficient data available. A study conducted in 
Baden-Württemberg between the years 2004 and 2005 
reported the prevalence of known type 2 diabetes in 0- to 
20-year-old children and adolescents as 2.3 per 100,000 
persons [14]. For North Rhine-Westphalia, the prevalence 
among 5- to 19-year-old children and adolescents in 2010 
was estimated at 5.8 per 100,000 persons. According to 
the study, 600 to 800 5- to 19-year-old children and ado-
lescents had a known type 2 diabetes in 2010 [15]. Accord-
ing to data from the nationwide DPV register, in the last 10 
years about 5% to 6% of children and adolescents aged 11 
to 18 years newly diagnosed with diabetes have type 2 dia-
betes [16]. Based on 2009 and 2010 statutory health insur-
ance data, the national prevalence for under-20-year-old 
girls and boys was estimated to be much higher at 30 and 
40 cases, respectively, per 100,000 persons [7]. On the 
basis of claims data from all over Germany, the prevalence 
in 2009 and 2015 for 0- to 19-year olds was estimated as 
66 and 41 cases per 100,000 persons, respectively [3]. How-
ever, it is a well-known fact that claims data leads to an 
These data sources also indicate the long-term trends for 
the incidence of type 1 diabetes in this age group [1-3]. In 
addition, the data from these three regional incidence reg-
istries feed into the European surveillance of 
type 1 diabetes within the framework of the EURODIAB 
(Epidemiology and Prevention of Diabetes) study group 
[4-6]. The project described here aims to make this data 
available for national level diabetes surveillance too.
However, only limited information is available on the inci-
dence of type 1 diabetes among adults. Based on the data 
from statutory health insurances, national prevalences 
across all age groups in 2009 and 2010 were estimated at 
300 cases per 100,000 persons [7]. Accordingly, there were 
around 256,000 persons with type 1 diabetes in Germany in 
2009 and 252,000 in 2010. Germany-wide claims data 
between 2009 and 2015 estimate similar prevalences, as well 
as a downward trend from 330 to 280 cases per 100,000 
persons [8]. Projected for the German population, around 
230,000 persons, accordingly, had type 1 diabetes in 2015. 
Reports from the disease management programs (DMP) of 
statutory health insurances estimated a significantly higher 
figure of around 311,000 persons with type 1 diabetes across 
all age groups for 2014 [9]. According to the DMP quality 
report for type 1 diabetes in Westfalen-Lippe, there were 
22,807 DMP registered patients across all age groups in 2015 
[10]. This corresponds to a prevalence of 314 per 100,000 
persons among those covered by statutory health insurance. 
Taking into account the estimated completeness of DMP in 
Westfalen-Lippe (78.4% to 89.4%), this would result in a 
prevalence of 351 to 400 per 100,000 persons [10].
Based on 2009 and 2010 statutory health insurance 
data, national age-specific incidences of type 1 diabetes 
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2.1. Definition of type 1 and type 2 diabetes
Our analysis uses the term type 1 diabetes only in the sense 
of ‘classical’ clinically diagnosed type 1 diabetes. The prac-
tice guidelines of the German Diabetes Association also 
classify patients with latent autoimmune diabetes in adults 
(LADA) as type 1 diabetes, i.e. a form of immune-mediated 
diabetes, which in most cases leads to complete insulin 
insufficiency in patients shortly after the onset of diabetes 
[17]. Diagnosing this form of diabetes requires complex 
laboratory examinations. However, an examination of all 
newly diagnosed adult diabetes patients for beta-cell anti-
bodies (indicating the immune reaction against insulin-pro-
ducing cells in the pancreas) and for C-peptide (reflecting 
the remaining insulin secretion by islet cells), is currently 
not diagnostic standard. This lack of standardisation means 
that results are only comparable to a limited extent, we 
therefore have not categorised LADA as type 1 diabetes. 
The diagnosis of type 2 diabetes is based on the German 
Diabetes Association’s current guidelines [18].
2.2  Data sources 
Table 1 provides an overview of the data sources used. To 
estimate the incidence and prevalence of type 1 diabetes 
in adults (≥ 18 years) in North Rhine-Westphalia and nation-
wide, the population-based diabetes registry of North 
Rhine-Westphalia [1] and the national DPV registry [19] were 
used as data sources.
The North Rhine-Westphalian registry has collected data 
for 0- to 14-year-old children and adolescents since 1996. 
overestimation of the prevalence, also because other forms 
of diabetes, when no insulin therapy is prescribed, are erro-
neously categorised as type 2 diabetes.
The diabetes registry of North Rhine-Westphalia pro-
vides estimates for the incidence of type 2 diabetes in chil-
dren and adolescents. Recently, an average incidence of 1.3 
per 100,000 person-years was estimated for the period 
2002 to 2014 for children and adolescents aged 5 to 19 
years, whereby the incidence between 2011 and 2014 was 
1.6 per 100,000 person-years. Accordingly, 130 to 160 per-
sons in the 5- to 19-year-old age group developed type 2 
diabetes annually. Again, based on Germany-wide claims 
data for the 2012 to 2014 period, a 15-fold higher incidence 
of 20 and 30 cases per 100,000 person-years was estimated 
for girls and boys under the age of 20, respectively. [8].
So far, a continuous provision of estimates based on a 
standardised methodology to account for the incidence 
and prevalence of type 1 diabetes across the entire adult 
age spectrum, as well as of type 2 diabetes in adolescents, 
has not been established in Germany, although such data 
would be relevant to diabetes surveillance and the further 
development of the infrastructure of health care provision. 
Precisely, because many diabetes prevention approaches 
target the group of young, at risk people, surveillance would 
need to reliably and promptly show changes in the inci-
dence in this age group. The objectives of this project in 
the context of diabetes surveillance at the Robert Koch 
Institute (RKI) were therefore to network with existing 
structures and develop supplementary structures for the 
continuous monitoring of the regional and the national 
incidence and prevalence in this group of patients.
Journal of Health Monitoring
Journal of Health Monitoring 2019 4(2)
Types of diabetes are not limited to age groups: type 1 diabetes in adults and type 2 diabetes in children and adolescents
32
FOCUS
and data on prevalence in Baden-Württemberg (under 
20-year-olds). 
The data source in Saxony was a survey (by post, tele-
phone or e-mail) on the number of new cases of type 2 dia-
betes in children and adolescents (11 to 18 years) in 2016 
among the clinics participating in Saxony’s diabetes regis-
try (all 31 paediatric clinics) and specialised diabetological 
practices [20, 21]. 
The data source in Baden-Württemberg was a survey 
(by telephone, e-mail or fax) on the number of children and 
adolescents with type 2 diabetes (under 20 years of age) 
treated in 2016 among the participating clinics of the DIARY 
registry (Diabetes Incidence Registry in Baden-Württem-
berg, 31 paediatric clinics and one diabetes centre) [22, 23], 
the 242 members of the German association of diabetol-
ogists (BVND) in Baden-Württemberg as well as the 266 
members of the working group diabetes in Baden-Würt-
temberg (ADBW). An initial written request was made in 
July 2017, a second request in September 2017. According 
to an earlier analysis of the prevalence of type 2 diabetes 
and the available care in Baden-Württemberg, around 50% 
of type 2 diabetes patients aged under 20 years of age are 
treated in paediatric clinics, 39% by office-based diabetol-
ogists, 7% by diabetologists in clinics, 2% in clinics and 
2% in practices without diabetologists. The current survey 
of paediatric clinics and office-based diabetologists there-
fore covers around 90% of all cases.
The population data necessary to estimate incidence 
and prevalence was obtained from the Federal Statistical 
Office. Unless otherwise stated, the population data result 
from an update of the population level for 2015 on the basis 
of the 2011 census [24], since the population data for North 
It has recorded newly diagnosed cases of type 1 and type 2 
diabetes in the 0- to 34-year-old age group since 2002 based 
on three data sources: the clinic-based German Paediatric 
Surveillance Unit (ESPED), annual surveys of medical spe-
cialists working in private practices, paediatricians, general 
practitioners, as well as the national DPV registry.
The DPV initiative was started throughout Germany in 
1995 and is a computer-aided longitudinal collection of 
data on treatment of diabetes patients and outcomes. For 
the diabetes surveillance at the RKI, only the data from 
German centres (420 institutions: 181 internal medicine 
and 239 paediatric centres) was used. Data for older age 
groups is presumably far less complete, because DPV data 
collection only began in the mid 1990s and patients aged 
over 35 years in 2016 would have developed the disease 
well before 1990. 
The incidence and prevalence of type 2 diabetes in 11- to 
18-year-old children and adolescents in North Rhine-West-
phalia and at the national level was estimated by using the 
population-based diabetes registry of North Rhine-West-
phalia and the nationwide DPV registry. In addition, data 
on incidence was collected in Saxony (11- to 18-year-olds) 
Table 1
Indicators and data sources 
Own table
Indicators Data sources 
Incidence and 
prevalence of 
type 1 diabetes 
in adults




type 2 diabetes 
in children and 
adolescents
▶ Diabetes registry of North Rhine-Westphalia
▶ DPV registry
▶ Interview survey Saxony (only incidence)
▶  Interview survey Baden-Württemberg  
(only prevalence)
DPV = Diabetes patient documentation
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therefore necessary to make a plausible assumption for 
the completeness of the DPV registry for older age groups. 
The presumed completeness of ascertainment for older 
age groups was varied in terms of a sensitivity analysis. 
Incidence and prevalence with 95% confidence intervals 
(95%-CI, range in which the true value lies with 95% cer-
tainty) were estimated applying a Poisson distribution [28, 
29]. A detailed description of the methodology can be found 
in [25-29].
3.  Results 
3.1  Incidence of type 1 diabetes
Incidence of type 1 diabetes in 18- to 34-year-olds in 
North Rhine-Westphalia between 2014 and 2016 
Between 2014 and 2016, the Rhine-Westphalian diabetes 
registry recorded 391 newly diagnosed type 1 diabetes 
patients in the 18- to 34-year-old age group. This is an inci-
dence of 3.6 per 100,000 person-years. The registry cap-
tured an estimated 29.5% of the population; adjusted for 
undereporting, the incidence was therefore estimated at 
12.0 per 100,000 person-years (Table 2). Correspondingly, 
the absolute figure for new cases between 2014 and 2016 
was 1,326, i.e. an average of 442 new cases per year. Adjust-
ed for undereporting, the incidence for women was only 
about half that for men (7.9 vs. 16.1 per 100,000 per-
son-years) and the incidence was slightly higher for 18- to 
24-year-olds than for 25- to 34-year-olds (12.9 vs. 11.7 per 
100,000 person-years). Table 2 also shows the incidence 
for registered cases by age and gender.
Rhine-Westphalia (and Baden-Württemberg) were not yet 
available for 2016 at the time of the analysis. This also 
applies to the calculations for person years 2014 to 2016, 
which are based on 2014 and two times on 2015.
2.3  Statistical methods
The recording of new cases of diabetes by the registry of 
North Rhine-Westphalia, which is based on three data 
sources, allows estimating the completeness of the data 
collected by applying capture-recapture methods. Thereby, 
the proportion of patients who appear in more than one 
data source allows an estimate of the number of patients 
who were not recorded. Subsequently, the figures can then 
be adjusted. To estimate the completeness of the data col-
lected, a suitable statistical model was adapted to the data 
(log-linear model that accounts for overdispersion) [25, 26]. 
After applying a standard statistical criterion (AICC [27]), 
the model was chosen that best describes the available 
registry data. Both the completeness of the registry in gen-
eral and, in addition, of the DPV database was estimated.
Estimates regarding the completeness of the North 
Rhine-Westphalia registry were used to calculate estimates 
corrected for underreporting for the incidence and preva-
lence in North Rhine-Westphalia from the data observed 
in the North Rhine-Westphalia registry. Estimates for the 
completeness of the DPV data basis for North Rhine-West-
phalia were used to calculate ascertainment corrected esti-
mates of incidence and prevalence for Germany in national 
DPV data. Based on the North Rhine-Westphalia and DPV 
registries, completeness of ascertainment could only 
be estimated for the 18- to 34-year-old age group; it was 
Currently, around 4,150 
adults and 3,100 children 
and adolescents (aged 0 to 17) 
develop type 1 diabetes 
annually.
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(Table 2). The ascertainment rate of DPV for the 18- to 34-year-
old age group was estimated at 17.2% based on the North 
Rhine-Westphalia registry. Assuming that DPV has the 
same capture rate in older age groups too, the incidence 
in the age group 18 years and older adjusted for undere-
porting was estimated as 6.1 per 100,000 person-years. 
Incidence of type 1 diabetes in adults over 18 years of age 
in Germany between 2014 and 2016
Between 2014 and 2016, 2,144 patients at least 18 years of 
age were registered in the DPV diabetes registry with newly 
diagnosed type 1 diabetes. Against 205,986,915 person-years 
[31], this is an incidence of 1.0 per 100,000 person-years 
Study population 2014 - 2016
Incident cases Incidence (95% CI)1
Registered CR2 Adjusted3,4 Registered5 Adjusted3
North Rhine-Westphalia 18-34 years
Total 391 29.5% 1,326 3.6 (3.2-3.9) 12.0 (11.4-12.7)
Women 138 32.6% 423 2.6 (2.2-3.1) 7.9 (7.2-8.7)
Men 253 27.8% 911 4.5 (3.9-5.1) 16.1 (15.1-17.2)
18-24 years 184 32.3% 569 4.2 (3.6-4.8) 12.9 (11.9-14.0)
25-34 years 207 26.8% 772 3.2 (2.7-3.6) 11.7 (10.9-12.5)
Germany ≥18 years
Total 2,144 17.2%6 12,495 1.0 (1.0-1.1) 6.1 (6.0-6.2)
Women 895 15.7%6 5,685 0.9 (0.8-0.9) 5.4 (5.3-5.5)
Men 1,249 21.3%6 5,857 1.2 (1.2-1.3) 5.8 (5.7-6.0)
18-24 years 436 17.2% 2,541 2.3 (2.1-2.5) 13.5 (12.9-14.0)
25-34 years 546 17.2% 3,182 1.7 (1.6-1.9) 10.1 (9.8-10.5)
35-44 years 367 17.2%7 2,139 1.2 (1.1-1.4) 7.2 (6.9-7.5)
45-54 years 384 17.2%7 2,238 1.0 (0.9-1.1) 5.6 (5.3-5.8)
55-64 years 226 17.2%7 1,317 0.7 (0.6-0.8) 3.9 (3.7-4.1)
65-74 years 122 17.2%7 711 0.5 (0.4-0.6) 2.9 (2.6-3.1)
≥75 years 63 17.2%7 367 0.2 (0.2-0.3) 1.4 (1.2-1.5)
CR  = coverage rate, ESPED = German Paediatric Surveillance Unit, DPV = diabetes patient documentation,  
AICC = Akaike information criterion, adjusted version for small samples, CI = Confidence interval
1  per 100,000 person-years
2  Estimated coverage rate based on capture-recapture analysis using three sources of data (ESPED, practices, DPV) according to best log linear model based on 
AICC criterion with main effects ESPED, practices and DPV for models of incidence and prevalence, and interactions ESPED*practices and ESPED*DPV for 
prevalence models for the data from the diabetes registry North Rhine-Westphalia (type 1 diabetes 18- to 34-years-old, type 2 diabetes 11- to 18-years-old)
3  Adjusted according to the estimated underreporting
4  The sum of adjusted case numbers for both genders and/or age groups may not correspond to the adjusted case number for the total group because the number 
of cases is estimated based on different log linear models
5  Estimated based on registered number of cases
6  Estimated as sum of all captured cases across all age groups divided by the sum of all cases adjusted by under-coverage for all age groups
7  Assumed DPV coverage rate according to the 18- to 34-year-old age group
Table 2 
Incidence and prevalence 
of type 1 diabetes in Germany
Source: Diabetes registry of North Rhine-West-
phalia, Diabetes patient documentation 
(DPV registry) [1, 19] Continued on next page
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Study population 2016 (2015, 2014)
Prevalent cases Prevalence (95% CI)1
Registered CR2 Adjusted3,4 Registered5 Adjusted3
North Rhine-Westphalia 18-34 years
Total 11,284 72.5% 15,554 303.8 (298.3-309.5) 418.8 (412.3-425.4)
10,803 70.4% 15,352 290.9 (285.4-296.4) 413.4 (406.9-420.0) (2015)
10,291 67.2% 15,313 286.6 (281.1-292.2) 426.4 (419.7-433.2) (2014)
Women 5,123 72.9% 7,030 285.7 (277.9-293.6) 392.1 (382.9-401.3)
Men 6,161 72.5% 8,499 320.8 (312.8-328.9) 442.5 (433.1-452.0)
18-24 years 5,099 88.6% 5,754 344.1 (334.7-353.7) 388.3 (378.4-398.5)
25-34 years 6,185 59.6% 10,379 277.1 (270.2-284.1) 465.0 (456.1-474.0)
Germany ≥18 years
Total 83,215 24.4%6 340,664 120.5 (119.7-121.3) 493.3 (491.7-495.0)
79,812 24.1%6 331,203 115.9 (115.1-116.7) 481.1 (479.4-482.7) (2015)
76,450 23.6%6 324,393 112.3 (111.5-113.1) 476.4 (474.8-478.1) (2014)
Women 38,733 24.7%6 157,063 109.7 (108.6-110.8) 445.0 (442.8-447.2)
Men 44,582 24.2%6 183,446 131.8 (130.6-133.0) 543.5 (541.0-546.0)
18-24 years 21,259 79.1% 26,879 336.1 (331.6-340.6) 425.0 (419.9-430.0)
25-34 years 22,978 42.6% 53,932 217.0 (214.2-218.4) 509.4 (505.1-513.7)
35-44 years 10,131 15.0%7 67,540 102.5 (100.5-104.5) 683.6 (678.4-688.8)
45-54 years 9,702 15.0%7 64,680 73.3 (71.8-74.7) 488.4 (484.6-492.1)
55-64 years 8,072 15.0%7 53,813 70.2 (68.6-71.7) 467.8 (463.8-471.7)
65-74 years 5,229 15.0%7 34,860 63.6 (61.9-65.4) 424.2 (419.7-428.6)
≥75 years 5,844 15.0%7 38,960 62.9 (61.3-64.5) 419.3 (415.3-423.5)
CR  = coverage rate, ESPED = German Paediatric Surveillance Unit, DPV = diabetes patient documentation,  
AICC = Akaike information criterion, adjusted version for small samples, CI = Confidence interval
1  per 100,000 persons
2  Estimated coverage rate based on capture-recapture analysis using three sources of data (ESPED, practices, DPV) according to best log linear model based on 
AICC criterion with main effects ESPED, practices and DPV for models of incidence and prevalence, and interactions ESPED*practices and ESPED*DPV for 
prevalence models for the data from the diabetes registry North Rhine-Westphalia (type 1 diabetes 18- to 34-years-old, type 2 diabetes 11- to 18-years-old)
3  Adjusted according to the estimated underreporting
4  The sum of adjusted case numbers for both genders and/or age groups may not correspond to the adjusted case number for the total group because the number 
of cases is estimated based on different log linear models
5  Estimated based on registered number of cases
6  Estimated as sum of all captured cases across all age groups divided by the sum of all cases adjusted by under-coverage for all age groups
7  Assumed DPV coverage rate according to the 18- to 34-year-old age group
Table 2 Continued 
Incidence and prevalence 
of type 1 diabetes in Germany
Source: Diabetes registry of North Rhine-West-
phalia, Diabetes patient documentation 
(DPV registry) [1, 19]
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3.2  Prevalence of type 1 diabetes
Prevalence of type 1 diabetes in 18- to 34-year-olds in 
North Rhine-Westphalia between 2014 and 2016
In 2016, 11,285 patients with type 1 diabetes aged 18 to 34 
years were registered in the North Rhine-Westphalian dia-
betes registry. Against a total population of 3,713,823 [31], 
the prevalence was 303.8 per 100,000 persons (Table 2). 
The estimated coverage rate was 72.5%, and the 
underreporting-adjusted prevalence was therefore estimat-
ed at 418.8 per 100,000 persons. Accordingly, in 2016, 
around 15,554 adults in the 18- to 34-year-old age group 
had type 1 diabetes in North Rhine-Westphalia. Adjusted 
for underreporting, the prevalence was 426.4 per 100,000 
persons in 2014 and 413.4 per 100,000 persons in 2015. 
In 2016, the underreporting-adjusted prevalence for wom-
en was around 12% to 13% lower than for men (392.1 vs. 
442.5 per 100,000 persons, Figure 1) and the adjusted 
prevalence was significantly higher for 25- to 34-year-olds 
compared to 18- to 24-year-olds (465.0 vs. 388.3 per 
Accordingly, there was an absolute number of 12,495 new 
cases between 2014 and 2016, i.e. an average of 4,165 new 
cases per year. Assuming a completeness of DPV in the age 
group over 35 years of 22.2% or 12.2% (17.2±5%), this gives 
an adjusted incidence estimate of 5.3 (95% CI 5.2-5.4) or 7.4 
(95% CI 7.3-7.5) per 100,000 person-years. The absolute 
number of new cases was then estimated as 3,653 and 5,082.
The incidence adjusted for undereporting of type 1 dia-
betes was slightly lower for women compared to men (5.4 
vs. 5.8 per 100,000 person-years) and decreased continu-
ously with age, from 13.5 per 100,000 person-years in 18- 
to 24-year-olds to 1.4 per 100,000 person-years in the group 
aged at least 75. Table 2 moreover shows the incidence for 
registered cases by age and gender as well as correspond-
ing estimates of ascertainemnet rates and incidences.
Incidence and number of new cases of type 1 diabetes 
among children and adolescents aged 0 to 17 years in 
Germany
To provide a fuller picture, we include previously published 
figures on paediatric type 1 diabetes patients. According to 
current estimates from North Rhine-Westphalia, the inci-
dence for type 1 diabetes in the 0- to 17-year-old age group 
is 23.6 per 100,000 person-years, so that for Germany we 
can assume a figure of 3,100 new cases of type 1 diabetes 
annually [30].
Total number of new cases of type 1 diabetes for Germa-
ny (all age groups)
Based on these estimates, annually, around 7,265 persons 









North Rhine-Westphalia 2016 Germany 2016
Prevalence of type 1 diabetes
Around 341,000 adults  
and 32,000 children and 




of type 1 diabetes according to gender 
in the age groups 18 to 34 years 
(North Rhine-Westphalia) 
and 18 years and older (projected for Germany)
Source: Diabetes registry of North Rhine- 
Westphalia, Diabetes patient documentation 
(DPV registry) [1, 19]
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Prevalence and number of children and adolescents aged 
0 to 17 years with type 1 diabetes in Germany
According to current estimates from North Rhine-West-
phalia, the prevalence of type 1 diabetes in the 0- to 17-year-
old age group was 240 per 100,000 persons, which means 
that around 32,000 children and adolescents in Germany 
had type 1 diabetes [32].
Total number of persons with type 1 diabetes in Germany
Based on these estimates, the total number of type 1 dia-
betes patients across all age groups in Germany is current-
ly almost 373,000.
3.3  Incidence of type 2 diabetes in children and adoles-
cents
Incidence of type 2 diabetes in children and adolescents 
aged 11 to 18 years in North Rhine-Westphalia between 
2014 and 2016
Between 2014 and 2016, 105 patients with newly diagnosed 
type 2 diabetes aged 11 to 18 years were registered in the 
North Rhine-Westphalian diabetes registry. Against a total 
of 4,308,426 person-years, the incidence was 2.4 per 
100,000 person-years (Table 3). The registry coverage rate 
was 71.9%, and the estimated underreporting-adjusted 
incidence, correspondingly, 3.4 per 100,000 person-years. 
Accordingly, there were an absolute number of 146 new 
cases between 2014 and 2016, which is an average annual 
incidence of 49 cases. For girls, the underreporting-adjust-
ed incidence rate was over 60% higher than for boys (4.2 
vs. 2.6 per 100,000 person-years). No significant difference 
was found between the 11- to 14-year-old and the 15- to 18 
100,000 persons). Furthermore, Table 2 shows the preva-
lence for registered cases by age and gender as well as the 
corresponding coverage rates and prevalence estimates.
Prevalence of type 1 diabetes in adults over 18 years of 
age in Germany between 2014 and 2016
In 2016, 83,215 patients with type 1 diabetes aged 18 years or 
older were registered in the DPV diabetes registry. Against a 
population of 69,051,391 (as at 31.12.2016) [31], the prevalence 
was 120.5 per 100,000 persons (Table 2). The coverage rate 
of DPV in the 18- to 24 and 25- to 34-year-old age group was 
estimated as 79.1% and 42.6%, respectively. Assuming a DPV 
coverage rate of 15% in the higher age groups, a prevalence 
of 493.3 per 100,000 persons was estimated for the age group 
of 18 years or older in 2016. For 2015 and 2014, the underre-
porting-adjusted prevalence was 481.1 and 476.4 per 100,000 
persons, respectively. Correspondingly, in 2016, 340,664 
adults had type 1 diabetes in Germany. Assuming a DPV 
coverage rate of the age group over 35 years of 20% and 10%, 
respectively, an adjusted prevalence estimate of 399.3 
(95% CI 397.8-400.8) and 681.5 (95% CI 679.6-683.5) per 
100,000 persons resulted for 2016. The absolute number of 
adults with type 1 dia betes was then estimated to be 275,701 
and 470,591, respectively, in 2016.
The underreporting-adjusted prevalence in 2016 was 
around 18% lower for women than for men (445.0 vs. 543.5 
per 100,000 persons, Figure 1). Moreover, in 2016, the 
underreporting-adjusted prevalence rose from 425.0 per 
100,000 persons in the 18- to 24-year-old age group to 
683.6 per 100,000 persons in the 35- to 44-year-old age 
group and then decreased with age continuously to 419.3 
per 100,000 persons aged 75 and over (Table 2).
Currently, about 175 children 
and adolescents aged  
11 to 18 years develop  
type 2 diabetes annually.
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Incidence of type 2 diabetes in children and adolescents 
aged 11 to 18 years in Saxony in 2016
The 2017 interview surveys in Saxony achieved response 
rates of 100% among paediatric hospitals (n=31) and 88.1% 
among diabetological practices (n=119). In 2016, ten new 
cases of type 2 diabetes were registered, three cases in 
paediatric clinics and seven in diabetological practices. 
year-old age group (3.5 vs. 3.3 per 100,000 person-years). 
Table 3 also shows the incidence for registered cases by age 
and gender, as well as the corresponding estimates of cov-
erage rates and incidences.
Study population 2014-2016
Incident cases Incidence (95% CI)1
Registered CR2 Adjusted3,4 Registered5 Adjusted3
North Rhine-Westphalia 11-18 years
Total 105 71.9% 146 2.4 (2.0-3.0) 3.4 (2.9-4.0)
Girls 63 72.4% 87 3.0 (2.3-3.9) 4.2 (3.4-5.2)
Boys 42 72.4% 58 1.9 (1.4-2.6) 2.6 (2.0-3.4)
18-24 years 53 74.6% 71 2.6 (2.0-3.4) 3.5 (2.7-4.4)
25-34 years 52 69.2% 75 2.3 (1.7-3.0) 3.3 (2.6-4.1)
Saxony 11-18 years
10 90.9%6 11 4.0 (1.5-6.4) 4.3 (1.8-6.9) (2016)
21 84.0%6 25 4.2 (2.4-6.1)  5.1 (3.1-7.1) (2014/2015)7
Germany 11-18 years
Total 273 51.6% 529 1.5 (1.3-1.6) 2.8 (2.6-3.1)
Girls 172 55.1% 312 1.9 (1.6-2.2) 3.4 (3.1-3.9)
Boys 101 45.7% 221 1.1 (0.9-1.3) 2.3 (2.0-2.6)
11-14 years 81 57.7% 140 0.9 (0.7-1.1) 1.6 (1.3-1.9)
15-18 years 192 49.3% 389 2.0 (1.7-2.3) 4.0 (3.6-4.4)
CR  = coverage rate, ESPED = German Paediatric Surveillance Unit, DPV = diabetes patient documentation,  
AICC = Akaike information criterion, adjusted version for small samples, CI = Confidence interval
1  per 100,000 person-years
2  Estimated coverage rate based on capture-recapture analysis using three sources of data (ESPED, practices, DPV) according to best log linear model based on 
AICC criterion with main effects ESPED, practices and DPV for models of incidence and prevalence, and interactions  ESPED*practices and ESPED*DPV for 
prevalence models for the data from the diabetes registry North Rhine-Westphalia (type 1 diabetes 18- to 34-years-old, type 2 diabetes 11- to 18-years-old)
3  Adjusted according to the estimated underreporting
4  The sum of adjusted case numbers for both genders and/or age groups may not correspond to the adjusted case number for the total group because the number 
of cases is estimated based on different log linear models.
5  Estimated based on registered number of cases
6 Response rate for surveys of paediatric and diabetological practices in Saxony
7 Estimated total coverage rate by [14]
Table 3
Incidence and prevalence of type 2 diabetes 
in Germany
Source: Baden-Württemberg DIARY 
(Diabetes Incidence Registry), diabetes registry 
of North Rhine-Westphalia, diabetes registry of 
Saxony, Diabetes patient documentation 
(DPV registry) [1, 19-23] Continued on next page
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an incidence – adjusted for the estimated coverage rate  – 
of 5.1 per 100,000 person-years.
Against a total of 252,919 person-years, this was an inci-
dence of 4.0 per 100,000 person-years (Table 3). Adjusted 
for the response rate, the incidence was 4.3 per 100,000 
person-years. For 2014 to 2015, previous surveys estimated 
Study population 2016 (2015, 2014)
Prevalent cases Prevalence (95% CI)1
Registered CR2 Adjusted3,4 Registered5 Adjusted3
North Rhine-Westphalia 11-18 years
Total 150 77.3% 194 10.4 (8.8-12.2) 13.5 (11.7-15.5)
167 76.6% 218 11.6 (9.9-13.5) 15.2 (13.2-17.3) (2015)
165 78.2% 211 11.5 (9.8-13.4) 14.7 (12.8-16.9) (2014)
Girls 91 76.5% 119 13.1 (10.6-16.1) 17.2 (14.2-20.6)
Boys 59 78.7% 75 7.9 (6.0-10.2) 10.1 (7.9-12.6)
11-14 years 30 71.4% 42 4.5 (3.0-6.4) 6.2 (4.5-8.4)
15-18 years 120 78.4% 153 15.7 (13.0-18.8) 20.0 (17.0-23.5)
Baden-Württemberg <20 years
80 90.0%6 89 3.8 (3.0-4.6) 4.2 (3.4-5.2) (2016)
50 90.0%6 56 2.4 (1.8-3.1) 2.7 (2.0-3.5) (2015)6
Germany 11-18 years
Total 445 58.7% 758 7.1 (6.5-7.8) 12.2 (11.3-13.0)
554 57.2% 968 8.8 (8.1-9.5) 15.4 (14.4-16.3) (2015)
652 57.4% 1,136 10.5 (9.7-11.3) 18.2 (17.2-19.3) (2014)
Girls 273 60.4% 452 9.1 (8.0-10.2) 15.1 (13.7-16.5)
Boys 172 55.8% 308 5.3 (4.5-6.1) 9.6 (8.5-10.6)
11-14 years 106 54.8% 194 3.6 (2.9-4.3) 6.6 (5.6-7.5) 
15-18 years 339 60.1% 564 10.4 (9.3-11.5) 17.2 (15.8-18.7)
CR  = coverage rate, ESPED = German Paediatric Surveillance Unit, DPV = diabetes patient documentation,  
AICC = Akaike information criterion, adjusted version for small samples, CI = Confidence interval
1  per 100,000 persons
2  Estimated coverage rate based on capture-recapture analysis using three sources of data (ESPED, practices, DPV) according to best log linear model based on 
AICC criterion with main effects ESPED, practices and DPV for models of incidence and prevalence, and interactions  ESPED*practices and ESPED*DPV for 
prevalence models for the data from the diabetes registry North Rhine-Westphalia (type 1 diabetes 18- to 34-years-old, type 2 diabetes 11- to 18-years-old)
3  Adjusted according to the estimated underreporting
4  The sum of adjusted case numbers for both genders and/or age groups may not correspond to the adjusted case number for the total group because the number 
of cases is estimated based on different log linear models.
5  Estimated based on registered number of cases
6 Estimated total coverage rate by [14]
Table 3 Continued
Incidence and prevalence of type 2 diabetes 
in Germany
Source: Baden-Württemberg DIARY 
(Diabetes Incidence Registry), diabetes registry 
of North Rhine-Westphalia, diabetes registry of 
Saxony, Diabetes patient documentation 
(DPV registry) [1, 19-23]
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estimated at 13.5 per 100,000 persons. For 2015, the under-
reporting-adjusted prevalence was 15.2, and for 2014 14.7 
per 100,000 persons. Accordingly, in 2016, 194 11- to 
18-year-old children and adolescents had diagnosed type 2 
diabetes, 218 in 2015 and 211 in 2014. In 2016, the under-
reporting-adjusted prevalence was 70% higher for girls 
than for boys (17.2 vs. 10.1 per 100,000 persons) and 
around three times higher for 15- to 18-year-olds compared 
to 11- to 14-year-olds. Table 3 also shows the prevalence for 
recorded cases by age and gender as well as the corre-
sponding coverage rates and prevalence estimates.
Prevalence of type 2 diabetes in children and adolescents 
under 20 years of age in Baden-Württemberg
In the 2017 survey in Baden-Württemberg, the response 
rate for the paediatric DIARY network (31 paediatric clinics 
and 1 diabetes centre) was 78.1% (25/32) and for diabetol-
ogists caring for adults 21.4% (57/266) (BVND 14.5% 
(35/242), ADBW 8.3% (22/266)). 
In 2016, a total of 80 patients with type 2 diabetes under 
the age of 20 years were recorded in Baden-Württemberg 
(Table 3), 34 patients in the DIARY network, i.e. in paedi-
atric care, 26 BVND patients and 20 patients in the regional 
ADBW association. For a population of 2,097,929 children 
and adolescents [31], this is a prevalence of 3.8 per 100,000 
persons. Taking account of the estimated 90% coverage 
rate provides a prevalence of 4.2 per 100,000 persons. 
A previous estimate had reported a lower prevalence of 2.4 
(95% CI 1.8-3.1) and a lower adjusted prevalence of 2.7 (95% 
CI 2.0-3.5) per 100,000 persons.
Incidence of type 2 diabetes in children and adolescents 
aged 11 to 18 years in Germany between 2014 and 2016
Between 2014 and 2016, 273 patients with newly diagnosed 
type 2 diabetes aged 11 to 18 years were registered in the 
DPV diabetes registry. With a total of 18,774,057 per-
son-years [31], this resulted in an incidence of 1.5 per 
100,000 person-years (Table 3). The DPV coverage rate was 
51.6%, so that a underreporting-adjusted incidence of 2.8 
per 100,000 person-years was estimated. Accordingly, there 
was an absolute number of 529 new cases between 
2014 and 2016, i.e. an average of 176 new cases per year. 
Adjusted for underreporting, the incidence for girls was 
50% higher than for boys (3.4 vs. 2.3 per 100,000 person- 
years). Adjusted for underreporting, the incidence in the 
15- to 18-year-old age group was 2.5 times higher than in 
the 11- to 14-year-old age group (4.0 vs. 1.6 per 100,000 
person-years). Table 3 moreover shows the incidence for 
recorded cases by age and gender, as well as correspond-
ing estimates of coverage rates and incidences.
3.4  Prevalence of type 2 diabetes in children and adoles-
cents 
Prevalence of type 2 diabetes in children and adolescents 
aged 11 to 18 years in North Rhine-Westphalia between 
2014 and 2016
In 2016, 150 patients with type 2 diabetes aged 11 to 18 years 
were registered in the diabetes registry of North Rhine-West-
phalia. For a population of 1,437,776 adolescents of this 
age group [31], this is a prevalence of 10.4 per 100,000 per-
sons (Table 3). The estimated coverage rate was 77.3%, and 
the underreporting-adjusted prevalence was therefore 
Around 950 children and 
adolescents aged 11 to 18 
years have type 2 diabetes.
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For the first time, current estimates for the incidence of 
type 1 diabetes across all age groups for adults aged over 
18 are provided. For young adults aged 18 to 34 years, the 
incidence estimates from North Rhine-Westphalia fit well 
to national incidence figures (12.0 vs. 11.8 per 100,000 per-
son-years). For the group of all adults (aged over 18) a low-
er incidence of an estimated 6.1 per 100,000 person-years 
was found, which reflects the decreasing incidence of 
type 1 diabetes with age. Statutory health insurance data 
provides a similar incidence, yet only for the limited age 
ranges 15 to 55 (7.1 per 100,000 person-years) and 20 to 55 
(6.1 per 100,000 person-years) [11]. As the incidence of 
type 1 diabetes decreases with age, the incidence estimates 
for all adults based on statutory health insurance data 
should be lower.
According to the current prevalence estimate (493 per 
100,000 persons), about 341,000 adults at the age of at 
least 18 years are affected by type 1 diabetes at the national 
level. This estimate is higher than previous ones based on 
statutory health insurance data. According to the reports 
of the structured treatment programs run by statutory 
health insurances (DMP programs), there were around 
279,000 type 1 diabetes patients over 18 years of age in 
Germany in 2014 [9]. Prevalence estimates based on stat-
utory health insurance data estimated that there were 
229,000 adults aged over 20 with type 1 diabetes in Ger-
many in 2009 and 224,000 in 2010. Prevalences calculated 
on the basis of claims data yielded 262,000 type 1 diabetes 
Prevalence of type 2 diabetes in children and adolescents 
aged 11 to 18 years in Germany between 2014 and 2016
In 2016, 445 patients with type 2 diabetes aged 11 to 18 
years were registered in the DPV diabetes registry. Against 
a population of 6,237,040 children and adolescents (as at 
31.12.2016) [31], this is a prevalence of 7.1 per 100,000 
(Table 3). Coverage rate was an estimated 58.7%, giving an 
estimated underreporting-adjusted prevalence of 12.2 per 
100,000 persons. The underreporting-adjusted prevalence 
was 15.4 for 2015 and 18.2 per 100,000 persons for 2014. 
Accordingly, in 2016, 758 11- to 18-year-old children and 
adolescents had type 2 diabetes. In 2014 and 2015, it was 
1,136 and 968 children and adolescents, respectively, i.e. 
an average of around 950 children and adolescents in the 
years 2014 to 2016. In 2016, the underreporting-adjusted 
prevalence was nearly twice as high for girls compared to 
boys (15.1 vs. 9.6 per 100,000 persons, Figure 2) and 
around 2.5 times higher for 15- to 18-year-olds compared 
to 11- to 14-year-olds. Table 3 also shows the prevalence for 
recorded cases by age and gender as well as the corre-








North Rhine-Westphalia 2016 Germany 2016
Prevalence of type 2 diabetes
Incidence and prevalence of 
type 1 diabetes is lower in 
women than in men.
Figure 2
Underreporting-adjusted prevalence 
of type 2 diabetes according to gender 
in the age group 11 to 18 years
Source: Diabetes registry of North Rhine- 
Westphalia, Diabetes patient documentation
(DPV registry) [1, 19]
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surveillance at the RKI. Both DIARY clinics, all ADBW (work-
ing group diabetes in Baden-Württemberg) members, as 
well as the BVND (German association of diabetologists) 
in Baden-Württemberg took part in the survey. 
The first prevalence survey in Baden-Württemberg was 
conducted between 2004 and 2006 and indicated a preva-
lence of 2.4 per 100,000 persons (95% CI 1.7-3.1) for the 
age group under 20 years. For 2015, the prevalence was 
2.3 per 100,000 persons (95% CI 1.7-2.9). During a ten year 
period, the prevalence of type 2 diabetes in adolescents 
therefore remained stable [14]. An update within the con-
text of this sub-project of the national diabetes surveillance 
showed a prevalence of 2.4 (adjusted for undereporting 
2.7) for 2015 for 100,000 persons, yet a significantly higher 
prevalence of 3.8 (adjusted for underreporting 4.2) per 
100,000 persons for 2016.
Point estimates for the incidence of type 2 diabetes vary 
significantly for North Rhine-Westphalia, Saxony and Ger-
many overall, yet taking into account the uncertainty of 
estimates relativises these differences. All current estimates 
are higher than the average incidence in North Rhine-West-
phalia between 2002 and 2014, a fact which indicates an 
increase in the rate of new cases. The incidence between 
2012 and 2014 for under-20-year-olds estimated on the 
basis of claims data is many times higher [8]. Presumably 
this is due to the differences in forms of data collection 
and different case definitions. The observed changes to the 
incidence in Saxony are probably related to random fluctu-
ations in incidence of this ultimately rare disease, as well 
as the potential factor of differences in the quality of data 
collection. Due to the great uncertainty of estimates (broad 
confidence intervals), evidence for incidence changes is 
patients in 2009 and 230,000 in 2015 [3]. However, because 
they fail to account for the privately insured – around 10% 
of the population – incidence and prevalence estimates 
based on statutory health insurance data most likely under-
estimate the true number of cases.
Combined with estimates for the 0- to 17-year-old age 
group, there are around 7,250 new cases of type 1 diabetes 
annually in Germany and there is a total of about 373,000 
type 1 diabetes patients.
Type 2 diabetes
At the turn of the millennium, reports on a significant 
increase of cases of type 2 diabetes at adolescent age began 
to multiply. Such reports came mainly from North Ameri-
ca and Asia, and were based on an increase in the obesity 
prevalence in this age group [33, 34]. This was contrasted 
by European surveys, which pointed at a significantly low-
er prevalence of type 2 diabetes in adolescents [14, 35-37]. 
Between 2004 and 2006, the first comprehensive 
cross-sectional study of type 2 diabetes among children 
and adolescents was conducted in Baden-Württemberg 
[14]. With its population of 10.7 million, of which 22.7% are 
under 20 years of age, Baden-Württemberg is the third larg-
est federal state. With the DIARY network (Diabetes Inci-
dence Registry), Baden-Württemberg has a federal state 
wide comprehensive surveying structure that binds in all 
paediatric clinics in the state, as well as one diabetes cen-
tre. The first cross-sectional survey was conducted within 
the framework of this network and with the participation 
of internal medicine clinics and diabetological practices. 
In 2016, ten years later, a new cross-sectional survey was 
conducted as a sub-project with the national diabetes 
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neighbouring countries such as Sweden [36], the UK [35] 
or Austria [37]. Compared to North America and Asia, 
type 2 diabetes among children and adolescents therefore 
remains a (still) relatively rare disease in Germany [39].
While the observed regional differences in the incidence 
and prevalence of type 2 diabetes among children and ado-
lescents may point to actual regional differences, they could 
also be related to differences in surveying methods and 
coverage rates. Regional differences in the disease rate of 
type 2 diabetes among adults, in particular a North-South 
and an East-West gradient have been described by the 
DIAB-CORE (Diabetes-Collaborative Research of Epidemi-
ologic Studies) project of the diabetes competency network 
and secondary analyses of statutory health insurance data 
[8, 40, 41]. Type 2 diabetes, as well as the key risk factor 
obesity, are closely tied to individual social status and 
regional levels of deprivation [42-44]. However, differences 
in surveying methods and the quality of data collection also 
influence incidence and prevalence estimates. In North 
Rhine-Westphalia, more than 20% of patients were found 
in general practitioners' practices, a care level that was not 
comprehensively covered by the survey in Baden-Württem-
berg. Due to local and historical specificities, there are dif-
ferences in the diabetological treatment patients receive 
depending on whether they are living in Baden-Württem-
berg, Saxony or North Rhine-Westphalia.
4.2 Limitations
Type 1 diabetes
The analyses only took into account patients with a medi-
cal diagnosis of ‘classical’ type 1 diabetes. In routine care, 
lacking and results from longer periods of observation are 
to be seen.
Point estimates for the prevalence of type 2 diabetes in 
North Rhine-Westphalia, Baden-Württemberg and Germany 
overall likewise show substantial discrepancies. Particularly 
notable is the low prevalence in Baden-Württemberg 
(2015/2016: 2.4/3.8 and adjusted for underreporting 2.7/4.2 
per 100,000 persons) compared to North Rhine-Westphalia 
and nationwide estimates (12 – 18 per 100,000 persons). 
Based on statutory health insurance data, the estimates for 
the prevalence for under-20-year-olds were many times 
higher. For 2009 to 2010, the prevalence was estimated as 
30 to 40 per 100,000 persons [7]. Age-specific estimates 
reported in [8] provided an estimated prevalence of 66 or 
41 per 100,000 persons for 2009 and 2015, respectively. 
The great discrepancy with regard to other surveys is pre-
sumably linked to differences in surveying methods and a 
different classification of type 2 diabetes.
All data sources point to a higher number of female 
adolescent type 2 diabetes cases. Higher body fat and a 
lower insulin sensitivity, as well as lower levels of physical 
activity among obese female children and adolescents 
could play a causal role here.
The fact that the frequency of type 2 diabetes in this age 
group in central Europe is far lower than for example in 
North America can be explained by the ethnic composition 
of the population. People of Afro-American and Hispan-
ic-American background, from Asia and the Pacific Islands, 
as well as Native Americans have a significantly higher 
type 2 diabetes risk and are not an important proportion 
of the European population [38]. The prevalence rates found 
in Baden-Württemberg are comparable to those found in 
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Rhine-Westphalia registry 2002). Assumptions on the cov-
erage rate of the DPV registry used could lead to distor-
tions of national incidence and prevalence estimates. In 
terms of a sensitivity analysis, however, the assumptions 
regarding the completeness of capture were varied.
Type 2 diabetes
The registries only include diagnosed cases of type 2 dia-
betes in children and adolescents. They therefore estimate 
only the incidence and prevalence of known type 2 dia betes. 
However, a significant number of undiagnosed cases can-
not be ruled out, though precise estimates for children and 
adolescents do not exist. For adulthood, a proportion of 
unknown type 2 diabetes in the total prevalence of 20% to 
50% has been reported [45]. Moreover, a clear distinction 
between type 2 diabetes and monogenetic diabetes forms 
is not always easy in children and adolescents, which may 
lead to erroneous categorisation.
The coverage rate of the North Rhine-Westphalian 
registry for the incidence and prevalence of type 2 diabetes 
in 11- to 18-year-old children and adolescents was estimated 
at 72% or 77%. The corresponding rates in the DPV data 
for North Rhine-Westphalia were 52% or 59%. The esti-
mates of national incidence and prevalence are therefore 
more uncertain than the estimates from North Rhine-West-
phalia.
For the surveys in Saxony and Baden-Württemberg no 
formal estimates of total coverage rate were possible. The 
figures in Saxony were adjusted based on the survey 
response rate and in Baden-Württemberg based on an ear-
lier estimate of the coverage rate [14]. Due to the anonymised 
data collection, double reporting could lead to an overes-
however, without full laboratory analysis, a clear distinction 
between type 1 diabetes and LADA often cannot be made. 
Therefore, it cannot be ruled out that a certain number of 
patients is categorised with the wrong diabetes type. How-
ever, the numbers of false categorisations are presumably 
so small that they do not relevantly influence incidence and 
prevalence estimates.
The coverage rate for new cases of type 1 diabetes in 
young adults aged 18 to 34 years was only 30%. The cov-
erage rate for the prevalence of type 1 diabetes in young 
adults was 73% and, hence, substantially higher. Therefore, 
a bias in the incidence estimates for North Rhine-West-
phalia cannot be entirely ruled out; prevalence estimates 
are to be considered as more valid.
The coverage rate of the DPV registry for type 1 diabetes 
could only be estimated for young adults (18- to 34-years-
old) using the data of the North Rhine-Westphalian regis-
try. In this case too, the coverage rate for incident cases 
(around 17%) were far lower than for prevalent cases 
(around 61%). Moreover, it should be noted that uncertain-
ties in the estimation of coverage rates were not consid-
ered when estimating adjusted incidences and prevalences.
For coverage rates at older ages, plausible assumptions 
on the completeness of capture of the DPV registry had to 
be made. For incident cases, the estimated coverage rate 
for young adults (18- to 34-years-old) was applied to older 
age groups, for prevalent cases a coverage rate of 15% was 
chosen. An underreporting of adult prevalent cases must 
already be expected, because prevalent type 1 diabetes 
cases at the age of e.g. over 26 in 2016, who therefore devel-
oped diabetes before 1990, were less likely to be registered 
due to the late start of registries (DPV mid 1990s, North 
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epidemiological parameters in the future and therefore 
also to assess trends over time. The provided data com-
plements the available epidemiological data on child and 
adolescent type 1 diabetes (three incidence registries in 
Baden-Württemberg, North Rhine-Westphalia and Saxony, 
as well as the national DPV registry) and on type 2 dia betes 
in adults (regional and national surveys, as well as anal-
yses of the data provided by statutory health insurances), 
so that diabetes surveillance can monitor the epidemiology 
of type 1 and type 2 diabetes across all age groups. For 
health policy and public health institutions this is key to 
planning future health care needs, and is also important 
for the interested public. Annually updating this data is 
furthermore important to assess whether prevention mea-
sures are effective at the population level.
To consolidate the diabetes surveillance, data on type 1 
diabetes in adults and type 2 diabetes in children and ado-
lescents should also be collected and evaluated in the com-
ing years. For the manifestation year 2018 this has already 
occurred (co-operation project 2019). A further perspective 
for the future of diabetes surveillance could be to expand 
the scope beyond type 1 and type 2 diabetes and include 
analyses of rare forms at national level which are neverthe-
less relevant for an overall evaluation of diabetes, such as 
genetic-based (for example MODY diabetes) or secondary 
diabetes forms (for example in mucoviscidosis patients) 
because valid epidemiological data on rare forms of dia-
betes cannot be collected through population-based rep-
resentative samples [46].
timation if the patient is treated simultaneously in a spe-
cialised diabetological practice and an outpatient clinic or 
if patients move. However, the determined case numbers 
probably underestimate the true prevalences. The estimates 
presented here are therefore only rough approximations.
4.3 Conclusion and outlook
Initially, the project ‘Type 1 diabetes in adults and type 2 
diabetes in children and adolescents’ focused on develop-
ing and providing methods and procedures to estimate the 
incidence and prevalence of type 1 diabetes at adult age 
and type 2 diabetes at child and adolescent age in close 
co-operation with the available local registries in 
Baden-Württemberg, North Rhine-Westphalia and Saxony, 
as well as the national DPV registry. For paediatric clinics 
(participants in the diabetes registries in Saxony and 
Baden-Württemberg) and diabetological clinics, surveys 
were established on treated child and adolescent type 2 
diabetes in Baden-Württemberg (prevalence) and newly 
diagnosed child and adolescent type 2 diabetes in Saxony 
(incidence). Furthermore, in a co-operation between the 
DPV registry Ulm and the diabetes registry in North 
Rhine-Westphalia, methods and procedures to estimate 
the national incidence and prevalence of type 1 diabetes in 
adults and type 2 diabetes in children and adolescents were 
provided. Gender-specific aspects were also taken into 
account.
The structures to estimate the national incidence and 
prevalence of type 1 diabetes in adults and type 2 diabetes 
in children and adolescents established by this project pro-
vide the basis for a continuous surveillance of these 
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Secondary data in diabetes surveillance – co-operation projects and 
definition of references on the documented prevalence of diabetes
Abstract
In addition to the Robert Koch Institute’s health surveys, analyses of secondary data are essential to successfully developing 
a regular and comprehensive description of the progression of diabetes as part of the Robert Koch Institute’s diabetes 
surveillance. Mainly, this is due to the large sample size and the fact that secondary data are routinely collected, which 
allows for highly stratified analyses in short time intervals. The fragmented availability of data means that various sources 
of secondary data are required in order to provide data for the indicators in the four fields of action for diabetes surveillance. 
Thus, a milestone in the project was to check the suitability of different data sources for their usability and to carry out 
analyses. Against this backdrop, co-operation projects were specifically funded in the context of diabetes surveillance.
This article presents the results that were achieved in co-operation projects between 2016 and 2018 that focused on a 
range of topics: from evaluating the usability of secondary data to statistically modelling the development of epidemiological 
indices. Moreover, based on the data of the around 70 million people covered by statutory health insurance, an initial 
estimate was calculated for the documented prevalence of type 2 diabetes for the years 2010 and 2011. To comparably 
integrate these prevalences over the years in diabetes surveillance, a reference definition was established with external 
expertise.
  DIABETES SURVEILLANCE · DIABETES MELLITUS · SECONDARY DATA · EPIDEMIOLOGY · PUBLIC HEALTH 
1.  Introduction
A pilot project to establish diabetes surveillance at the 
Robert Koch Institute (RKI) was launched in 2016. This step 
highlights diabetes mellitus’ great relevance to public 
health as a disease and cause of complications. Based on 
indicators agreed upon in consensus by experts, in future 
diabetes surveillance will report on diabetes-relevant devel-
opments as defined by its conceptual framework [1]. The 
presentation of results based on these indicators makes 
use of further data sources in addition to the data provid-
ed by the RKI in the context of health monitoring (primary 
data). The main objective of health monitoring is to pro-
vide representative information on the trends for the most 
important diseases, health behaviour and subjective assess-
ments of the health of the population in Germany stratified 
by age, gender and socioeconomic status (see the article 
on Social inequality and diabetes mellitus in this issue)[2].
Conducting interview and examination surveys is 
time-consuming because the content must be coordinated 
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indicators, their definition and the sources of data has been 
published on the RKI website [3]. 11 indicators that rely 
mainly on RKI health monitoring data also require sec-
ondary data. The diabetes surveillance data model (Figure 1) 
therefore includes RKI health monitoring, type 1 diabetes 
registry data (see the article on Type 1 diabetes in adults 
and type 2 diabetes in children and adolescents in this 
issue) as well as claims data of the statutory health insur-
ance. This latter data is primarily collected for accounting 
and only secondarily used in scientific analyses, which is 
why such data has become known as secondary data [4]. 
Secondary data is process-produced data and therefore 
contains only limited information on socioeconomic sta-
tus, subjective health, risk factors or undiagnosed diseases. 
The advantages of this data, however, are large samples 
and the availability of a constant inflow of new data.
Data from the social security system provides the core 
of secondary data, i.e. the data from the main providers of 
outpatient, inpatient and rehabilitative medicine: statutory 
health insurances (GKV) and the German pension insur-
ance (DRV). Due to Germany’s regionally segregated health 
care structure, much of this routinely collected data is not 
centrally available, is processed by different institutions 
and therefore not always equally available to research [5]. 
Data on the provision of rehabilitation services through 
DRV for example are kept by the German pension insur-
ance. Evaluating the use of medical rehabilitation services 
by diabetes patients is therefore only possible based on 
this data [6]. And GKV data is for example segregated by 
insurance providers and sector. While some health insur-
ances do use the data of insured persons to calculate dis-
ease prevalences, the demographic and socioeconomic 
with each other, and organisational planning and meticu-
lous quality and data protection procedures also take time. 
Furthermore, as the objective is to collect information as 
efficiently as possible, the number of cases in primary stud-
ies is limited. To fully implement the objective of surveil-
lance, i.e. provide in-depth stratification for specific indi-
cators and at short time intervals, requires further sources 
of data. Reviewing potential sources of data, modes of 
accessing this data and adequate analyses were therefore 
key project tasks in the establishment of diabetes surveil-
lance. To achieve these objectives, tenders for co-operation 
projects were organised in order to help define evaluation 
potentials, identify and close data gaps, and reveal options 
for data analysis for the entire duration of the project.
Out of the 40 indicators of diabetes surveillance 
14 require only secondary data. A detailed description of 
Figure 1 
Data model of diabetes surveillance
Own diagram 
RKI = Robert Koch Institute 
GNHIES98 = German National Health Survey 1998
DEGS1 = German Health Interview and Examination Survey for Adults (2008-2011)
GEDA = German Health Update
DaTraV = Data according to the Data Transparency Regulations
DRV = German pension insurance
DRG statistic = Diagnosis-Related Groups Statistic




(DaTraV, DRV, DRG statistic, Zi)
Official statistics
(cause of death statistics, 
disease-related cost accounts)
RKI health surveys
(GNHIES98, DEGS1, GEDA, 
Add-on Survey)
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more difficult. Furthermore, particularly with diabetes, the 
differentiation between the different forms of the disease 
in analyses of secondary data is tied to a set of assump-
tions. Frequently one finds unspecific or aetiologically 
mutually exclusive diagnoses, such as a diagnosis of 
type 1 and type 2 diabetes simultaneously coded together 
[10]. A reference definition, which will be applied to DaTraV 
data, aims to increase the reliability, transparency and com-
parability of documented prevalence within the framework 
of diabetes surveillance. The definition of prevalence also 
provides the basis to determine further indicators such as 
those of mortality and incidence.
This article provides an overview of the results of the 
co-operation projects developed and co-operation partners 
found in the context of diabetes surveillance, who have all 
contributed significantly to the development of this project. 
We also present initial results on the prevalence of type 2 
diabetes based on DaTraV data. The critical review of and 
experiences with this first set of results led to the definition 
of a frame of reference, which we also present here and 
which will provide the foundation for future diabetes surveil-
lance reporting of documented prevalence and the calcu-
lation of further indicators.
2.  Methodology
Since 2016, diabetes surveillance has published tender 
notices annually to promote co-operation projects. Suit-
able projects were selected based on specifically developed, 
standardised application and evaluation criteria, which 
were annually adapted in accordance with the stage of the 
project. The main criteria by which to evaluate the projects 
differences, as well as the differences in health risks 
between those insured by different insurers make compar-
isons difficult [5]. This makes it difficult to generalise, for 
example on the prevalence of diabetes among all people 
with statutory health insurance, and means prevalence can 
only be estimated based on assumptions [7].
The Central Research Institute of Ambulatory Health 
Care (Zi) in Germany holds a complete set of outpatient 
claims data for all people covered by statutory health insur-
ance. However, this data does not contain information on 
people covered by statutory health insurance with no out-
patient consultations and totally lacks data on inpatient 
care [8]. Information on all people covered by statutory 
health insurance is contained in the data set held by the 
German Institute of Medical Documentation and Informa-
tion (DIMDI) on the basis of Germany’s Data Transparency 
Regulations (DaTraV) [9]. However, this data too has its 
limitations. While it contains complete data on out- and 
inpatient diagnoses as well as prescribed medicines, it pro-
vides no information on inpatient or outpatient medical 
services. Furthermore, this data currently comes with a 
four-year delay and can so far only be evaluated regionally 
for individual reporting years. Moreover, neither the Zi nor 
the DIMDI data set provide information on people covered 
by private insurance. Info box 1 describes the data provided 
by DaTraV and its usability in surveillance systems, as well 
as an overview of planned reforms. 
Beyond the problems posed by fragmented and incom-
plete data described above, the criteria to define diabetes 
in routine data (selection criteria) also vary. Differences in 
selection criteria, which can be justified based on content, 
produce different results and make comparability over time 
Info box 1: 
Data by the Data Transparency Regulations (DaTraV) 
The data processing unit at the Institute of Med-
ical Documentation and Information (DIMDI) can 
provide analyses based on the routine data of the 
around 70 million people covered by statutory 
health insurance (DaTraV data), which help plan, 
manage and assess the needs of the German 
health care system while ensuring the protection 
of the identity of ensured persons. DaTraV data 
can be evaluated across sectors of care and health 
insurance companies. It allows long-term assess-
ments of disease progress for individual patients. 
As various publications have shown, using DaTraV 
data in the surveillance of noncommunicable dis-
eases in particular principally makes sense. Yet 
there is room for improvements and an amend-
ment to the data transparency regulations is 
planned. Changes will probably include
  Transferral of the diagnoses and medication 
data from the morbidity-oriented risk structure 
compensation scheme (Morbi-RSA), also of 
deceased individuals by the German Federal 
Insurance Office, 
  reducing the delay in data provision from four 
to two years.
One aim is to reduce the current processing time 
for applications. Based on an external evaluation 
of the organisation, an increase of staff was 
applied for. Already, data on place of residence for 
2009, 2010 and 2011 are available for analyses. 
From 2020, it will be possible to continuously 
analyse reporting years regionally by postal codes.
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3.1  Results of co-operation projects
Table 1 presents the authors of the co-operation projects, 
the indicators or contributions they worked on and the 
benefits these provide to diabetes surveillance.
3.1.1  Time series on amputations and hospitalisation in 
patients with diabetes
Hospitalisations due to lower limb amputations (major 
amputations) or other diabetes-related complications in 
diabetes patients are considered potentially preventable 
because diabetes can be controlled well with adequate 
structures for outpatient treatment. The Organisation for 
Economic Co-operation and Development (OECD) there-
fore uses hospitalisations as a population-related indicator 
that allows conclusions to be drawn on availability and 
quality of outpatient care [12]. These indicators are calcu-
lated for diabetes surveillance based on the Diagnosis-Re-
lated Groups Statistic (DRG statistic). 76,139 women with 
diabetes were hospitalised due to complications and 2,560 
had amputations in Germany in 2016; for men, the figures 
were 108,386 hospitalisations due to complications and 
5,402 amputations. After age standardisation using the 
German standard population in 2005, the number of hos-
pital cases in the female population declined over time 
from 234 cases per 100,000 inhabitants in 2005 to 174 cas-
es per 100,000 inhabitants in 2016. For men, the decrease 
was from 311 cases per 100,000 inhabitants in 2005 to 302 
cases per 100,000 inhabitants in 2016 (Figure 2). The 
amputation rate for women during this same period 
dropped from 11.6 cases per 100,000 inhabitants to 
5.4 cases per 100,000 inhabitants and from 23.0 cases per 
included a high public health relevance and easy integra-
tion within current surveillance, replicability of results, clar-
ity of the method and feasibility of the project proposal 
within a one year time span. Developing indicators, sifting 
suitable sources of data and selecting co-operation pro-
jects were all done in parallel.
During a workshop in March 2017 [11], co-operation 
partners presented the identified data sources and exem-
plary analyses from projects implemented during the first 
funding years and discussed them with experts. During the 
workshop, DaTraV data and the possibilities to analyse this 
data using the data processing unit of DIMDI were pre-
sented and discussed. At the same time, we applied for an 
initial DaTraV output data set to calculate the prevalence 
of diabetes in 2010 and 2011. The results for type 2 dia-
betes were presented stratified by age group and gender 
and put in the context of current literature. Based on a crit-
ical contextualisation of results, in co-operation with the 
data processing unit and external expertise, we developed 
the reference definition presented here, which will serve as 
a basis to calculate documented prevalence and further 
indicators.
3.  Results
In the following, the results of the cooperation projects 
from 2016 to 2018 will be presented first. Then the figures 
from the initial analysis of DaTraV data in the context of 
diabetes surveillance on the documented prevalence of 
type 2 diabetes during 2010 and 2011 will be presented and 
critically discussed. 
25 of 40 indicators of 
diabetes surveillance were 
either entirely or at least 
partially populated with 
secondary data.
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Adjusted for age and gender, a regional focus reveals 
particularly high rates of hospitalisations due to complica-
tions as well as for amputations in the former East German 
federal states with the exception of Berlin [13]. The great 
influence of diabetes prevalence is an important factor to 
100,000 inhabitants in 2005 to 14.9 cases per 100,000 
inhabitants in 2016 for men. The development of rates 
could indicate an improved quality of outpatient care for 
diabetes patients over time or otherwise a greater adher-
ence of patients to prescribed therapies [13]. 
Table 1 
Co-operation projects of diabetes 
surveillance, role within the project, 
authors and project description 
Own table 
Co-operation project Project year Contribution Use Authors 
Surveillance of ambulatory 
care-sensitive conditions  
in diabetes mellitus
2016 Amputations and hospitali-
sation (Section 3.1.1)
Regular presentation of  





Use of DMP documentation data 
for diabetes surveillance
No funding All indicators of DMP quality 
assurance (Section 3.1.2)
Exclusive evaluation of DMP 
data for diabetes surveillance
Bernd Hagen
Measuring quality of care based 
on routine data
2016-2017 Feasibility study on the 
potential of GKV data  
(Section 3.1.3)
Comprehensive estimate as a 
basis for definitions and anal-
yses based on secondary data 
Gunter Laux,  
Joachim Szecsenyi, 
Stephanie Kümmel
Projections of prevalence and 
incidence of diabetes in Germany
2017 Prevalence prognosis mod-
els (Section 3.1.4)
Innovative epidemiological 
methods to model different sce-
narios for the development of 
number of cases
Ralph Brinks,  
Thaddäus Tönnies, 
Annika Hoyer
Co-operation with the data  
processing department to 
improve the use of DaTraV data 
in epidemiological research
No funding Providing an overview of 
DaTraV data (Info box 1)
Reference evaluation with 
DaTraV data
Jochen Dreß
Feasibility study on the applica-
bility of data on obesogenic envi-
ronments in the surveillance of 
diabetes risk factors
2017 Obesity in tight-knit associ-
ation with environmental 
factors (Section 3.1.5)





Michael Laxy,  
Werner Maier
Updating of public health- 
relevant indices for diabetes  
surveillance and projections for 
the prevalence of diabetes and its 
limitations
2018 Disease burden figures 
(Section 3.1.6)
Use of biometric methods to 
estimate and provide prognoses 
for disease burden figures
Annika Hoyer,  
Thaddäus Tönnies, 
Ralph Brinks
Evaluation of St. Vincent targets 
based on diabetes mellitus- 
related complications: terminal 
renal insufficiency in patients 
with or without diabetes
2018 Renal replacement therapy 
and renal insufficiency  
(Section 3.1.7) 
Results from diverse data  
sources/development of  





GKV = statutory health insurance, DaTraV = Data according to the data transparency regulations, DMP = disease management program(s)
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chronically ill patients. A central feature of the disease man-
agement programs introduced for type 2 diabetes in 2003 
and type 1 diabetes in 2006 is the quarterly or semi-annu-
al documentation of standardised indicators by the partic-
ipating doctor’s surgeries. Based on these indicators the 
DMP defines a set of quality objectives to describe the qual-
ity of treatment for patients in DMP cross-sectionally and 
longitudinally. Across Germany, 4.4 million patients are 
registered in the diabetes DMP. On average, inscribed 
patients have been attended to for 7.5 years (type 2 dia-
betes) or 7.1 years (type 1 diabetes) in the DMPs of the 
Association of Statutory Health Insurance Physicians 
Nordrhein (KV-Nordrhein) [15]. This provides a large data 
set that permits differentiated findings on quality of care 
by age or duration of illness.
The usability of DMP data is limited particularly due to 
the following factors: 
(1) As participation in DMPs is generally voluntary and pro-
grams are only open to patients in statutory health insur-
ance who can still actively and independently handle 
their illness, selection effects are likely. 
(2) Documentation parameters and quality targets change 
over time, new indicators are created or indicators are 
replaced that have been used for many years. This cre-
ates gaps in surveillance over time. 
(3) Although the group of patients in the type 2 diabetes 
DMP is very large and probably very diverse regarding 
the duration of illness, there are no contractual bases 
to represent this diversity with regard to quality of care.
In spite of these limitations DMPs have provided a num-
ber of important results: diabetes DMPs reach a large pro-
take into account here, i.e. regional differences in preva-
lence already explain the differences in rates of amputa-
tions and hospitalisations [14].
Integrating the OECD indicators in diabetes surveillance 
is easily feasible in terms of methodology, however, the 
changing definitions of indicators are challenging for com-
parisons over time. Over the course of the co-operation 
project, for example, the definition of amputations changed 
to exclude patients who had died in hospital. When inter-
preting indicators regarding their spatial distribution, pre-
dictors such as the regional differences in diabetes preva-
lence or socioeconomic factors must be taken into account.
3.1.2 Potential uses for the Disease Management Programs
Disease Management Programs (DMP) are structured 
treatment programs for specific diseases that aim to 
improve treatment processes and the quality of care of 
Figure 2 
Hospitalisations and amputations over time 
(age standardised rates) for diabetes mellitus in 
Germany according to gender 
Source: Diagnosis-Related Groups Statistic 
(DRG statistic) 2005 to 2016















Over the course of the 
project, co-operation projects 
are promoted that specifi-
cally encourage the use of 
secondary sources of data.
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ther expand the indicator set. Consensus was found on 70 
quality indicators.
47 of these 70 indicators, i.e. over two thirds of the set, 
can be calculated using secondary data. Importantly, how-
ever, this always requires evaluating the validity of the 
underlying secondary data. In addition, adequate proce-
dures must ensure both internal and external validity, i.e. 
performing plausibility checks for results regarding the data 
itself (internal) as well as regarding other data sources 
(external) [17]. A report for the DIMDI on the access to and 
potential uses of data for care research [18] enumerates a 
number of advantages of GKV data has as well as its limi-
tations. This report also considers other social insurance 
carriers, official statistics and federal health reporting, as 
well as private health insurance data.
Overall, the project made it very clear that secondary 
data, such as the data from AOK Baden-Württemberg used 
here, if specifically prepared and analysed, has the poten-
tial to close certain data gaps within a comprehensive dia-
betes surveillance approach. To reach a consensus on the 
set of 40 indicators, the indicators identified during the 
project were compared against the indicators found by the 
diabetes surveillance literature search. The project results 
led to the inclusion of these four additional indicators in 
the indicator set of diabetes surveillance: diabetic neuropa-
thy, diabetic foot syndrome, renal replacement therapy and 
age at diagnosis.
3.1.4  Epidemiologic parameters and projections for dia-
betes surveillance
The constant spread of diabetes poses considerable chal-
lenges to the healthcare system. Beyond taking stock of 
portion of diabetes patients. Over the course of time, the 
guideline-based treatment that diabetes patients receive 
has significantly improved. Continuous participation in 
DMPs increases the chances to achieve quality targets, and 
there is a clear decrease of severe complications for patients 
participating in type 2 DMPs. For diabetes surveillance, 
DMP data from North Rhine-Westphalia is presented to 
demonstrate the achievement of quality targets for both 
type 1 and type 2 diabetes. In future, the different frequen-
cies of target achievement stratified by gender and age 
group over time will be reported and integrated into dia-
betes reporting.
3.1.3  Routine data to measure quality: definitions and 
measurement
As part of this co-operation project, a complete data set 
for one statutory health insurance (AOK Baden-Württem-
berg) was used to analyse to what extent secondary data 
can contribute towards the overall project of establishing 
diabetes surveillance at the RKI.
To start, the aQua Institute for Applied Quality Improve-
ment and Research in Health Care in Göttingen conducted 
a review of literature searching for type 2 diabetes indica-
tors. In a first step it defined inclusion and exclusion crite-
ria. Included were all indicators that can be applied to adult 
type 2 diabetes patients. Indicators of type 1 diabetes or 
gestational diabetes were excluded.
In November 2016, an expert panel took place in Göt-
tingen. With external expertise, an indicator set was agreed 
in consensus. The experts evaluated all the indicators that 
had been found in the search in terms of their relevance 
for diabetes surveillance. The meeting offered room to fur-
Co-operation project results 
indicate increasing case 
numbers by 2040 but also 
improved treatment for 
diabetes patients.
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tions of the trends until 2040, predict increases of over 
50% [20].
3.1.5  Using geocoding services to gain information on 
the obesogenicity of environments
A feasibility study tested the potential of data from online 
geocoding services to be used for the surveillance of envi-
ronmental factors associated with type 2 diabetes. Using 
obesity as an example, initially the literature was searched 
for factors related to an obesogenic environment, i.e. an 
environment that is conducive to obesity [21-23]. Features 
of the environment that previous studies had associated 
positively with obesity were defined as obesogenic factors 
(for example fast food restaurants) and those defined as 
negative as protective factors (such as green areas). Subse-
quently, these factors were operationalised through expert 
interviews (n=4) based on the variables provided by the 
geocoding services Google Maps and OpenStreetMap. 
Using the statistics software R, new automated query scripts 
were developed to download and analyse relevant data in 
particular regarding the specific features of environments.
Site visits and an online search had the objective to val-
idate the data from four pilot areas in Bavaria. This served 
to verify that the place and type of environmental features 
that had been detected were correct and whether there 
were additional relevant features that had been omitted 
from the identified data. The project showed that the 
demands for completeness of data, download capacity and 
the diversity of variables are relevant dimensions to select 
a particular geocoding service. Finally, for the city of Augs-
burg, kernel density estimations and heat maps were pro-
duced and cluster algorithms applied to describe the spa-
current case numbers, resource planning will require the 
most accurate prediction possible of future developments. 
Current estimates for Germany indicate that the number 
of diabetes patients is set to increase sharply in the future, 
these projections are however either based on figures for 
specific age ranges or solely on the data from particular 
statutory health insurances [19]. Due to the diversity of the 
demographic and socioeconomic characteristics of the 
groups insured by different health insurances, basing pre-
dictions on the data provided by individual insurances is 
problematic.
To better predict future figures of people with type 2 dia-
betes, this project applies the age- and gender-specific 
preva lence of type 2 diabetes from the year 2015 to the 
future age structure of the German population until 2040 
as predicted by the Federal Statistical Office [20]. The 
assumed prevalence is thereby based on the data of all 
statu tory health insurances in Germany, or DaTraV data [10].
Assuming that demographic ageing continues, yet that 
the age-specific prevalence of type 2 diabetes for women 
and men remains constant between 2015 and 2040, the 
number of people with type 2 diabetes will increase from 
6.9 million in 2015 to 8.34 million in 2040, which would be 
a 21% increase. Predicting the future number of diabetes 
cases by using current age-specific prevalence is the sim-
plest form to calculate a projection. Improved treatment 
of diabetes patients due to medical progress and the result-
ing longer average life expectancy will very likely lead to a 
rising age-specific prevalence, making the results presented 
here a conservative estimate. More realistic scenarios are 
obtained by modelling the interaction between incidence 
and mortality rates, which, when based on realistic assump-
Initial results, which are 
based on the data of all 
people covered by statutory 
health insurance, indicate an 
increase in documented 
prevalences of type 2 
diabetes from 7.7% (2010) to 
8.1% (2011) for women and 
8.2% to 8.6% for men, 
respectively.
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diabetes will lose less life years than people without dia-
betes compared to 2015. This applies to all age groups. 
Women, in general, will lose less life years than men. 
Assuming an annually decreasing relative death risk 
between 2015 and 2040 would result in a relative decrease 
of YLL of up to 64% over the same period.
The model scenarios in their majority in principle indi-
cate an increase of healthy life years (HLY) for the period 
considered across almost all age groups. One exception 
are the results for the over-80 age group. For example, an 
over-80-year-old man in 2040 can expect on average to live 
another 5 years without diabetes, whereas in 2015 it was 
5.5 years. Our results are in line with the results of interna-
tional studies on changes to diabetes-related morbidity [25]. 
3.1.7  Renal replacement therapy in people with and with-
out diabetes
Renal insufficiency belongs to the severe conditions dia-
betes patients may develop. At advanced stages this is 
treated with renal replacement therapy, which is associ ated 
with higher mortality and costs [26, 27]. For this reason, 
renal replacement therapy has been included as an indica-
tor to diabetes surveillance, with the objective of analysing 
the disease burden over time [4]. However, there is so far 
no long-term data on whether the figures for renal replace-
ment therapy (incidence) have decreased for people with 
and without diabetes in Germany.
So far, the incidence of renal replacement therapy has 
been analysed based on the data from doctors’ surgeries 
in North Rhine-Westphalia [26], as well as from the 
Gmünder Ersatzkasse (statutory health insurance data) of 
people with and without diabetes in the 2000s and pro-
tial distribution of variables. Cartographic analysis was then 
used to identify the areas with a high density of either obe-
sogenic or protective environmental factors. Correspond-
ingly, this study helped develop a suitable method to pre-
pare and represent data from online geocoding services 
for the description of obesogenic environments suitable 
for diabetes surveillance. However, to assess the predictive 
power of this method for actual obesity and/or diabetes 
risks, the method will need to be tested in further surveys 
with population-based data.
3.1.6  Indices relevant to public health and their projec-
tion relative to diabetes
The projection of diabetes-related years of life lost (YLL) 
and healthy life years (HLY) is based on prevalence, inci-
dence and mortality rate ratio (MRR) data. Age- and gen-
der-specific 2010 prevalences [10] were used to calculate 
YLL and HLY between 2015 and 2040 based on different 
scenarios of diabetes incidence and mortality.
As the long-term development of diabetes incidence in 
Germany is unknown, three hypothetical scenarios are cur-
rently being discussed: an unchanging incidence rate and 
an increase or a decrease in the incidence rate by 0.5%, 
respectively. Moreover, the advance of medicine will pre-
sumably lead to a greater decrease in the mortality of dia-
betes patients relative to people without diabetes, so the 
relative mortality risk is varied. We are therefore looking at 
scenarios with an annual 2% decrease in the mortality risk. 
YLL are calculated using a birth cohort framework, HLY by 
applying the Sullivan method [24].
During the period considered, the number of life years 
lost decrease for women and men. In 2040, people with 
A definition was developed 
that will serve as a basis for 
future calculations and 
enhance the reliability and 
comparability of results for 
documented prevalence in 
the context of diabetes 
surveillance.
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2011 for the documented prevalence of type 2 diabetes. 
Prevalent type 2 diabetes was defined as at least one 
assured documented out- or inpatient type 2 diabetes diag-
nosis coded according to the International Statistical Clas-
sification of Diseases and Related Health Problems, 10th 
revision (ICD-10: E11.-).
Together with experts from the diabetes surveillance sci-
entific advisory board and based on the feedback from the 
data processing unit, the results of the query and of co-op-
eration projects served as a starting point to define a ref-
erence analysis to determine documented prevalence 
(Info box 2). In future, this should provide robust results 
on the overall prevalence of diabetes as well as segregated 
by type 1, type 2 and other forms of diabetes mellitus for 
Germany and German federal states. The reference anal-
ysis will apply validation data sets. For one, the number of 
people who receive diabetes medication without having 
been diagnosed with diabetes will be determined. Further-
more, diabetics who according to the data only have a sec-
ondary inpatient diagnosis of diabetes will also be deter-
mined. This validation data set should help to better assess 
the consensually agreed definition.
Irrespective of the results of the reference definition, the 
applied for results for the reporting years 2010 and 2011 
show the DaTraV data potential for diabetes surveillance. 
Information on age, gender and diabetes diagnosis was 
analysed for a total of 66.2 million statutory health insured 
for the year 2010 and 66.4 million for 2011. The results in 
Figure 3 are stratified by gender and year for type 2 
diabetes and evidence an increase in administrative preva-
lence. In women, documented prevalence increased from 
7.7% (2010) to 8.1% (2011) and in men from 8.2% to 8.6%. 
vided results that can be compared well [28]: the age stan-
dardised incidence rate for the population with diabetes 
was between around 190 and 215 per 100,000 person-years, 
for the population without diabetes roughly between 
30 and 40. Therefore, for diabetes patients the risk to have 
renal replacement therapy was around six to eight times 
higher. No significant trend over time was found. During 
the current project, the evaluation of data from doctors’ 
surgeries was expanded to cover the period between 2002 
and 2016. The results are expected in 2019.
Moreover, there are plans to analyse the prevalence and 
incidence of renal replacement therapy in people with and 
without diabetes based on the data of several GKVs across 
Germany during the last decade. The project aims to anal-
yse the possibilities to reliably describe renal replacement 
therapy through diagnoses based on the International Sta-
tistical Classification of Diseases and Related Health Prob-
lems (ICD) using health insurance data. The objective of 
this project is to evaluate the suitability of DaTraV data for 
this project, which as described above contains informa-
tion on all statutory health insured. In a final step, a meet-
ing of experts will discuss the comparability of different 
data sources (doctors’ surgeries, GKV and DaTraV data). 
One particular focus will be to discuss the possibilities to 
standardise the algorithms that apply to define renal 
replacement therapy and renal insufficiency in routine data.
 
3.2  Initial results for the documented prevalence of type 2 
diabetes in DaTraV data
The first DaTraV application by diabetes surveillance 
referred to a comparison of the reporting years 2010 and 
Info box 2: 
Reference definition to define documented preva-
lence of diabetes mellitus in the context of dia-
betes surveillance based on DaTraV data 
Total diabetes 
Denominator: people insured for at least 360 days 
of one year with data on year of birth and gender, 
no insured residing abroad or those opting for 
reimbursement of costs according to section 13 
(2) or section 53 (4) of Book 5 of the German 
Social Code (SGB V). 
Numerator: people with at least two assured out-
patient or at least one inpatient documented ICD-
10 diagnoses of diabetes mellitus (E10.- to E14.-1) 
Type 1 diabetes
Denominator: see above
Numerator: people with at least two assured out-
patient documented ICD diagnoses E10.- or with 
an outpatient assured documented ICD diagnosis 
E10.- and at least one further ambulatory assured 
documented ICD diagnosis diabetes mellitus 
according to E12.- to E14.- or an inpatient docu-
mented ICD-10 diagnosis E10.-
Excluded: people with at least one ambulatory or 
inpatient documented ICD diagnosis E11.-
Type 2 diabetes
Denominator: see above
Numerator: people with at least two outpatient 
assured documented ICD diagnoses E11.- or with 
one outpatient assured documented ICD-10 diag-
nosis E11.- and at least one further outpatient 
assured diagnosis ICD-10 diabetes mellitus accord-
ing to E12.- to E14.- or an inpatient documented 
ICD-10 diagnosis according to E11.-
Excluded: people with at least one outpatient 
assured diagnosis or inpatient documented ICD-10 
diagnosis according to E10.- 
continued on next page
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of the administrative prevalence of diabetes within the 
context of diabetes surveillance (Info box 2).
4.  Discussion
Secondary data is an important element to determine indi-
cators for diabetes surveillance. It can be used to prepare 
time series as a basis for numerous indicators.
In particular, DaTraV data is well suited for the pur-
poses of surveillance, because it is a complete data set 
of all statutory health insured in Germany that is updated 
annually. The planned revision of DaTraV can overcome 
current limitations of this data set such as the transfer of 
diagnosis and medications data also for the year of leav-
ing the GKV system and the current four-year delay. In 
addition, there is an objective to reduce the time required 
to process applications in particular by employing more 
staff. In future, this will ensure an even better depiction 
of regularly repeated observations of the disease burden 
at short intervals.
Meaningfully comparable analyses of secondary data 
require transparent and consensually agreed definitions of 
selection and applicability criteria. The presented reference 
definition to calculate the overall prevalence of diabetes, 
as well as differentiated by type 1, type 2 and other forms 
of diabetes based on DaTraV data is a step towards greater 
transparency. The developed definition thereby is not only 
important for comparisons of prevalence over time, but 
also serves as a reference for further indicators of diabetes 
surveillance. For example, the definition is also used to 
depict numerous diabetes complications, incidence and 
mortality based on DaTraV data.
Furthermore, the results confirm the known age-related-
ness of type 2 diabetes, as for both genders an increase of 
prevalence with age is observed. The results resemble other 
analyses based on DaTraV data [10]. However, the age 
group over 80 is too large to describe the effect of decreas-
ing prevalence among the very old aged over about 85 [8]. 
The definition of diabetes used for Figure 3, which bases 
itself on a definitive out- or inpatient diagnosis in the report-
ing year, differs from the generally used criterion of at least 
two quarterly periods. According to this criterion, a defini-
tive outpatient diagnosis of diabetes must be coded during 
at least two quarters of one year to rule out documentation 
effects. The analysis moreover showed, that for numerous 
cases instead of specific diagnoses of either type 1 or type 
2 diabetes, diagnoses were either unspecific or mutually 
exclusive. For these reasons, in co-operation with experts 
from epidemiology and care, the reference definition 
described below was developed to allow future description 
Info box 2 (Continued): 
Other forms
Denominator: see above
Numerator: people with at least two outpatient 
assured or at least one inpatient documented ICD-
10 diagnosis in groups E10.- to E14.-
Excluded: people who were already assigned to 
type 1 or type 2 diabetes based on the algorithm 
mentioned above.
ICD-10 = International Statistical Classification of Diseases 
and Related Health Problems, 10th revision
E10 = Insulin-dependent diabetes mellitus (type 1 diabetes)
E11 = Non-insulin-dependent diabetes mellitus (type 2 dia-
betes)
E12 = Malnutrition-related diabetes mellitus
E13 = Other specified diabetes mellitus
E14 = Unspecified diabetes mellitus 
An outpatient diagnosis can, depending on docu-
mentation, be a diagnosis that is suspected, related 
to a state following a certain illness (such as a heart 
attack), ruled out or assured. Only diagnoses clas-
sified as assured are used here to define documen-
ted prevalence.
Validation data sets for total diabetes
1)  people who have been prescribed antidiabetic 
drugs without documented diabetes  
2)  people with only an inpatient secondary diag-
nosis
Figure 3 
Comparison of the documented prevalence 
of type 2 diabetes mellitus for the 
years 2010 and 2011 according to gender
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An international comparison of noncommunicable disease  
reporting: the case of diabetes mellitus
Abstract
Against the background of the growing burden associated with diabetes mellitus, the German Federal Ministry of Health 
commissioned the Robert Koch Institute to develop a national diabetes surveillance. The periodic publication of up-to-
date data needed by diverse target audiences (dissemination) to develop subsequent public health measures is a crucial 
aspect of disease surveillance. The study produced an overview of diabetes surveillance in various countries with the 
intention of developing a dissemination strategy. This involved a two-stage process beginning with an online survey of 
public health experts from 46 countries. Structured Internet research was then carried out for countries that did not 
provide a response (19 out of 46). The majority of countries (38 out of 46; 83%) include diabetes in their health reporting; 
three quarters (29 out of 38; 77%) of these countries rely on an indicator-based reporting system. The study found that 
the most common formats used to publish information about diabetes and other noncommunicable diseases were 
topic-specific reports (24 out of 36; 67%) and national health reports (23 out of 36; 64%), followed by online formats 
such as websites or databases (20 out of 36; 57%). Moreover, health reporting primarily targets politicians (19 out of 20; 
95%) as well as the media and the press (16 out of 20; 80%). The study found that both printed and online publications 
form part of a comprehensive dissemination strategy, however address different audiences.
  HEALTH REPORTING · DISSEMINATION · DIABETES MELLITUS · NCD SURVEILLANCE
1. Introduction
The burden associated with diabetes mellitus and other 
noncommunicable diseases (NCDs) is steadily increasing 
in Germany as it is throughout the world [1, 2]. In 2013, the 
World Health Organization (WHO) adopted the Global 
Action Plan for the Prevention and Control of NCDs as a 
means of facing up to the growing challenges posed by 
noncommunicable diseases [3]. The WHO’s action plan 
contains six objectives, one of which includes monitoring 
the trends and determinants of NCDs. This led the Ger-
man Federal Ministry of Health to commission the Robert 
Koch Institute (RKI) to set up a diabetes surveillance sys-
tem that could serve as a pilot project for the surveillance 
of other noncommunicable diseases in Germany. Together 
with the project’s scientific advisory board, a framework 
for the surveillance of diabetes was developed and 40 indi-
cators were defined [4].
Public health surveillance is defined as the continuous, 
systematic collection, analysis and interpretation of 
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be used to provide NCD-related information, nor does it 
provide guidance on which information should be provided 
to the various target audiences. When it comes to formats 
and communication channels, however, advances in digi-
tisation, in particular, are opening up new ways of visual-
ising and processing data [13]. Moreover, social media and 
social networks offer further opportunities with which to 
disseminate health-related information [10, 14].
In addition to building on the experience gained by other 
public health institutes, best practice examples from other 
countries are to be used as a model to develop a dissem-
ination strategy for diabetes surveillance at the RKI. An 
international workshop was held in this context at the RKI 
in June 2018 that also involved the presentation of innova-
tive formats [15]. Furthermore, a study of health reporting 
on NCDs was performed using diabetes as an example. 
The aim of the study was to provide an overview of formats 
and target audiences of health reporting by the member 
states of the Organisation for Economic Co-operation and 
Development (OECD), the European Union (EU), and other 
selected European countries.
2. Methodology
The study used a two-step approach to collect data about 
national health reporting of diabetes and noncommunica-
ble diseases (Figure 1). The first step involved surveying 
national public health experts from the selected countries 
using an online survey in English. The survey focused on 
diabetes and NCD-specific health reporting including the 
formats that were being used and the target audience that 
was being addressed. The results were supplemented by 
health-related data that is needed for the implementation 
of public health measures aimed at protecting and promot-
ing the health of the population (‘data for action’) [5]. This 
definition implies that health monitoring data should be 
processed in a manner that reflects the needs of its vari-
ous target audiences. Data from health surveillance can be 
used to (1) identify high-risk populations, (2) develop pre-
vention strategies, (3) draw up new hypotheses on diseases 
dynamics, (4) raise awareness about trends and disease-re-
lated risk factors, and (5) encourage people to take con-
scious decisions about their health [6, 7].
In order for health reporting data to be used in this man-
ner, target audiences must be provided with up-to-date 
information (dissemination). In public health sciences, as 
in other fields, a gap exists between the production of new 
knowledge and its translation into practice and policy [8]. 
This underscores the importance of developing a dissem-
ination strategy as part of the surveillance system that can 
provide the basis for the development of informed health 
policy measures [9]. However, it is essential that formats 
and the communication channels used to disseminate the 
information reflect the competences and level of expertise 
that a specific target audience has with regard to a particu-
lar aim [10, 11]. 
The WHO identifies four target audiences as part of its 
Global Monitoring Framework for the surveillance of non-
communicable diseases: (1) healthcare providers, (2) pol-
icy makers, (3) service providers, and (4) the general pop-
ulation [12]. In addition, other groups that also need to be 
addressed include patients, doctors who treat diabetics, 
and scientists and scientific institutions. The WHO does 
not state which formats or communication channels should 
83% of countries include 
diabetes in their national 
health reporting.
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reporting sought to address. Furthermore, respondents 
were also asked to upload the reports they mentioned dur-
ing the questionnaire or to provide a link to documents 
that were available online. After the online survey had been 
completed, a review was undertaken to ensure that each 
country had only provided one response. If more than one 
survey existed for a country, the data provided on these 
questionnaires were merged.
2.2 Structured Internet research
Between August and September 2018, structured Internet 
research was conducted into countries that had not sup-
plied any data by the end of the online survey period (July 
2018). The analysis focused on the country’s framework, 
indicators, and the formats used for diabetes and NCD-spe-
cific health reporting. The Internet research was carried 
out in the following manner: first, a search was conducted 
of the websites of the respective national public health 
institutes, health ministries and statistical offices for key-
words linked to diabetes and noncommunicable diseases. 
The Google search engine was then used to search for a 
combination of terms. In each case, the search term con-
sisted of either diabetes, noncommunicable disease or 
NCD, alongside surveillance, monitoring, strategy, report, 
health reporting or indicators. Lastly, the respective coun-
try name (in English) was added to the search term. The 
study then examined the first 30 search results. Public 
health institutes, ministries of health or statistical insti-
tutes do not always provide relevant information in 
English, German or French. In these cases, their websites 
were translated into English using Google Translate and 
structured Internet research into countries that did not 
participate in the expert survey. Finally, examples of best 
practices from successful health reporting were also select-
ed. The selection was based on a narrative analysis of the 
results of the online survey and Internet research.
The survey was limited to OECD and EU member states 
and other selected European countries; 46 countries were 
included in the study (Table 1).
2.1 Online survey
The online survey of public health experts took place 
between April and July 2018. The survey used a question-
naire created with the Acuity4 survey software (version 
5.5.1.205) from Voxco®. In order to recruit suitable partic-
ipants, the RKI’s network was used to contact EU and 
OECD public health institutes as well as those from other 
European countries. The aim was to ensure that people 
with expertise in diabetes and health reporting participat-
ed in the study. In cases where it was impossible to find 
someone suitable to answer the questionnaire, a request 
to participate in the survey was sent to health ministries 
and national statistical offices. Other institutions were only 
contacted if they had been named by a member of one of 
these institutions.
The online survey comprised 39 questions and was 
divided into two subject areas (Annex Table 1). On the one 
hand, the questionnaire focused on the framework behind 
diabetes-specific health reporting, its integration into a dia-
betes strategy, and the indicators and data sources that 
were used. On the other hand, it also examined the formats 
that were being used and the target audiences that health 
Infobox 1:  
An international comparison  
of noncommunicable disease 
reporting: the case of diabetes  
mellitus
Data owner: Robert Koch Institute
Aim: To develop an overview of the strategy, 
content, formats and target audiences of  
the health reporting of noncommunicable 
diseases conducted in OECD and  
EU countries.
Geographical focus: 46 OECD or EU  
member states, as well as other selected 
European countries
Study design: Two-stage process
    Online survey of public health experts
    Structured Internet research into  
countries that did not participate  
in the online survey
Participants:
    Experts from 27 countries participated  
in the study
    Structured Internet research was carried 
out for 19 countries
Study period: April to September 2018
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carried out for the remaining 19 countries so that diabe-
tes-specific health reporting could be evaluated for all 46 
countries included in the study.
the resulting translations were searched for the keywords 
mentioned above.
The research was limited to the framework (strategy, 
indicators, data sources) and formats (reports, websites, 
databases) used by the country for health reporting. Fur-
thermore, only reports and formats published in or after 
2000 were included in the study. Unfortunately, it was 
impossible to identify the reports’ target audiences as the 
websites that published them provided no relevant infor-
mation about this issue.
3. Results
Of the 46 countries included in the overall study, 27 (59%) 
participated in the online survey (Figure 1). The majority 
of participants were from public health institutes (20 out 
of 27; 74%) and, albeit less frequently, from health minis-
tries (5 out of 27; 19%). Structured Internet research was 
OECD OECD and EU EU Other countries
Australia Belgium Austria Bulgaria Albania
Canada Denmark Czech Republic Croatia Liechtenstein
Chile Estonia Hungary Cyprus Montenegro
Iceland Finland Poland Malta North Macedonia
Israel France Portugal Romania Serbia
Japan Germany Slovakia
Mexico Greece Slovenia
New Zealand Ireland Spain
Norway Italy Sweden
South Korea Latvia The Netherlands
Switzerland Lithuania United Kingdom
Turkey Luxemburg
United States of America
EU = European Union, OECD = Organisation for Economic Co-operation and Development
Table 1 




Overview of the process of surveying expert 















1 Includes further selected European countries
 EU = European Union, OECD = Organisation for Economic Co-operation and Development
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disease burden, complications and comorbidities, risk 
factors, quality of care, and public health measures. The 
15 most common indicators are shown in Figure 3. The 
ranking demonstrates that most countries use epidemio-
logical indicators such as incidence, prevalence and mor-
tality of diabetes as well as behavioural risk factors. Indi-
cators covering quality of care, complications and 
comorbidities were reported less frequently. In 23 out of 
28 countries (82%), the indicators relied on data sources 
that included regularly conducted national health surveys. 
Routine data, such as claims data from hospitals and med-
ical practices, insurance data and data from other institu-
tions, are included in diabetes health reporting in 19 out 
of 28 (68%) countries.
In addition to questions about the framework govern-
ing diabetes surveillance, the study focused on the formats 
used and the intended audience of diabetes-specific health 
reporting. The study found that different formats were 
being used to deliver the results (Figure 4). These can be 
The first part of the study focused on the framework 
employed for diabetes health reporting and the indicators 
used to depict developments in the course of the disease. 
In total, four out of five countries include diabetes mellitus 
in their national health reporting (Figure 2). Of these, over 
three quarters have defined a national diabetes strategy or 
action plan. In addition, half of the countries that conduct 
diabetes health reporting state that they follow the WHO’s 
NCD Global Monitoring Framework [16]. However, no con-
clusions could be made about ten of the 38 (26%) countries. 
The majority of countries (29 out of 38; 77%) use an indi-
cator-based system for reporting diabetes, with eight coun-
tries using a system exclusively for diabetes mellitus and 
21 countries including diabetes in their surveillance of non-
communicable diseases.
The evaluation of the indicators determined by the study 
led to the identification of 142 different indicators or indi-
cator clusters that are used in diabetes surveillance. These 
were divided into the following six areas: epidemiology, 
Figure 2 
Concept of diabetes-specific health reporting 
(n=38 countries)
Source: An international comparison 
of noncommunicable disease reporting: 
the case of diabetes mellitus
Percent
Percent
Health reporting on diabetes*
Diabetes strategy/action plan
Alignment with the WHO’s framework 
Indicator-based health reporting
0                 20               40              60               80              100                  
Yes No Do not know
0                      20                   40                   60                80                 100                  
*n = 46 countries 
 WHO = World Health Organization77% of countries use an  
indicator-based surveillance 
system for health reporting 
on diabetes.
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(12 out of 36; 33%) as well as scientific publications (7 out 
of 36; 19%) are used to a much lesser extent. In addition 
to traditional printed formats, results in 20 out of 36 (56%) 
countries are provided on a website or online database, 
with 9 out of 36 (25%) countries providing a database that 
enables the results to be queried directly. More than half 
of the websites and online databases included tools for 
interactive data visualisation. Furthermore, 7 out of 36 
(19%) countries use other formats to publish results. 
These are mainly newer formats related to social media 
such as Twitter, Facebook or YouTube, but also include 
press releases. According to the respondents, these for-
mats are primarily used to draw attention to the issue of 
diabetes and to raise awareness in society about this health 
problem.
divided into printed formats (including digital formats in 
print layouts such as Word and PDF) and formats that 
were only available online (web pages and databases). The 
study evaluated a total of 67 reports, 25 online formats 
and nine other formats from 36 countries. These were 
either provided as links, uploaded by the respondents, or 
were found during the Internet research. Due to the com-
mon ground covered by the reports and for reasons of 
clarity, health reports on diabetes mellitus (DM) and on 
noncommunicable diseases (NCD) were summarised as 
DM/NCD reports. Two thirds of countries (24 out of 36; 
67%) publish their results in a specific report on diabetes 
or together with other noncommunicable diseases. Fur-
thermore, results are often included in countries’ interdis-
ciplinary national health reports. Flyers and fact sheets 
Figure 3 
The 15 most commonly used indicators in 
diabetes mellitus surveillance (n=29 countries)
Source: An international comparison 
of noncommunicable disease reporting: 
the case of diabetes mellitus
Percent
Epidemiology Risk factors
Quality of care Complications and comorbidities










HbA1c value among diabetics
Hyperlipidaemia among diabetics
Medical treatment of diabetes
Hypertension among diabetics
Myocardial infarction among diabetics
Stroke among diabetics
HbA1c = haemoglobin A1c (long-term blood sugar value)
Topic-specific and general 
health reports (67%) are  
the most commonly  
used formats to publish 
information about diabetes.
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a year (35 out of 67; 52%) or within two to five years 
(28 out of 67; 42%).
The public health experts were also asked about the tar-
get audiences that diabetes-specific health reporting was 
seeking to address (Figure 5). Almost all of the countries 
surveyed primarily target policy and decision-makers in the 
health sector, followed by the media and the press, and 
Reports, flyers, websites and online databases are gen-
erally made available in a country’s own language. In 
about half of the cases (48 out of 92; 52%), they are also 
available in English. However, English is an official lan-
guage in seven of these countries. Most formats (67 out 
of 92; 73%) are published or updated regularly. The major-
ity of reports, websites and databases are updated once 
Figure 4 
Formats used in diabetes health reporting 
(n=36 countries) 
Source: An international comparison 
of noncommunicable disease reporting: 









Part of the 
national health 
report
Website or  











DM = diabetes mellitus, NCD = noncommunicable diseases
Figure 5 
Target audiences of diabetes-specific 
health reporting (n=20 countries) 
Source: An international comparison 
of noncommunicable disease reporting: 
the case of diabetes mellitus
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their intended audience (Figure 6). However, since articles 
in scientific journals are primarily aimed at scientists, and 
the category ‘other formats’ contained a diverse range of 
formats, neither was included in the overall evaluation. 
Health sector professionals had provided information 
about the target audiences of 54 reports, all of which were 
then used in the study. The analysis demonstrated that 
interdisciplinary national health reports primarily target 
healthcare policy and decision-makers (21 out of 22; 96%) 
and the media and the press (20 out of 22; 91%). However, 
researchers (16 out of 22; 73%) and the general population 
(13 out of 22; 59%) were addressed in more than half of 
these cases. A similar picture emerges for topic-specific 
scientists and the general population. Slightly more than 
half of the surveyed countries list doctors who treat diabet-
ics as their target audience. Diabetes patients are specifi-
cally addressed by just one in four countries. These results 
are based entirely on the data gathered from the countries 
that participated in the online survey; no information was 
available about the audience targeted by the documents 
identified through Internet research. In total, 20 countries 
provided information about the audiences that their for-
mats were seeking to address (seven countries provided 
no information about this at all).
Different formats are used to address different audi-
ences and, as such, they were evaluated with respect to 
56% of countries use 
websites or online databases 
to provide information about 
diabetes.
Figure 6 
Presentation addressees depending 
on the format used for diabetes-specific 
health reporting (n=54 formats)
Source: An international comparison 
of noncommunicable disease reporting: 
the case of diabetes mellitus
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more traditional printed publications and more modern 
online formats.
The study also sought to select examples of best prac-
tices from the formats identified by the online survey and 
the Internet research (Table 2). Ultimately, the study iden-
tified print and online publications from four countries that 
the authors view as having successfully implemented var-
ious aspects of health reporting.
4. Discussion
The online survey of public health experts and the Internet 
research enabled a structured overview of diabetes-specif-
ic health reporting in the EU and OECD countries to be 
developed. The majority of countries under study include 
diabetes mellitus in their national health reporting and 
have established indicators for disease surveillance. Health 
reports that were either printed or typeset and published 
online were the most commonly used formats. Online 
health reports on diabetes and noncommunicable diseases. 
Just under half of these reports target the media and the 
press. In contrast, flyers and fact sheets on diabetes were 
primarily aimed at the general population (4 out of 4) and, 
to a lesser extent, at political decision-makers and the 
media (3 out of 4). In addition, treating physicians as well 
as diabetes patients themselves are also named as target 
audiences in these cases (2 out of 4). Online formats 
(mainly websites) were aimed at the general population 
(9 out of 9) as well as the media and the press (7 out of 9). 
However, some online formats were also directed at dia-
betes patients (5 out of 9; 57%) and their physicians (5 out 
of 9). 
This results in a clear picture: whereas political deci-
sion-makers are particularly targeted by interdisciplinary 
and topic-specific health reports, online formats, flyers and 
fact sheets are mainly used to address the general popu-
lation. The media and the press, as the second most com-
monly mentioned target audiences, are addressed via both 
Table 2 
Best practice examples from diabetes 
health reporting
Own table
Interactive graphics Flexible data analysis An informative,  
illustrated health report
An informative flyer  
for social media use
Institute Federal Office  
of Public Health
Public Health England National Institute for Public 
Health and the Environment
Centers for Disease Control 
and Prevention





depiction of various 
indicators
Platform enabling  
a flexible visualisation 
of data on diabetes and 
a variety of options for 
evaluation
A well-structured report on the 
development of health in the 
Netherlands. Implements  
a balanced design using text  
and illustrations
Informative infographics and 
innovative formats involving 
social media aimed at the gen-
eral population











The study’s participants 
maintained that policy  
and decision-makers in  
the healthcare sector were 
the most important target 
audiences of diabetes  
health reporting.
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surveys and routine data to map the dynamics of the 
disease. Information about the strengths and weaknesses 
as well as the opportunities offered by these data sources 
can be found in this issue of the Journal of Health 
Monitoring in the contributions entitled Social inequality 
and diabetes mellitus and secondary data in diabetes 
surveillance.
At the same time, the literature also provides very few 
recommendations or reviews of the formats and commu-
nication channels that are used for health reporting in the 
context of diabetes and other NCDs. As part of its frame-
work, the WHO recommends the publication of fact sheets 
and data books (comprehensive volumes containing tables) 
that are entirely focused on the data [12] and that only take 
the requirements of target audiences with regard to format 
and data processing into account to a limited extent.
The study found that traditional printed reports are the 
most common publications used to provide information 
from disease surveillance. However, websites and online 
databases also offer a variety of options for data visualisa-
tion and are already being used by some countries to pre-
sent the results from the surveillance of noncommunicable 
diseases. These tools are already being used to a greater 
extent in the surveillance of infectious diseases [18]. For 
example, the AIDSVu project uses regional analyses to 
identify vulnerable groups and subsequently implement 
targeted public health interventions in the most affected 
communities [19]. This approach could also open up 
diverse opportunities for NCD surveillance. For example, 
the Fingertips platform operated by Public Health England 
(Table 2) provides detailed analyses of various diabetes 
indicators that are used at the regional level to plan public 
formats such as websites and databases are used in more 
than half of the countries under study, some of which also 
provide innovative visualisation tools. All of the countries 
principally targeted policy makers, followed by the media 
and press, individuals and institutions involved in public 
health research, and the general population.
The literature provides very little information that could 
offer an overview of the surveillance systems used to col-
lect data on noncommunicable diseases in various coun-
tries. However, as part of its action plan for the prevention 
and control of NCDs, the WHO regularly reports on the 
progress that each member state is making towards reach-
ing the action plan’s objectives, and also publishes relevant 
documents [17]. The proportion of countries with an iden-
tified diabetes strategy is comparable to the results of the 
online survey. The few exceptions that did occur were due 
to the fact that five cases from the online survey involved 
general NCD strategies that only implicitly included diabe-
tes.
Although the WHO Framework [16] recommends that 
countries monitor behavioural risk factors (alcohol con-
sumption, tobacco consumption, physical inactivity, obe-
sity and overweight, unhealthy dietary habits) as part of 
their disease surveillance, the study found that only half of 
countries do so. However, closer analysis of the indicators 
demonstrates that two thirds of indicator systems include 
behavioural risk factors as indicators, and, thus, the major-
ity of indicator systems do indeed reflect the WHO’s 
approach. Moreover, the majority of countries also use data 
sources that contain both primary and secondary data. Dia-
betes surveillance at the RKI also includes behavioural risk 
factors among its indicators [4] as well as data from health 
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politics; as of this time, the impact of the media is yet to 
have been unequivocally proven [21]. Moreover, personal 
contact, which can take place during individual meetings 
and symposia, is particularly important when it comes to 
addressing politicians [10]. In summary, it is crucial that 
the needs of different target audiences are considered 
[22, 23] and that indicators are used to review the use of 
the formats provided [10, 24, 25].
4.1 Limitations
The two-step approach and the use of two different meth-
ods to collect data on diabetes-specific health reporting 
means the study faces a number of limitations. As some 
countries did not participate in the online survey, the only 
information and documents available in these cases were 
those that were found on the Internet. These were avail-
able in English, German or French or via Google Translate. 
Moreover, as data about target audiences are not freely 
available and can only be supplied by public health experts, 
the Internet research was unable to provide information 
about the intended target audiences in these cases. Simi-
larly, as no information was available about the people who 
were actually using the respective formats, it was impos-
sible to judge whether the intended audiences were actu-
ally being reached. Furthermore, the study was limited to 
publications by state institutions and ministries; publica-
tions by non-governmental organisations, such as patient 
associations or professional associations, were not includ-
ed in the analyses. Equally, the study’s focus on national 
health reporting meant that regional reports or other 
regional formats were not considered. Finally, it is unclear 
health measures [15]. In addition, social media offer new 
opportunities to provide information to the public [10] and 
are already being used in some countries. In these cases, 
the focus is on raising awareness about diseases such as 
diabetes and their related risk factors. Similarly, the CDC 
(Centers for Disease Control and Prevention) in the United 
States of America have developed infographics that provide 
information about diabetes to the general public (Table 2). 
However, more research is needed into the effectiveness 
of public health interventions via social media [14].
The online survey found that diabetes reporting primar-
ily seeks to address policymakers and health-care deci-
sion-makers, followed by the media and press. The WHO 
also identifies policymakers and health-care decision-mak-
ers as two of its four target audiences for information from 
NCD surveillance in addition to service providers and the 
general population [12]. The literature also emphasises the 
importance of addressing service providers and the gen-
eral public during the establishment of public health surveil-
lance systems [6, 7, 10]. Whereas diabetes surveillance 
tends to target politicians with the aim of encouraging the 
development of interventions and other public health mea-
sures (data-based decision-making) [20], the primary pur-
pose of providing information to the general public is to 
raise awareness about diseases and risk factors as well as 
to provide other information that is relevant to public health 
[7]. The media and the press can serve as important dis-
seminators of information aimed at the general public and, 
therefore, indirectly raise awareness among politicians of 
the importance of specific topics [9]. However, a discus-
sion is currently taking place in the literature about the 
effectiveness of the media in terms of its impact on 
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noncommunicable diseases. In order to address these audi-
ences, a website is to be developed to provide visual rep-
resentation of the results of diabetes surveillance; social 
media, such as Twitter and YouTube, are also to be used 
more regularly. The examples of best practices, which were 
collected during the survey and Internet research, will pro-
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whether the results of the study can be applied to all non-
communicable diseases, as diabetes receives greater atten-
tion than other diseases.
4.2 Conclusion and outlook
Public health surveillance systems provide the data required 
to make health policy decisions and to establish public 
health policies. The growing complexity caused by the 
increasing number of data sources and findings from sci-
entific research means that information needs to be pro-
vided transparently and understandably. In addition to 
more traditional formats, such as reports, new tools for 
visualisation and interactive databases can enable data to 
be depicted in a manner that is understandable and which 
facilitates access to different target audiences.
Health reports about NCDs primarily address politicians 
and health policy decision-makers. However, these individ-
uals can be reached in different ways. In addition to reports, 
established communication tools and social media also 
provide appropriate communication channels that can 
raise the priority and awareness of specific public health 
challenges. Discussions and symposia also constitute an 
important aspect of dissemination strategies.
The study’s findings are to be used to develop a dissem-
ination strategy for diabetes surveillance at the RKI. Dia-
betes surveillance particularly targets politicians and deci-
sion-makers in the healthcare sector. In line with the results 
of this study, a diabetes report is to be drawn up for this 
target audience. In addition, information is also to be pro-
vided to the general public and the media with the aim of 
raising awareness about the growing challenges posed by 
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2. Diabetes mellitus surveillance
2.1 Do you know whether there is a national  




3: Do not know
2.2 Does the national diabetes reporting follow  
the WHO framework for surveillance of  
noncommunicable diseases?
Table 1: Framework for national NCD surveillance
Exposures
Behavioural risk factors: tobacco use, physical inactiv-
ity, the harmful use of alcohol and unhealthy diet.
Physiological and metabolic risk factors: raised blood 
pressure, overweight/obesity, raised blood glucose, and 
raised cholesterol.
Social determinants: educational level, household 
income, and access to health care.
Outcomes
Mortality: NCD-specific mortality.
Morbidity: Cancer incidence and type (as core).
Health system capacity and response
Interventions and health system capacity: infrastruc-
ture, policies and plans, access to key health-care inter-
ventions and treatments, and partnerships.
1. Introduction
1.1 Would you like to participate in this survey?
1: Yes
2: No
1.2 For which country do you answer this  
questionnaire?
Please enter the country here
1.3 What kind of institution are you working for?
1: Ministry
2: National public health institute
3: Regional or local public health institute
4: Other governmental institution
5: University
6: Research institute
7: Health insurance body
8: Think tank, private consultancy
9: NGO, association or interest organization
10: Medical care facility
11: Social care facility
12: Others, namely:
13: No reply






'Health reporting on diabetes mellitus'
Own table 
Surveillance of Noncommunicable Diseases. Report of a 
WHO Meeting. Geneva, World Health Organization, 2010.
1: Yes
2: No
3: Do not know
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Annex Table 1 Continued
Online survey 
'Health reporting on diabetes mellitus'
Own table 
2.3 Has there been a national diabetes strategy  




3: Do not know
2.3.1 Is the national diabetes strategy (action plans  
or health targets) available in English?
1: Yes
2: No
3: Do not know
2.3.2 Please enter the corresponding internet link/ 
URL address or upload the national diabetes  
strategy here.
Text field
2.4 Is there an established set of health-related indica-
tors (social and environmental determinants, risk 
factors, health-related outcomes) in your country, 
which is used for health reporting of noncommu-
nicable disease and/or diabetes mellitus?
1:  Yes, for noncommu nicable disease including 
diabetes mellitus
2: Yes, specifically for diabetes mellitus only
3: No
4: Do not know
2.4.1 Please enter the corresponding internet link/URL 
or upload the document of the indicator system 
for health reporting on diabetes mellitus or NCDs 
in your country here.
Text field
2.4.2 Do you distinguish within your set of health- 
related indicators between core indicators and 
additional indicators?
1: Yes, we have defined a subset core indicators
2:  No, we do not distinguish within the set  
of indicators
3: Do not know
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3. Formats
3.1 What formats are used for publication of health reports covering diabetes mellitus in your country at national level?
Multiple answers allowed
Information on diabetes mellitus is published…
1: … as specific chapter in a comprehensive national health report. 
2:  … as part of a comprehensive report on noncommu nicable diseases.
3:  … as comprehensive report solely on diabetes mellitus.
4: … as short report on diabetes mellitus.
5: … as fact sheet/flyer.
6: … as publication in a peer-reviewed journal.
7: … as statistical online-database.
8:  … as main topic on the website of a national public health institute or another institution.
9: … as another report format.
10: Do not know
3.2 For the health reports including diabetes mellitus you know, please name the …
- Title
- Type of report
- Publishing institution
- Year of publication/Regular publication
In case of regularly published national health reports please list only the latest issue.  
If the reports are available in English we invite you to upload the document in a later step.






Report is regularly published Year of  
publication 
(latest issue)
Report available in English




Annex Table 1 Continued
Online survey 
'Health reporting on diabetes mellitus'
Own table 
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3.2.1 For the reports, which are published regularly, could you please indicate the publication frequency?
Publication frequency (<1 year, annually, biannually, every 3-5 year, every 5-10 year, >10 year)
Report 1
…





















4. Database (only if applicable)
4.1 You have indicated that surveillance data on  
diabetes mellitus is part of an online database. 
What is the name of the online database?
Text field
4.2 Which institution hosts the database?
Text field
4.3 Is the database available in English?
1: Yes
2: No
3: Do not know
Annex Table 1 Continued
Online survey 
'Health reporting on diabetes mellitus'
Own table 
4.4 Does the database include a tool for regional visuali-
zation, e.g. an interactive map showing different indi-
cators like prevalence by region within the country?
1: Yes
2: No
3: Do not know
4.5 How frequently is the information of the  
database updated?
1: Regularly - Please indicate timeframe in years___
2: Only irregular updates
3: Do not know
4.6 Is the database publically available?
1: Yes - Please indicate the link/URL __________
2: No
3: Do not know
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5. Website (only if applicable)
5.1 You mentioned that diabetes mellitus is a main topic of the website of a national public health institute  
or another institution in your country. 
What is the name and link/URL of the website?
Text field
5.2 Which institution hosts the website?
Text field
5.3 Is the website available in English?
1: Yes
2: No
3: Do not know

























5.5 Does the website include a tool for regional  
visualization of data on diabetes mellitus, e.g. an 
interactive map showing different indicators like 
prevalence by region within the country?
1: Yes
2: No
3: Do not know
5.6 How frequently is the information of the  
website updated?
1:  Regularly - Please indicate timeframe  
in months____________
2: Only irregular updates
3: Do not know
Annex Table 1 Continued
Online survey 
'Health reporting on diabetes mellitus'
Own table 
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6. Other format (only if applicable)
6.1 You have indicated that health information on diabetes mellitus is published in a format other than those listed. 
Could you please describe the format in more detail (print vs. online, content of the format, etc.)?
Text field
6.2 Which institution publishes this format?
Text field
























6.4 Is this format published regularly?
1: Yes
2: No
3: Do not know
6.5 Is this format on diabetes mellitus available in English?
1: Yes
2: No
3: Do not know
6.6 Please enter the corresponding internet link/URL address or upload the diabetes mellitus report format here.
Text field
Annex Table 1 Continued
Online survey 
'Health reporting on diabetes mellitus'
Own table 
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7. Data Sources
7.1 You have indicated that in your country there  
is an indicator system for the monitoring of  
diabetes mellitus in place. Which data sources  
are you using to collect this data?
Multiple answers allowed
Primary data using…
1:  … a national health survey specifically  
on diabetes mellitus.
2:  … a national health survey on noncommunicable 
diseases including diabetes mellitus.
3:  … a general national health survey covering several 
topics including diabetes mellitus.
Secondary data using
4:  … other institutions/ministries, namely_______
5:  … data from insurance companies
6:  … data from hospitals/doctors
Other
7:  … Other sources, namely ________
8:  Do not know
 




8.1 If you know of a relevant health report on the 
national, sub-national or international level which 
you consider a good-practice-model for reporting 
on noncommu nicable diseases or diabetes  
mellitus, please indicate the internet link/URL 
address and/or upload the report here.
Text field
8.2 Do you have any further comments about health 
reporting on diabetes mellitus or this survey?
Text field
Thank you for your participation!
Annex Table 1 Continued
Online survey 
'Health reporting on diabetes mellitus'
Own table 
Journal of Health Monitoring
Journal of Health Monitoring 2019 4(2)
CONCEPTS & METHODSAn international comparison of noncommunicable disease reporting: the case of diabetes mellitus
85
The Robert Koch Institute is a Federal Institute within  
the portfolio of the German Federal Ministry of Health
This work is licensed under a 
Creative Commons Attribution 4.0 
International License.
Imprint 






Susanne Bartig, Johanna Gutsche, Dr Birte Hintzpeter,  
Dr Franziska Prütz, Martina Rabenberg, Dr Alexander Rommel,  
Dr Livia Ryl, Dr Anke-Christine Saß, Stefanie Seeling,  
Martin Thißen, Dr Thomas Ziese
Robert Koch Institute













External contributions do not necessarily reflect the opinions of the 
Robert Koch Institute.
Journal of Health Monitoring
Journal of Health Monitoring 2019 4(2)
CONCEPTS & METHODSThe selection and definition of indicators in public health monitoring for the 65+ age group in Germany
86
Journal of Health Monitoring · 2019  4(2) 
DOI 10.25646/5990 
Robert Koch Institute, Berlin 
Maike M. Grube 1, Christa Scheidt-Nave 1,  
Beate Gaertner 1, Denise Lüdtke 1,  
Michael Bosnjak 2, Stephanie Heinrich 3,  
Nils Lahmann 4, Gabriele Meyer 3, Kilian Rapp 5, 
Steffi Riedel-Heller 6, Martina Schäufele 7,  
Karin Wolf-Ostermann 8, Susanne Zank 9,  
Judith Fuchs 1
 1 Robert Koch Institute, Berlin
 2  Leibniz Institute for Psychology  
Information Trier
 3 Martin Luther University Halle-Wittenberg
 4 Charité-Universitätsmedizin Berlin
 5 Robert Bosch Hospital, Stuttgart
 6 Leipzig University
 7 Mannheim University of Applied Sciences
 8 University of Bremen




The selection and definition of indicators in public health  
monitoring for the 65+ age group in Germany
Abstract
Selecting relevant indicators is an important step in the development of public health monitoring for older people. 
Indicators can be used to combine information comprehensively from various data sources and enable recurring, 
comparable findings to be made about the health of older people. Indicators were systematically compiled from existing 
international monitoring systems. An indicator set on health in old age was developed using a multistage, structured 
consensus-based process together with an interdisciplinary panel of experts. The resulting 18 indicators were assigned 
to three health areas: (1) environmental factors, (2) activities and participation, and (3) personal factors. Data sources 
that can be used for the indicators are the health surveys within the framework of the Robert Koch Institute’s (RKI) health 
monitoring system, as well as surveys from other research institutes and official statistics. In the future, the indicator 
set is to be developed further and integrated into an overall approach that is geared towards health reporting and the 
monitoring of chronic diseases in all phases of life.
  PUBLIC HEALTH · SURVEILLANCE · AGE · INDICATORS · HEALTH MONITORING 
1. Introduction
Public health monitoring involves the systematic and con-
tinual provision of health-related information from various 
data sources that enables health care stakeholders and 
health and social policy makers to use the best available 
evidence to make decisions [1, 2]. In its 2017 Global Strat-
egy and Action Plan on Ageing and Health [3], the World 
Health Organization (WHO) describes the implementation 
of a sustainable and efficient system to monitor the health 
of older people as a priority area for improving health in 
old age. Moreover, the report stresses that agreement on 
important core concepts and internationally comparable 
measures is essential. However, such agreement requires 
open debate about health priorities and values, and needs 
to involve key stakeholders, including older people. Despite 
the fact that promising indicator-based approaches to 
health monitoring for older people have already been 
advanced internationally [4, 5], Germany has yet to see 
comparable developments at the federal level.
The Improving Health Monitoring in Old Age (IMOA) 
project took place between 2016 and 2018 and was funded 
by the Robert Bosch Stiftung. The project set itself the goal 
of developing a concept for a nationwide system of public 
health monitoring that would cover the entire population 
aged 65 or above. Moreover, it was aimed at developing a 
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conceptual framework and to select relevant indicators that 
would permit recurring and comparable health information 
to be made available for the population aged 65 and above. 
In addition to using data from the nationwide examination 
and interview surveys regularly undertaken as part of the 
health monitoring at the Robert Koch Institute (RKI), data 
from other sources, such as registry data and health insur-
ance administrative data need to be considered in an indica-
tor-based health information system to a greater extent, as 
these data are available regularly and cover all age groups [6].
This paper describes the selection and definition of indi-
cators for a public health monitoring of the older popula-
tion in Germany.
2. Methodology
Indicators were selected together with an interdisciplinary 
panel of experts consisting of fifteen appointees and two 
alternates from the fields of general practice, geriatrics, 
gerontology, public health, survey methods and nursing 
science as well as from a civil society organisation (Annex 
Table 1). In line with the WHO’s World Report on Ageing 
and Health [7] and the International Classification of Func-
tioning, Disability and Health (ICF) [8], the following three 
areas on health in old age were agreed upon: (1) environ-
mental factors, (2) activities and participation, and (3) per-
sonal factors. These areas provided the overall framework 
for further indicator development. In March 2017, a joint 
one-day workshop – supported by a qualitative content 
analysis of national and international health goals for old-
er people – chose relevant topics from each of the three 
areas on which the indicators were to focus [9]:
1. Health care provision, nursing and community care, 
physical environment, and social environment
2. Social participation and activities of daily living
3. Physical health, mental health, physical and  
cognitive functioning, and health behaviour
The systematic inventory of existing indicator sets was 
followed up by a multistage, structured consensus-based 
process that was used to select and define relevant indica-
tors with which to monitor health in older age.
2.1 Indicator research
Between June and July 2017, comprehensive research was 
conducted into national, indicator-based monitoring sys-
tems of health in older age. A detailed description of the 
study’s methods and findings has been published else-
where [10]. The research was limited to the 35 member 
states of the Organisation for Economic Co-operation and 
Development (OECD). Indicator sets were only taken into 
account if they were written in English or German, had been 
published or updated after 1 January 2007, if data were 
available from more than one source, for example from 
survey data and from health insurance administrative data, 
and if information was available about how the indicators 
were being operationalised. No restrictions were placed 
on a particular format, meaning that indicator sets were 
accepted as reports, brochures, web pages or scientific 
papers. The research focused on the websites of national 
public health institutes, involved a supplementary search 
of the Internet using the Google search engine, as well as 
a literature review (via PubMed) of the Medline electronic 
The selection of relevant 
indicators is an important 
step in the development  
of continual public health 
monitoring of older people.
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the experts were provided with a standardised evaluation 
form via e-mail. The panel was able to use this form to 
include additional notes and to raise questions about the 
indicators.
The panel used the following criteria to assess the indi-
cators [12]: 
   Higher indicator values point to improved health-relat-
ed quality of life and/or a healthy life expectancy among 
older people. 
   Higher indicator values point to reduced health inequal-
ities among older people.
   Indicators can be influenced by policy measures or pub-
lic health interventions.
   Indicators are meaningful and relevant for the public 
and for stakeholders from the fields of politics and 
health care.
   The indicator is easy to understand and interpret.
   The indicator is valid and reliable – it measures what it 
is intended to measure.
Fourteen of the fifteen evaluation forms were filled in 
and returned to the RKI. Each potential indicator was 
ranked according to the distribution of the points given in 
the evaluation sheets, taking into account the median and 
the first quartile (Q0.25) (Figure 1):
   Indicators were classified as highly relevant if more than 
75% of the ratings were in the top range (7-9 points), i.e. 
the median and the first quartile (Q0.25) were 7-9 points.
   Indicators were classified as relevant if more than 50% 
and less than 75% of the ratings were in the top range 
database. Ten sets of indicators from Finland, the United 
Kingdom, Ireland, New Zealand, Switzerland and the US 
met the previously-defined criteria for inclusion, and their 
structure, related development processes and content were 
subsequently analysed.
2.2 Indicator selection and evaluation
Two independent reviewers assessed and evaluated the indi-
cators identified by the research. Indicators that fitted into 
the previously-defined conceptual framework for indicator 
selection were included in the next step. In addition, the 
following exclusion criteria were defined: (1) duplicates of 
content, (2) indicators that were not fully compatible with 
the German health or social care system, (3) indicators that 
were not clearly worded and, thus, were difficult to interpret, 
and (4) indicators that were used for regional comparisons 
only and, therefore, could not be aggregated to the nation-
al level. The remaining indicators were supplemented by 
indicators proposed by the RKI project team that had not 
been included in existing monitoring systems but that pro-
vided information about the topics that had been given pri-
ority in the development of the conceptual framework.
This step was followed by a structured consensus-based 
process that was carried out as a three-stage modified Del-
phi technique based on an approach developed by the 
EU-initiated and funded Joint Action on Chronic Diseases 
initiative [11].
During the first stage, which took place between Octo-
ber and November 2017, the fifteen members of the expert 
panel were asked to use a 9-point scale (1 = low relevance; 
9 = high relevance) to rate the indicators. On this account, 
Indicator-based public health 
monitoring enables  
comparable assessments  
to be made of the health  
of older people over time  
and can be used to support  
policy-related  
decision-making.
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cators that had been categorised as of medium relevance 
during the first stage. In line with the framework provided 
by the European Core Health Indicators (ECHI) [13], the 
following factors were taken into account while preparing 
the indicator set: definition, available data sources, type 
and periodicity of the data sources, reference population, 
and the possibility of stratification by gender and socioe-
conomic status. In addition, a short summary was drawn 
up of each indicator’s scientific background, which also 
included a list of important references. The resulting set 
was presented to the experts who were then asked to 
re-evaluate the indicators and to provide their views in writ-
ing (per e-mail). The experts used a 9-point scale and were 
able to make proposals, provide criticism and call for 
changes to be made to the proposed operationalization 
and listed data sources. Eleven of the fifteen evaluation 
sheets were returned to the RKI as part of the third evalu-
ation stage.
(7-9 points), i.e. the median was 7-9 points and the first 
quartile (Q0.25) was below 7 points.
   Indicators were classified as of medium relevance if at 
least 50% of the ratings were in the lower (1-3 points) 
and medium (4-6 points) range, i.e. the median was 
below 7 points.
   Indicators were classified as of low relevance if at least 
50% of the ratings were in the lowest range (1-3 points), 
i.e. the median was below 4 points.
On 15 December 2017, the experts were invited to Ber-
lin to take part in a one-day workshop – the second stage 
of the Delphi technique. Nine of the fifteen experts partic-
ipated. The workshop began with a presentation of the 
results of the first stage. This also included a discussion 
of the questions and proposals regarding the individual 
indicators that had been raised on the evaluation forms. 
At the end of the workshop, the participants were once 
again asked to provide a written assessment of the indica-
tors that had been classified as either highly relevant or 
relevant during the first stage. The evaluation was carried 
out in writing and the format of the evaluation sheets was 
identical to that used in the first stage.
Indicators that had been classified as highly relevant 
during the second stage of evaluation (those where at least 
75% of the ratings were in the top range – between 7 and 
9 points) went on to the third and final stage of the Delphi 
technique. Indicators that the participants had not classi-
fied as highly relevant were excluded in order to concen-
trate on those that they considered as most important. 
However, after reconsidering the scientific evidence, the 
participants requested a reassessment of some of the indi-
Figure 1 
Grading system to rate indicators according 
to their relevance for public health monitoring 
for the 65+ age group
Own diagram
1 2 3 4 5 6 7 8 9
High relevance  >75%     7-9 points
>50 % –75%     7-9 points
 ≥50%      <7 points




1 2 3 4 5 6 7 8 9
1 2 3 4 5 6 7 8 9
1 2 3 4 5 6 7 8 9
Median
First Quartil (Q0,25)
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The remaining 17 indicators were rated as of medium rel-
evance and were excluded from the next stage of the eval-
uation. This led to 49 indicators for the second stage of 
evaluation.
The feedback provided during the second stage resulted 
in 33 indicators being classified as highly relevant, 13 indi-
cators as relevant and 3 indicators as of medium relevance. 
During a workshop that preceded this stage of the evalua-
tion, the participants had decided to make a number of 
modifications to the indicator set. This resulted in the com-
bination of three potential indicators (‘recipient of inpatient 
care’, ‘recipient of outpatient care’ and ‘level of long-term 
care needs’) to form a single indicator (‘recipient of long-
term care’), and the addition of a further indicator – ‘psy-
chotropic medication’. Finally, five out of the 17 indicators 
classified as of medium relevance during the first stage 
(‘influenza vaccination’, ‘pneumococcal vaccination’, ‘pres-
sure sores’, ‘difficulty walking’ and ‘grip strength’) were to 
be re-evaluated after a review of the scientific evidence.
The indicators that were not classified as highly relevant 
were excluded prior to the third and final stage. This pro-
cess resulted in 37 indicators being selected. Information 
on these was documented in accordance with the schema 
described above (definition, data sources, type and perio-
dicity of the data sources, reference population, options 
for stratification, scientific background and references) and 
was presented to the experts for evaluation and comment. 
By the end of the third stage, 18 of the 37 indicators were 
still classed as highly relevant, 14 were now viewed as rel-
evant and five as of medium relevance.
The final indicator set is available on the RKI website. 
With 15 indicators, most of the 18 indicators selected in the 
3. Results
The final indicator set contains 18 indicators (Table 1). 
Figure 2 summarises the selection process. The results of 
the structured consensus-based process on which the 
selection of indicators is based are set out in detail in the 
Appendix (Annex Table 2).
As part of the indicator research, ten indicator systems 
with a total of 293 individual indicators were identified using 
the described search strategy. A total of 133 of these indi-
cators were assigned to one of the previously-defined top-
ics. Of these, 56 indicators were excluded as duplicates, 21 
indicators because they were not fully compatible with the 
German health or social care system, and ten indicators 
because they were not clearly formulated and difficult to 
interpret. A further indicator was excluded due to the fact 
that it allowed comparisons only at regional level. As the 
remaining indicators did not cover all of the issues that 
had been defined as relevant at the beginning of the study, 
the indicator set was supplemented by 21 additional indi-
cators. These particularly covered long-term care provision, 
participation and physical functioning. This resulted in an 
indicator set comprising 66 potential indicators for inclu-
sion in the structured consensus-based process. These 
indicators were attributed to the predefined topics as fol-
lows: health care (9), nursing and community care (8), 
physical environment (3), social environment (4), social 
participation (4), activities of daily living (2), physical health 
(9), mental health (10), physical functioning (11), cognitive 
functioning (2) and health behaviour (4).
During the first stage of the evaluation, 25 of the 66 indi-
cators were classified as highly relevant and 24 as relevant. 
The IMOA project  
selected its indicators by 
systematically compiling 
indicators from existing 
international monitoring 
systems.
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Table 1 
Health areas, domains, and indicators for 
public health monitoring for the 65+ age group 
Own diagram
Indicators Available data sources
Environmental factors
Health care
Unfulfilled care needs German Health Update (GEDA)
European Union Statistics on Income and Living Conditions (EU-SILC)
Dental care German Health Update (GEDA)
German Oral Health Study (DMS)
Psychotropic medication* German Health Interview and Examination Survey for Adults (DEGS1)
Nursing and community care
Recipient of long-term care Nursing care statistics from the Federal Statistical Office
Caregiver burden* German Health Interview and Examination Survey for Adults (DEGS1)
Physical environment
Access to important infrastructure European Quality of Life Surveys (EQLS)
Social environment
Social support German Health Update (GEDA)
German Health Interview and Examination Survey for Adults (DEGS1)
Loneliness** German Ageing Survey (DEAS)
Activities and participation
Activities of daily living
Restrictions in activities of daily living German Health Update (GEDA)
Restrictions in instrumental activities of daily living German Health Update (GEDA)
Personal factors
Physical health
Subjective health German Health Update (GEDA)
German Health Interview and Examination Survey for Adults (DEGS1)
European Union Statistics on Income and Living Conditions (EU-SILC)
Socio-Economic Panel (SOEP)
Multimorbidity German Health Update (GEDA)
German Health Interview and Examination Survey for Adults (DEGS1)
Mental health
Depressive symptoms German Health Update (GEDA)
German Health Interview and Examination Survey for Adults (DEGS1)
Life satisfaction German Health Update (GEDA)
Physical functioning
Pain German Health Update (GEDA 2013s special survey)
Falls* German Health Interview and Examination Survey for Adults (DEGS1)
Urinary incontinence German Health Update (GEDA)
Cognitive functioning
Cognitive impairments* Additional mental health module of the German Health Interview and 
Examination Survey for Adults (DEGS1)
Data only available up to a specified age limit: * Available for the age group 65 to 79 years; ** Available for the age group 65 to 85 years
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Figure 2 
Indicator selection for public health monitoring 
of the 65+ age group
Own diagram
Indicator research:                           293 indicators




Delphi technique, first stage:
 ▶ 25 indicators: high relevance
 ▶ 24 indicators: relevance
 ▶ 17 indicators: medium relevance
Changes agreed upon during workshop:
 ▶ three indicators were combined
 ▶ one additional indicator included
 ▶ five indicators reviewed once more
Integration of further indicators (n=21)
Exclusion of indicators that were not classified as relevant or highly 
relevant (n=17)
Assessment by independent reviewers and exclusion 
(n=88) due to:
 ▶ Duplications (n=56)
 ▶ Lack of transferability (n=21)
 ▶ Too complex (n=10)
 ▶ Only possible to collect data at regional level (n=1)
33 indicators
Delphi technique, second stage:
 ▶ 33 indicators: high relevance
 ▶ 13 indicators: relevance
 ▶   3 indicators: medium relevance
37 indicators included in the indicator set
18 indicators in the final indicator set
Delphi technique, final stage of consensus building:
 ▶ 18 indicators: high relevance
 ▶ 14 indicators: relevance
 ▶   5 indicators: medium relevance
Exclusion of indicators that were not classified as highly relevant 
(n=16)
Exclusion of indicators that were not classed as highly relevant 
(n=19)
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4. Discussion and outlook
With the final indicator set, we hope to contribute towards 
building a sustainable and reliable health reporting for old-
er age in Germany. All the 18 indicators selected in the final 
stage can be presented on a national level using adequate 
and sustainable data sources. Almost all of the indicators 
rely on primary data collected by the Robert Koch Institute 
or other research institutions; just one of the indicators 
(‘recipient of long-term care’) can be presented using rou-
tine data. Primary data are survey or examination data that 
have been collected mainly for scientific purposes. Routine 
data include administrative data from health insurance and 
other social insurances as well as data from official statis-
tics such as long-term care and cause of death statistics. 
The combination of primary and routine data is particular-
ly valuable [21]. Primary data not only enable indicators to 
be stratified by gender or age group, but also by socioeco-
nomic status. In addition, subjective health outcomes, such 
as health-related quality of life and subjective care needs, 
can only be displayed using survey data. On the other hand, 
routine data are not affected by non-response bias and they 
enable indicators to be updated periodically. Besides, they 
are not affected by age restrictions often applied to inter-
view and examination surveys [15, 16], because older adults, 
especially older adults in poor health, are harder to reach 
by conventional recruitment and survey methods [22, 23]. 
Data for five of the 18 indicators selected for this set are 
available with an upper age limit of 79 or 85.
The integration of routine data (research data sets collated 
by statutory health insurers that are made available due to 
Germany’s Data Transparency Regulations, DaTraV) provides 
final stage of the consensus-based process can be repre-
sented by data from the nationwide health surveys con-
ducted at the Robert Koch Institute; three of the 15 indica-
tors can be represented both by these and by surveys 
conducted by external data providers. Two indicators rely 
on data from external studies and one indicator on data 
from official statistics. The indicators draw on data from 
the following studies: the German Health Update (GEDA) 
[14], the German Health Interview and Examination Sur-
vey for Adults (DEGS) [15], the German Ageing Survey 
(DEAS) [16], the German Oral Health Study (DMS) [17], 
the Socio-Economic Panel (SOEP) [18], the European Qual-
ity of Life Surveys (EQLS) [19] and the European Union 
Statistics on Income and Living Conditions study (EU-SILC) 
[20].
For five of the 18 indicators data are currently available 
for the population aged 65 or above, but not for the popu-
lation aged 80 or above. Four of these rely on data from 
the German Health Interview and Examination Survey for 
Adults (DEGS1, 2008-2011) and are, therefore, restricted 
to an upper age limit of 79 [15]. A fifth indicator relies on 
data from the German Ageing Survey (DEAS) [16] and is 
limited to the age of 85. However, all of the data sources 
used allow for the indicators to be stratified by gender and 
age group (albeit with the limitations mentioned above). 
With the exception of the ‘recipient of long-term care’ indi-
cator, which relies on official statistics, all other indicators 
can also be stratified by socioeconomic status or educa-
tion.
The final set of indicators on 
the health of older people 
comprises 18 indicators that 
are to be continuously  
developed further.
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different approach to selecting relevant health care meas-
ures: it combined an expert-led Delphi technique with a 
focus group of older people to ensure that their views were 
taken into account during the selection process [26].
No claims are made as to the comprehensiveness of 
the indicator set presented here, nor is it assumed that the 
set fully captures the health and well-being of older people. 
Rather, this is an ongoing process, and the indicator set 
will need to be adapted to account for new health and 
methodological challenges. Nevertheless, agreement on a 
conceptual framework as well as on relevant indicators for 
public health monitoring of the population over the age of 
65 means that it is now possible to conduct comparable 
assessments of the health of older people over time. The 
aim is also for these indicators to be integrated into an 
overall approach to the development of health monitoring 
and health reporting in the prevention of chronic diseases 
and to ensure good health in all stages of life in accordance 
with international action plans [27, 28]. The development 
and implementation of the national diabetes surveillance, 
which began in 2016, has laid valuable foundations for this 
undertaking [29]. Finally, in the long term, a data structure 
needs to be established that can be used to support policy 
decision-making processes, the evaluation of health goals 
and policy impact assessments.
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for better representation of indicators related to health care 
provision and the possibility to display the indicators on a 
regional level, at least down to the federal state level. The 
data sources currently available allow only limited regional 
analysis of the 18 indicators. Here, examples from other coun-
tries demonstrate that merging indicators based on data col-
lected at the national and regional level is technically possible 
and creates synergies [4]. Efforts are also being made to 
expand federal health reporting and reporting at the federal 
state level in Germany along similar lines [24, 25].
The approach to select indicators using a modified Del-
phi technique supplemented by a full-day workshop during 
which questions raised by the participants could be dis-
cussed and clarified, proved to be both effective and 
time-saving. However, the participants found the task of 
using various criteria to assess indicators in accordance 
with a single globally valid score challenging. Future con-
sensus processes might ask participants to assess criteria 
seperately, and, therefore, focus solely on the subject areas 
in which they have the most expertise. One limitation of 
the study is the fact that albeit representatives of different 
professions and institutions from practice and research 
participated in the selection process, the approach was 
mainly expert-led and older people’s views had limited 
influence during the development of the indicator set. In 
the future, it may be useful to base selection processes 
more along the lines of the approach used to draw up Ire-
land’s national positive ageing indicator set [5] – in addi-
tion to stakeholders from science and practice, older peo-
ple participated equally as participants in the Delphi 
technique. Similarly, the International Consortium for 
Health Outcomes Measurement (ICHOM) also chose a 
The indicators are to be  
integrated into a future 
overall approach to the  
monitoring of chronic 
diseases by the  
Robert Koch Institute.
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Annex Table 1 
Participants of the expert panel on 
indicator selection for public health 
monitoring of the 65+ age group
Prof Dr Michael Bosnjak Leibniz Institute for Psychology Information Trier
Min Dir a.D. Rudolf Herweck Federal Association of Senior Citizens Organizations, Bonn
Prof Dr Josefine Heusinger Institute for Gerontological Research, Berlin
PD Dr Nils Lahmann Charité – Universitätsmedizin Berlin
Prof Dr Gabriele Meyer Martin Luther University Halle-Wittenberg
Prof Dr Ursula Müller-Werdan Charité – Universitätsmedizin Berlin
Prof Dr Kilian Rapp Robert Bosch Hospital, Stuttgart
Prof Dr Steffi Riedel-Heller, MPH Leipzig University
Prof Dr Martina Schäufele Mannheim University of Applied Sciences
Prof Dr Martin Scherer University Hospital Hamburg-Eppendorf
Prof Dr Clemens Tesch-Römer German Centre of Gerontology, Berlin
Prof Dr Hans-Werner Wahl Heidelberg University
Prof Dr Karin Wolf-Ostermann University of Bremen
Prof Dr Susanne Wurm Friedrich Alexander University Erlangen-Nuremberg
Prof Dr Susanne Zank University of Cologne
Dr Stephanie Heinrich (as of stage 2) Martin Luther University Halle-Wittenberg
Dr Dagmar Lühmann (as of stage 2) University Hospital Hamburg-Eppendorf
Journal of Health Monitoring
Journal of Health Monitoring 2019 4(2)
CONCEPTS & METHODSThe selection and definition of indicators in public health monitoring for the 65+ age group in Germany
98
No. Indicator 1st evaluation stage 2nd evaluation stage Consensus round
Median Q0,25 Q0,75 Median Q0,25 Q0,75 Median Q0,25 Q0,75
Health area: environmental factors
Domain: health care
1 General practitioner (GP) care 6 3 8       
2 Medical home visits 4 3 5       
3 Unfulfilled care needs 8 3 9 8 8 9 8 7 9
4 Hospitalisations 6 5 8       
5 Dental care 7 6 8 7 7 8 8 7 9
6 Multimedication 7 5 8 8 8 8 8 6 9
Psychotropic medication    8 7 9
7 Influenza vaccination 6 5 7    5 4 7
8 Pneumococcal vaccination 6 4 7    4 3 6
9 General practitioner (GP) with additional  
qualification for geriatrics
6 5 7       
Domain: community and nursing care
10 Recipient of inpatient care 9 8 9 9 8 9  
11 Recipient of outpatient care 9 8 9 9 8 9  
12 Care level 9 8 9 9 8 9  
 Recipient of long-term care    8 8 9
13 Caregive burden 8 7 9 7 7 8 8 8 9
14 Employed in care provision 7 6 8 8 5 8    
15 Burden due to employment in care provision 7 4 8 7 5 8    
16 Pressure sores 6 5 9    7 5 8
17 Violence, neglect, abuse 8 6 9 8 7 8 7 5 9
Domain: physical environment
18 Safety of the living environment 6 3 7       
19 Access to important infrastructure 8 7 8 8 8 8 8 7 9
20 Accessibility of housing 7 6 8 5 4 8    
Domain: social environment
21 Practical support in daily life 6 4 8       
22 Social support 8 8 9 8 8 9 7 7 8
23 Loneliness 8 7 9 8 8 9 8 7 8
24 Age discrimination 6 3 8       
Annex Table 2
Results of the structured consensus- 
based process used to select indicators 
for public health monitoring 
of the 65+ age group
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No. Indicator 1st evaluation stage 2nd evaluation stage Consensus round
Median Q0,25 Q0,75 Median Q0,25 Q0,75 Median Q0,25 Q0,75
Health area: participation and activity
Domain: social participation
25 Political commitment 5 3 6       
26 Voluntary/unpaid work 8 6 8 7 6 8    
27 Childcare 6 5 7       
28 Social leisure activities 8 7 8 8 7 9 7 6 8
Domain: activities of daily living
29 Restrictions in activities of daily living 9 8 9 9 9 9 8 7 8
30 Restrictions in instrumental activities  
of daily living
8 7 9 9 9 9 8 7 9
Health area: personal factors
Domain: physical health
31 Further life expectancy 9 4 9 8 6 9    
32 Further life expectancy in health 9 5 9 8 6 9    
33 Subjective health 9 8 9 9 8 9 8 7 8
34 Chronic disease 8 5 9 8 6 9    
35 Multimorbidities 8 7 9 9 8 9 7 7 8
36 Frequency of various diseases 7 7 9 8 7 9 7 6 8
37 Obesity 7 3 8 5 2 7    
38 Malnutrition 8 6 8 8 8 8 8 6 8
39 Hip fractures 7 6 9 8 6 9    
Domain: mental health
40 Depressive disorder 8 7 9 7 2 8    
41 Depressive symptoms 8 7 9 9 8 9 8 7 8
42 Anxiety disorders 7 6 8 7 2 7    
43 Quality of life 8 7 9 7 6 8    
44 Life satisfaction 8 7 9 9 8 9 7 7 8
45 Locus of control 7 5 8 8 5 9    
46 Addiction to medicines 6 4 8       
47 Alcohol dependency 7 5 7 6 5 8    
48 Suicide rate 8 7 9 8 8 9 8 6 9
49 Health literacy 7 4 8 8 7 9 7 5 8
Annex Table 2 Continued
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No. Indicator 1st evaluation stage 2nd evaluation stage Consensus round
Median Q0,25 Q0,75 Median Q0,25 Q0,75 Median Q0,25 Q0,75
Health area: personal factors
Domain: physical functioning
50 Physical disability 8 7 8 8 8 9 6 6 8
51 Slow walking speed 5 2 8    5 3 7
52 Difficulty walking 7 7 8 8 7 8 7 3 7
53 Grip strength 6 5 7    5 3 6
54 Pain 8 8 9 8 8 9 8 7 8
55 Falls 8 8 9 8 8 9 8 7 8
56 Eyesight 8 6 8 8 8 8 7 6 8
57 Hearing 8 6 8 8 8 8 7 6 8
58 Dental health 8 7 8 7 7 8 7 6 8
59 Urinary incontinence 8 6 8 8 8 9 7 7 8
60 Faecal incontinence 8 7 9 8 8 9 7 6 8
Domain: cognitive functioning
61 Cognitive impairment 8 6 8 8 7 8 8 7 8
62 Memory difficulties 6 5 8       
Domain: health behaviour
63 Physical activity 8 7 8 8 8 9 8 6 8
64 Tobacco use 8 6 8 7 6 8    
65 Alcohol consumption 7 6 8 7 6 8    
66 Fruit and vegetable consumption 6 5 7       
Q0,25 = 25%-quantile, Q0,75 = 75%-quantile, bold = indicators included in the final indicator set 
          Considered at the next stage or for the final set of indicators 
          Not considered at the next stage
Annex Table 2 Continued
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